UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 6, 2025
NEURONETICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-38546 | 33-1051425 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
||
3222 Phoenixville Pike, Malvern, PA | 19355 | |||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (610) 640-4202
(Former name or former address, if changed since last report.) Not applicable.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name on each exchange |
||
Common Stock ($0.01 par value) | STIM | The Nasdaq Global Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 | Results of Operations and Financial Condition. |
Neuronetics, Inc. (the “Company”) issued a press release on May 6, 2025, announcing its financial results for the three months ended March 31, 2025. A copy of the press release is being furnished to the Securities and Exchange Commission (“SEC”) as Exhibit 99.1 to this report on Form 8-K and is incorporated by reference to this Item 2.02.
***
The information furnished pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May 6, 2025, the Company announced that Stephen Furlong, who has served as Chief Financial Officer since 2019, will retire on March 31, 2026. Mr. Furlong will continue in his current position until a successor is hired and will remain as an advisor to ensure a smooth transition. Mr. Furlong’s decision to resign is not the result of any dispute or disagreement with the Company, the Company’s management or the Company’s Board of Directors (the “Board”) on any matter relating to the Company’s operations, policies or practices. The Company has initiated a comprehensive search process to identify his successor.
Item 7.01 | Regulation FD Disclosure. |
On May 6, 2025, Neuronetics released a presentation (the “Presentation”) that it may present to certain investors. A copy of the Presentation is attached hereto as Exhibit 99.2. The information contained in Exhibit 99.2 is incorporated herein by reference.
The information in this report furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Certain statements in this report, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this report that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected.
The Company cautions investors not to place undue reliance on the forward-looking statements contained in this report. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our ability to successfully complete the announced restructuring plans; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our revenue has been concentrated among a small number of customers; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to achieve cash flow breakeven in the third quarter of 2025. For a discussion of these and other related risks, please refer to the Company’s recent filings with the SEC, which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this report. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events, or changes in the Company’s expectations.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit Number |
Description | |
99.1 | Press Release, dated May 6, 2025, of Neuronetics, Inc. | |
99.2 | Company Presentation May 2025 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEURONETICS, INC. | ||||||
(Registrant) | ||||||
Date: May 6, 2025 | By: | /s/ Stephen Furlong |
||||
Name: | Stephen Furlong | |||||
Title: | EVP, Chief Financial Officer and Treasurer |
Exhibit 99.1
Neuronetics Reports First Quarter 2025 Financial and Operating Results
MALVERN, PA., May 6 2025 – Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025.
First Quarter 2025 Highlights
• | First quarter 2025 revenue of $32.0 million, an 84% increase as compared to the first quarter 2024, primarily driven by the Greenbrook acquistion |
• | U.S. clinic revenue of $18.7 million in the quarter representing Greenbrook clinic revenue |
• | U.S. treatment session revenue of $9.6 million |
• | U.S. NeuroStar Advanced Therapy System revenue of $2.8 million |
• | Completed secondary offering, raising approximately $18.9 million in net proceeds in February 2025 after deducting underwriting discounts, commissions and estimated offering expenses |
Recent Operational Highlights
• | Chief Financial Officer Steve Furlong to retire in March 2026 |
• | Significant operational progress with the integration of Greenbrook |
• | Projecting cash flow positive in the third quarter of 2025 |
• | Major insurance coverage expansions for adolescent TMS treatment, with Evernorth Health Services (Cigna) joining Humana, Aetna, and several Blue Cross Blue Shield entities in covering adolescents 15+ |
• | Achieved milestone of over 202,000 global patients treated with 7.4 million treatment sessions |
“2025 is off to a great start as our approach to innovative mental health treatment is improving access to care for patients and delivering value for providers,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “Our growth initiatives for the Greenbrook clinics continue to exceed expectations, as we implement our proven operating model and continue to rollout SPRAVATO® across our network of locations and institute the buy-and-bill model. Simultaneously, our Better Me Provider program continues to prove its effectiveness, with participating sites continuing to see improvements in the number of patients treated, and the speed at which a patient begins therapy with NeuroStar TMS. As we execute on both fronts, we’re not only expanding access to effective mental health treatments but also strengthening our financial position while remaining on the path to achieving positive cash flow in the third quarter of this year.”
First Quarter 2025 Financial and Operating Results for the Three Months Ended March 31, 2025
Revenues by Geography Three Months Ended March 31, |
||||||||||||
2025 | 2024 | |||||||||||
Amount | Amount | % Change | ||||||||||
(Unaudited; in thousands, except percentages) | ||||||||||||
U.S. |
$ | 31,483 | $ | 16,793 | 87 | % | ||||||
International |
492 | 624 | (21 | )% | ||||||||
|
|
|
|
|
|
|||||||
Total revenues |
$ | 31,975 | $ | 17,417 | 84 | % | ||||||
|
|
|
|
|
|
Total revenues for the three months ended March 31, 2025 was $32.0 million, an increase of 84% compared to the revenues of $17.4 million in the first quarter of 2024, primarily driven by the Greenbrook acquisition. During the quarter, total U.S. revenue increased by 87% and international revenue decreased marginally over the first quarter of 2024. The increase in U.S. revenue was primarily attributable to U.S. clinic revenue of $18.7 million, added as a result of the acquisition of Greenbrook, partially offset by the absence of prior year quarter sales to Greenbrook of $2.9 million and a decrease of sales of $1.1 million relating to NeuroStar Advanced Therapy Systems and treatment session revenue.
U.S. Revenues by Product Category Three Months Ended March 31, |
||||||||||||
2025 | 2024 | |||||||||||
Amount | Amount | % Change | ||||||||||
(Unaudited; in thousands, except percentages) | ||||||||||||
NeuroStar Advanced Therapy System |
$ | 2,846 | $ | 3,310 | (14 | )% | ||||||
Treatment sessions |
9,612 | 12,988 | (26 | )% | ||||||||
Clinic revenue |
18,659 | — | — | % | ||||||||
Other |
366 | 495 | (26 | )% | ||||||||
|
|
|
|
|
|
|||||||
Total U.S. revenues |
$ | 31,483 | $ | 16,793 | 87 | % | ||||||
|
|
|
|
|
|
U.S. NeuroStar Advanced Therapy System revenue for the three months ended March 31, 2025 was $2.8 million, a decrease of 14% compared to $3.3 million in the first quarter of 2024. For the three months ended March 31, 2025, the Company shipped 31 systems. While the number of systems decreased, the average selling price per system increased by 9%.
U.S. treatment session revenue for the three months ended March 31, 2025 was $9.6 million, a decrease of 26% compared to $13.0 million in the first quarter of 2024. The decline was primarily attributable to the absence of $2.8 million in treatment session revenue from Greenbrook with the prior year quarter.
U.S. clinic revenue, which represents revenue generated by treatment centers from the Greenbrook acquisition, was $18.7 million for the three months ended March 31, 2025.
Gross margin for the first quarter of 2025 was 49.2% compared to the first quarter of 2024 gross margin of 75.1%. The decrease in gross margin was primarily a result of the inclusion of Greenbrook’s clinic business.
Operating expenses during the first quarter of 2025 were $26.8 million, an increase of $6.9 million, or 35%, compared to $19.9 million in the first quarter of 2024, mainly attributable to inclusion of Greenbrook’s general and administrative expenses of $6.2 million.
Net loss for the first quarter of 2025 was $(12.7) million, or $(0.21) per share, as compared to $(7.9) million, or $(0.27) per share, in the first quarter of 2024. Net loss per share was based on 61,464,725 and 29,471,516 weighted average common shares outstanding for the first quarters of 2025 and 2024, respectively.
Cash and cash equivalents were $20.2 million as of March 31, 2025. This compares to cash and cash equivalents of $18.5 million as of December 31, 2024. As a result of the strengthened balance sheet following the recent offering, the Company proactively settled Greenbrook’s legacy vendor payment plans and accelerated certain expenses to secure favorable vendor concessions. While this increased first quarter cash burn, it will reduce overall vendor spending in 2025. The Company also experienced a temporary lag in collections during the integration of new revenue cycle management software, which has subsequently normalized. Cash used in operations for the first quarter was $17.0 million. The Company expects second quarter operational cash usage to be less than $5 million, with year-end cash anticipated to be above $20 million.
Chief Financial Officer Steve Furlong to Retire
Steve Furlong, who has served as Chief Financial Officer since 2019, will retire on March 31, 2026. Mr. Furlong will continue in his current position until a successor is hired, and will remain as an advisory subsequently to ensure a smooth transition. The Company has initiated a comprehensive search process to identify his successor.
Expanding Insurance Coverage Increases Adolescent Access to NeuroStar TMS Therapy
Insurance coverage for adolescent NeuroStar transcranial magnetic stimulation (“TMS”) therapy continues to expand since receiving clearance from the U.S. Food and Drug Administration in March 2024 as the first and only TMS treatment approved for depression in adolescents aged 15 to 21. Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has extended coverage to adolescents 15 and older with major depressive disorder (“MDD”), joining Humana, Aetna, and several Blue Cross Blue Shield entities. This growing payor acceptance reflects the significant clinical need among the estimated 4.3 million U.S. adolescents affected by major depression and positions NeuroStar’s adolescent indication as an important long-term growth driver.
Strategic Financing Strengthens Balance Sheet
Neuronetics successfully completed a public offering of common stock with net proceeds of approximately $18.9 million after deducting underwriting discounts, commissions and estimated offering expenses, strengthening the Company’s financial position and providing additional flexibility to execute on key growth initiatives. This financing enhances the Company’s ability to potentially accelerate high-return programs such as the Spravato buy-and-bill expansion, accelerate Better Me Provider program implementation across the broader network, and enhance capabilities, all while maintaining the Company’s projected timeline to be cash flow positive in the third quarter of 2025.
Business Outlook
For the second quarter of 2025, the Company expects total worldwide revenue between $36.0 million and $38.0 million.
For the full year 2025, the Company now expects total worldwide revenue to be between $149.0 million and $155.0 million, as compared to prior guidance of $145.0 million and $155.0 million.
For the full year 2025, the Company continues to expect gross margin to be approximately 55%.
For the full year 2025, the Company continues to expect total operating expenses to be between $90.0 million and $98.0 million.
The Company expects second quarter operational cash usage to be less than $5.0 million, with year-end cash anticipated to be above $20.0 million.
Webcast and Conference Call Information
Neuronetics’ management team will host a conference call on May 6, 2025, beginning at 8:30 a.m. Eastern Time.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, you may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy (“NeuroStar Therapy”) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System (the “NeuroStar System”) and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Therapy, Spravato, and other treatment modalities for the treatment of MDD and other mental health disorders.
NeuroStar Therapy is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also cleared by the U.S. Food and Drug Administration as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15 to 21 with MDD. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our ability to successfully complete the announced restructuring plans; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our revenue has been concentrated among a small number of customers; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to achieve cash flow breakeven in the third quarter of 2025. For a discussion of these and other related risks, please refer to the Company’s recent filings with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
NEURONETICS, INC.
Consolidated Statements of Operations
(Unaudited; In thousands, except per share data)
Three Months ended March 31, |
||||||||
2025 | 2024 | |||||||
Revenues |
$ | 31,975 | $ | 17,417 | ||||
Cost of revenues |
16,237 | 4,329 | ||||||
|
|
|
|
|||||
Gross profit |
15,738 | 13,088 | ||||||
|
|
|
|
|||||
Operating expenses: |
||||||||
Sales and marketing |
11,999 | 11,641 | ||||||
General and administrative |
13,137 | 5,957 | ||||||
Research and development |
1,616 | 2,349 | ||||||
|
|
|
|
|||||
Total operating expenses |
26,752 | 19,947 | ||||||
|
|
|
|
|||||
Loss from operations |
(11,014 | ) | (6,859 | ) | ||||
|
|
|
|
|||||
Other (income) expense: |
||||||||
Interest expense |
1,922 | 1,826 | ||||||
Other income, net |
(247 | ) | (812 | ) | ||||
|
|
|
|
|||||
Net loss |
$ | (12,689 | ) | $ | (7,873 | ) | ||
|
|
|
|
|||||
Non-controlling interest |
(14 | ) | — | |||||
|
|
|
|
|||||
Net loss attributable to Neuronetics stockholders’ |
(12,675 | ) | (7,873 | ) | ||||
|
|
|
|
|||||
Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders’ |
$ | (0.21 | ) | $ | (0.27 | ) | ||
|
|
|
|
|||||
Weighted average common shares outstanding, basic and diluted |
61,465 | 29,472 | ||||||
|
|
|
|
NEURONETICS, INC.
Consolidated Balance Sheets
(Unaudited; In thousands, except per share data)
March 31, 2025 |
December 31, 2024 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 20,224 | $ | 18,459 | ||||
Restricted cash |
1,000 | 1,000 | ||||||
Accounts receivable, net of allowance of credit losses of $1,403 and $1,930 as of March 31, 2025 and December 31, 2024, respectively |
26,196 | 23,355 | ||||||
Inventory |
4,069 | 4,248 | ||||||
Current portion of net investments in sales-type leases |
202 | 206 | ||||||
Current portion of prepaid commission expense |
3,113 | 3,078 | ||||||
Current portion of note receivables |
696 | 930 | ||||||
Prepaid expenses and other current assets |
5,168 | 6,846 | ||||||
|
|
|
|
|||||
Total current assets |
60,668 | 58,122 | ||||||
|
|
|
|
|||||
Property and equipment, net |
5,846 | 6,242 | ||||||
Goodwill |
18,634 | 18,634 | ||||||
Intangible assets, net |
19,242 | 19,606 | ||||||
Operating lease right-of-use assets |
26,704 | 27,093 | ||||||
Net investments in sales-type leases |
74 | 86 | ||||||
Prepaid commission expense |
8,466 | 8,902 | ||||||
Long-term notes receivable |
316 | 295 | ||||||
Other assets |
2,038 | 1,923 | ||||||
|
|
|
|
|||||
Total assets |
$ | 141,988 | $ | 140,903 | ||||
|
|
|
|
|||||
Liabilities and Equity |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 8,482 | $ | 11,077 | ||||
Accrued expenses |
9,306 | 12,818 | ||||||
Current portion of deferred revenue |
785 | 974 | ||||||
Deferred and contingent consideration |
1,000 | 1,000 | ||||||
Other payables |
346 | 605 | ||||||
Current portion of operating lease liabilities |
4,922 | 4,791 | ||||||
|
|
|
|
|||||
Total current liabilities |
24,841 | 31,265 | ||||||
|
|
|
|
|||||
Long-term debt, net |
55,341 | 55,151 | ||||||
Deferred revenue |
— | 2 | ||||||
Operating lease liabilities |
22,275 | 22,686 | ||||||
|
|
|
|
|||||
Total liabilities |
102,457 | 109,104 | ||||||
|
|
|
|
|||||
Commitments and contingencies |
||||||||
Equity: |
||||||||
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on March 31, 2025 and December 31, 2024 |
— | — | ||||||
Common stock, $0.01 par value: 250,000 shares authorized; 65,820 and 55,679 shares issued and outstanding on March 31, 2025 and December 31, 2024, respectively |
658 | 557 | ||||||
Additional paid-in capital |
467,258 | 446,938 | ||||||
Accumulated deficit |
(432,464 | ) | (419,789 | ) | ||||
|
|
|
|
|||||
Total Stockholders’ equity |
35,452 | 27,706 | ||||||
Non-controlling interest |
4,079 | 4,093 | ||||||
|
|
|
|
|||||
Total equity |
39,531 | 31,799 | ||||||
|
|
|
|
|||||
Total liabilities and equity |
$ | 141,988 | $ | 140,903 | ||||
|
|
|
|
NEURONETICS, INC.
Consolidated Statements of Cash Flows
(Unaudited; In thousands)
Three months ended March 31, | ||||||||
2025 | 2024 | |||||||
Cash flows from Operating activities: |
||||||||
Net loss |
$ | (12,689 | ) | $ | (7,873 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
911 | 560 | ||||||
Allowance for credit losses |
— | 566 | ||||||
Inventory impairment |
5 | 71 | ||||||
Share-based compensation |
1,444 | 1,338 | ||||||
Non-cash interest expense |
189 | 161 | ||||||
Changes in certain assets and liabilities: |
||||||||
Accounts receivable, net |
(2,627 | ) | (2,667 | ) | ||||
Inventory |
175 | 1,328 | ||||||
Net investment in sales-type leases |
14 | 234 | ||||||
Prepaid commission expense |
401 | (154 | ) | |||||
Prepaid expenses and other assets |
1,785 | 116 | ||||||
Accounts payable |
(2,638 | ) | (1,983 | ) | ||||
Accrued expenses |
(3,511 | ) | (3,549 | ) | ||||
Other liabilities |
(193 | ) | — | |||||
Deferred revenue |
(259 | ) | (163 | ) | ||||
|
|
|
|
|||||
Net Cash used in Operating activities |
(16,993 | ) | (12,015 | ) | ||||
|
|
|
|
|||||
Cash flows from Investing activities: |
||||||||
Purchases of property and equipment and capitalized software |
(219 | ) | (375 | ) | ||||
Repayment of notes receivable |
— | 443 | ||||||
|
|
|
|
|||||
Net Cash (used in) provided by Investing activities |
(219 | ) | 68 | |||||
|
|
|
|
|||||
Cash flows from Financing activities: |
||||||||
Proceeds from the issuance of common stock |
20,700 | — | ||||||
Payments of common stock offering issuance costs |
(1,731 | ) | — | |||||
Proceeds from exercises of stock options |
8 | — | ||||||
|
|
|
|
|||||
Net Cash provided by Financing activities |
18,977 | — | ||||||
|
|
|
|
|||||
Net increase (decrease) in Cash, Cash equivalents and Restricted cash |
1,765 | (11,947 | ) | |||||
Cash, Cash equivalents and Restricted cash, Beginning of Period |
19,459 | 59,677 | ||||||
|
|
|
|
|||||
Cash, Cash equivalents and Restricted cash, End of Period |
$ | 21,224 | $ | 47,730 | ||||
|
|
|
|
|||||
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet: |
||||||||
Cash and cash equivalents |
20,224 | 47,730 | ||||||
Restricted cash |
1,000 | — | ||||||
|
|
|
|
|||||
Total cash, cash equivalents and restricted cash |
$ | 21,224 | $ | 47,730 | ||||
|
|
|
|
Non-GAAP Financial Measures (Unaudited)
EBITDA is not a measure of financial performance under generally accepted accounting principles in the U.S. (“GAAP”), and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes that the addition of the non-GAAP financial measure provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment.
The following table reconciles reported net loss to EBITDA:
Three Months ended March 31, | ||||||||
2025 | 2024 | |||||||
(in thousands) | ||||||||
Net loss |
$ | (12,689 | ) | $ | (7,873 | ) | ||
Interest expense, net |
1,675 | 1,014 | ||||||
Income taxes |
— | — | ||||||
Depreciation and amortization |
911 | 560 | ||||||
|
|
|
|
|||||
EBITDA |
$ | (10,103 | ) | $ | (6,299 | ) | ||
|
|
|
|
COMPANY PRESENTATION NASDAQ: STIM May 2025 Exhibit 99.2
Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain statements in this presentation, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this presentation that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal year 2025, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this presentation. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook TMS Inc. (“Greenbrook”) on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our ability to successfully complete the announced restructuring plans; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our revenue has been concentrated among a small number of customers; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to achieve cash flow breakeven in the third quarter of 2025. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this presentation. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events, or changes in the Company’s expectations.
Non-GAAP Financial Measures In addition to financial measures prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), from time to time we may use or publicly disclose certain non-GAAP financial measures in the course of our financial presentations, earnings releases, earnings conference calls, and otherwise. For these purposes, the SEC defines a non-GAAP financial measure as a numerical measure of historical or future financial performance, financial positions, or cash flows that (i) exclude amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with GAAP in financial statements, and (ii) include amounts, or is subject to adjustments that effectively include amounts, that are excluded from the most directly comparable measure so calculated and presented. Non-GAAP financial measures are provided as additional information to investors to provide an alternative method for assessing our financial condition and operating results. We believe that these non-GAAP measures, when taken together with our GAAP financial measures, allow us and our investors to better evaluate our performance and profitability. These measures are not in accordance with, or a substitute for, GAAP, and may be different from or inconsistent with non-GAAP financial measures used by other companies. These measures should be used in addition to and in conjunction with results presented in accordance with GAAP, and should not be relied upon to the exclusion of GAAP financial measures. Pursuant to the requirements of Regulation G, whenever we refer to a non-GAAP financial measure, we will also generally present, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference with such comparable GAAP financial measure.
39+ years of experience Keith Sullivan President & Chief Executive Officer Presenters Steve Furlong Executive Vice President, Chief Financial Officer & Treasurer 38+ years of experience
STRONGER together 213,500 Unique Patients Treated 7,620,000 Treatments Administered $129M annual revenue (2024) 1 Two of the nation’s largest mental health and device companies are now combined to create an organization with the ability to leverage its scale and capabilities to treat more patients suffering from mental health conditions (1) This revenue is the full year 2024 consolidated adjusted net proforma revenue as further defined on slides 24 and 25
A Diversified Business Model with Strategic Advantages from the Company’s Combined Expertise NeuroStar Market Leader in Transcranial Magnetic Stimulation (TMS) Greenbrook Mental Health Services Provider Large Network of Clinics Offer New Paradigms for Treating Depression Established and Growing Network of Referring Physicians Centralized, Scalable Business Infrastructure Patient Focused Service Unrivalled Clinical Results: Long-Term Relief for Depression Widely Reimbursed Proven Formula for Practice Success Top Tier Training and Best Practices Comprehensive Direct Sales and Support Team Neuronetics is now a vertically integrated organization providing greater access to mental health treatments through our collective expertise
Stronger Commercial Footprint & Opportunity Together Greenbrook Total Amount of Patients Treated 55,700 Patients 1.8M treatments Together, with Better Me Provider (BMP) practices… we have over 375 BMP clinics in 49 states Greenbrook Locations: Operating 95 Treatment Clinics in 15 States
A Compelling Investment Opportunity Combines one of the U.S.’s most utilized therapeutic platforms for the treatment of MDD with one of the largest service providers to renew even more lives Large patient population best served by managing the therapeutic paradigm Multiple initiatives in place to drive accelerated growth across the organization Significant, realized cost reductions enable immediate operating leverage Transformed financial profile adds scale and supportive balance sheet Poised to deliver mid-teens revenue growth and expected to achieve profitability in near-term The NEW
Senior Leadership Keith Sullivan Rob Cascella Board Chairman Management Team Board of Directors Sheryl Conley Glenn Muir Andrew Macan EVP, GC & Chief Compliance Officer Sara Grubbs SVP, Chief Revenue Officer Megan Rosengarten Keith Sullivan President & CEO Cory Anderson SVP, Chief Technology Officer Steve Furlong EVP, CFO and Treasurer Lisa Rosas SVP, Chief Marketing Officer Avinash Amin, MD Sasha Cucuz Bill Leonard EVP, Chief Clinic Officer
Over 29 Million Lives Affected by Depression and OCD U.S. Adults and Adolescents (ages 15-21) suffering from depression, depression with anxiety and OCD Total Available Market 29.3 million Nearly 8 million patients are poorly served by antidepressant medication Lack of Treatment Efficacy Intolerable Side Effects Adult Depression (MDD) 21 million suffering1 6.4 million on medication1,2,3 Anxious Depression 53% of MDD patients have significant anxiety6 Adolescent Depression 4.3 million suffering4 1 million on medications5 OCD 4 million suffering7 235k on medication8 New indication: 35% increase in addressable market (1) NIMH https://www.nimh.nih.gov/health/statistics/major-depression.shtml, accessed 4/29/2024. (2) Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration. (3) Journal of Clinical Psychiatry, accessed 3/7/2022. (4) Depression- Pharma Intelligence Disease Analysis, www.datamonitorhealthcare.com, Publication Date: June 2021. (5) Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. (6) Kalin N, The Critical Relationship Between Anxiety and Depression, Am J Psychiatry 2020; 177:365–367; doi: 10.1176/appi.ajp.2020.20030305. (7) Harvard Medical School, 2007. National Comorbidity Survey (NCSSC). (8) Definitive Health Diagnosis/Prescription Data: 3/25/22.
Patients Medication Management Medical Technology Psychotherapy Interventional Medication Our Combined Company is Positioned to Capitalize on Innovations in the Mental Health Space
#1 Physician Recommended TMS We’re inspired every day by the opportunity to help people live more fulfilling lives Market Leader in TMS1 Over 7.4 million treatment sessions performed in over 202,000 patients Robust R&D Pipeline 3rd generation system. Largest clinical dataset in the world to drive new indications Widely Reimbursed Dedicated to Practice Success Largest direct sales and customer support team in the industry to support over 1,100 U.S. offices1 Dedicated to driving health policy to ensure broad U.S. reimbursement among commercial and government payors (1) Neuronetics, Inc. internal estimate based on the Company’s data on treatment sessions and patients treated.
Proven, Long-Term Relief for MDD1 (1) Dunner DL, et al. (2014). J Clin Psychiatry. 75(12):1394-1401. (2) Sackeim HA, et al. (2020) J. Affect. Disord. 277:65-74. Based on a real-world, retrospective study using CGI-S and a sample size of 615 patients. Real-World Clinical Results for Patients with MDD2 83% Improvement in depression symptoms1 62% Symptom relief (remission)1 Clinically Proven Durability through 12 Months1
As the Market Leader, NeuroStar is Revolutionizing Mental Health with New Adolescent Indication 1st to Market 1st Line Treatment NeuroStar is the first FDA-cleared TMS treatment for adolescent depression1 For adolescents, NeuroStar can be used as an add-on treatment, without prior medication failures (1) FDA Clearance K231926.
Better Me Program (BMP) Transforms the Lives of More Patients 3x more patients treated in BMP vs. non-BMP 375+ NeuroStar Clinics are in BMP Program *Clinical evidence demonstrates superior outcomes for patients who complete a course of NeuroStar therapy compared to those who do not complete treatment. However, the actual number of sessions performed is subject to the medical judgment of the prescribing physician. The number of treatment sessions performed is not a selection criteria for entry into the Better Me Guarantee Program and will not be used as a basis to remove a provider from the program. Designed to lead the industry in the standards for patient care
With the 5-Standards, Better Me Practices are Quickly Addressing Interested Patients in Need All patient interest in Active BMP Local Consumable Offices; Feb 1, 2024 – Dec 31, 2024 vs. PY 2.2x Faster from potential patient interest to MT 2023 84 days 2024 38 days
NeuroStar University A 2-DAY COURSE HELD AT OUR STATE-OF-THE-ART TRAINING CENTER Practices learn how to achieve the best clinical outcomes and market their NeuroStar business, through a combination of instruction and peer to peer learning. Practices that attend NSU consistently outperform practices that do not on a quarterly basis. NSU attendees performed 30% more treatment sessions in Q1 2025 than the sites that did not attend NSU. *Data does not include Greenbrook or inactive sites – thru 3/31/2025 Since NSU opened in Q3 2022, NSU attendees have started 40% more patients than non-attendees.* Actual Treatment Session Utilization 2022 – Q1 2025: NSU Attendees vs. Non-Attendees NSU Opens
Partnering with Practices to Build Local Consumer Awareness1 – this one Co-Op Marketing: collaborative effort with practices to increase local patient awareness while sharing advertising costs +18% in new MTs* +20% treatment session utilization* * Q1 2025 vs. Q1 2024 data from accounts who participated in Co-Op in the prior two consecutive quarters (Q3 & Q4 2024). Data on file, Neuronetics, Inc.
SPRAVATO® Program In March 2019, the FDA approved SPRAVATO® (esketamine) nasal spray, in conjunction with an oral antidepressant, for Treatment Resistant Depression in adults and in August 2020, the FDA added a second indication for depressive symptoms in adults with MDD with acute suicidal ideation or behavior SPRAVATO® fills the gap in the treatment paradigm between or before TMS and Electroconvulsive Therapy, providing for a complimentary treatment to TMS, effectively broadening Greenbrook TMS’s offering to patients Delivered in a two-spray dispenser under supervision from a health care professional as patients self-administer Treatment consists of: Induction (8 treatments) - Twice a week for 4 weeks Taper (4 treatments) - Once a week for 4 weeks Maintenance - Once every one to two weeks for the next year We currently have a total of 76 Treatment Centers now offering SPRAVATO® and expect to have nearly 85 Treatment Centers offering SPRAVATO® by the end of Fiscal 2025 through an accelerated roll-out
Key Growth Initiatives for Network Clinics Focus on execution, profitable product diversification & expansion Drive growth in 95 clinics through enhanced RAM clinic engagement, leveraging automated referral systems and optimized digital/DTC targeting Fill the gap in treatment paradigm with SPRAVATO® expansion to all locations with Buy & Bill model that increases treatment revenue Standardize operational excellence across our network through comprehensive training, enhanced practice capabilities, and centralized services Expanding the Continuum of Care for Patients Identifying and Educating Patients Consistent Implementation of Best Operation Practices
Key Growth Initiatives for Customer Clinics Expand referral networks for 375+ BMP Clinics to increase patient flow, 110+ additional sites committed to the program Continued implementation of fully optimized digital/DTC investment benefitting patients and BMP practices Centralized call center to help BMP providers manage patient inquires more efficiently (billing and contracts) Patient Education Expand BMP Network Expanding Services to Existing Customers Harnessing the power of our proven programs to help more patients in need
Comprehensive Direct Sales & Customer Support Team 40 Practice Development Managers 10 Area Sales Managers 10 Reimbursement Specialists & Managers 18 Field Service and Technical Support 14 Sales Leaders 21 Regional Account Managers 02 Clinical Training Managers 07 Customer Service Representatives Experienced team dedicated to consistent growth and practice success
Significant Realized Cost Synergies1 Fully Executed Expected 1H 2025 (1) The Company executed on a number of cost staving initiatives in 2024 and has additional identified cost saving initiatives to be executed in the first half of 2025. The dollar savings identified above are the expected annualized savings from these cost saving initiatives.
Improved Financial Profile Adds Scale and Strength Fourth quarter and full year revenue 2024 was $22.5M and $74.9M, respectively (1) The unaudited, 2024 financial results presented above for 4Q 2024 and FY 2024 and cash and debt as of December 31, 2024, are based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures. This financial information does not represent a comprehensive statement of the Company’s or Greenbrook's financial results for 4Q 2024 or FY 2024 and remains subject to the completion of financial closing procedures and internal reviews. (2) See the accompanying financial table that reconciles Net Pro Forma Revenue, which is a non-GAAP financial measure, to revenue. 4Q 20241,2 Neuronetics Gross Pro Forma Revenue $19.2M Intercompany Eliminations ($2.4M) Neuronetics Net Pro Forma Revenue $16.8M Preliminary Greenbrook Gross Revenue $18.0M Impact of Greenbrook Clinic Closures ($0.9M) Greenbrook Adjusted Net Pro Forma Revenue $17.1M Consolidated Adjusted Net Pro Forma Revenue $33.9M FY 20241,2 Neuronetics Gross Pro Forma Revenue $71.5M Less Intercompany Eliminations ($9.9M) Neuronetics Net Pro Forma Revenue $61.6M Preliminary Greenbrook Gross Revenue $75.5M Impact of Greenbrook Clinic Closures ($7.7M) Greenbrook Adjusted Net Pro Forma Revenue $67.8M Consolidated Adjusted Net Pro Forma Revenue $129.4M Basic Shares Outstanding as of 12/31/24 55.688M Debt as of 12/31/24 $60.0M Cash as of 12/31/24 $18.5M
Non-GAAP Financial Measures (Unaudited) Neuronetics Adjusted Pro Forma Revenue is not a measure of financial performance under generally accepted accounting principles in the U.S. (“GAAP”), and should not be construed as a substitute for, or superior to, GAAP revenue. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes that the addition of the non-GAAP financial measure provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of Neuronetics Adjusted Pro Forma Revenue may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment. The following table reconciles reported revenue to Neuronetics Adjusted Gross Pro Forma Revenue and Neuronetics Adjusted Net Pro Forma Revenue: 4Q 2024 FY 2024 (in millions) (in millions) Consolidated Revenue $ 22.5 $ 74.9 Greenbrook Revenue (Post-Acquisition Period) $ (4.4) $ (4.4) Neuronetics Standalone Revenue $ 18.1 $ 70.5 Greenbrook Intercompany Revenue (Post-Acquisition Period) $ 0.6 $ 0.6 Assumed Greenbrook Revenue (Post-Acquisition Period)1 $ 0.5 $ 0.5 Neuronetics Proforma Gross Revenue $ 19.2 $ 71.5 Greenbrook Intercompany Revenue $ (2.4) $ (9.9) Neuronetics Proforma Net Revenue $ 16.8 $ 61.6 (1) Sales that Neuronetics would have recorded had Neuronetics billed Greenbrook as a separate entity from December 10, 2024 through December 31, 2024 for Greenbrook’s customary treatment session buying patterns through December 31, 2024.
Poised to Deliver Mid-Teens Growth and Profitability FY 2025 Guidance1 Revenue $149M to $155M (+15% to +19% Pro Forma YoY) Prior Guidance of $145M to $155M (+12 to +19% Pro Forma YoY)2 Gross Margin Approximately 55% Operating Expenses $90M - $98M Profitability Cash flow positive beginning in Q3 2025 Guidance as issued on May 6, 2025 Previously issued guidance as announced on March 27, 2025
Financial Overview Neuronetics transforming lives through NeuroHealth
Worldwide Quarterly Revenue1 Q1 2025 Revenue of $32.0M, an 84% increase from Q1 2024 ($ in millions) Guidance ($ in millions) (1) 2023 and 2024 actual revenue as reported and filed with the SEC for Neuronetics
Results of Operations1 ($ in thousands) ($ in thousands) (1) Actual results as reported and filed with the SEC for Neuronetics Neuronetics, Inc. Supplemental Financial and Operating Information For the period ended March 31, 2025 2017 2018 2019 2020 2017 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2023 2024 Revenue ($ thousands) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY NeuroStar Capital (1) $1,051.820000000003 $1,927.3699999999997 $2,243.19 $2,990.2869999999994 $1,908.65 $3,267.7 $3,427.723 $4,337.75 $2,938.8229999999999 $4,034.659999999998 $4,264.321800000002 $4,958.7665800000004 $2,410.320000000002 $2,223.8835899999999 $2,438.3874999999998 $3,445.80141 $8,211.9290000000001 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $16,195.687760000001 $10,518.104500000001 #REF! $12,941.823 $12,941.823 $12,941.823 $12,941.823 YoY Change 0.76 0.65 0.54 0.47 0.53973908259764736 0.2345276494170212 0.24398388667929116 0.14316559967725206 -0.17993291872290362 -0.44872404417776013 -0.4281498363363665 -0.30510917293469386 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.25142244334511443 -0.35056141759057968 #REF! 0.56999999999999995 0.56999999999999995 0.56999999999999995 0.56999999999999995 Sales $1,876 $3,277 $3,538 $4,385 $2,451 $3,754 $2,969 $4,070.4648999999999 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $13,244.464899999999 $13,244.464899999999 $13,244.464899999999 $13,076 $13,076 $13,076 $13,076 YoY 1.3318827646177938 0.9477318833436239 0.32356153513523145 0.3612288385696758 0.306503198294243 0.1455599633811413 -0.16082532504239688 -7.1729783352337484E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.2883519424900403E-2 1.2883519424900403E-2 1.2883519424900403E-2 0.59231771244003695 0.59231771244003695 0.59231771244003695 0.59231771244003695 Sales-Type-Leases $0 $0 $0 $0 $450 $350 $1,283 $996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $3,079 $3,079 $3,079 $0 $0 $0 $0 YoY nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm Other NeuroStar $32.35 $-9.65 $-,110.6 $-42.3 $37.573 $-69.5 $12.5 $-,107.69926 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $-,127.12626 $-,127.12626 $-,127.12626 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 YoY -0.41530508964719492 -1.2028674739320553 3.7153119737375082 -0.11580267558528445 0.16145285935084996 6.2020725388601035 -1.1130198915009042 1.5460817966903075 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -2.3607834101382341E-2 -2.3607834101382341E-2 -2.3607834101382341E-2 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 NeuroStar Operating Lease (2) $215 $293.95800000000003 $289 $234 $258 $181.13883999999999 $269 $231 $181.94399999999999 $187.08323999999999 $184.44399999999999 $176.66726 $155.417 $114.16689 $87.917000000000002 $79.167000000000002 $1,031.9580000000001 #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $730.13850000000002 $436.66789000000006 $279 $939 $939 $939 $939 YoY Change 0.13 -0.38379346709393869 -6.9204152249134898E-2 -0.02 -0.29479069767441868 3.2816816095322165E-2 -0.3143345724907064 -0.23520666666666667 -0.14579760805522568 -0.38975351292825589 -0.52334041768775341 -0.5518864106456397 #REF! #REF! -0.65876906627842169 7.3679689769727164E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.22350933218443014 -0.40193827609419308 -0.36107049226816301 -0.1 -0.1 -0.1 -0.1 Other (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $120 $210.995 $185 $228.95 $407.25 $167.084 $278 $29 $0 $15 $95.5 $852.0675 #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $1,081.2840000000001 $139.5 #REF! $722 $722 $722 $722 YoY Change NM -0.50207468879668049 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.3937499999999998 -0.20811393634920261 0.50270270270270268 -0.87333478925529595 -1 -0.91022479710804149 -0.65647482014388492 #REF! 1 19.333333333333332 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 0.49867150846506236 -0.87098671579344555 #REF! -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 Total U.S. NeuroStar Advanced Therapy System Revenues $1,274.820000000003 $2,462.3279999999995 $2,852.4075000000003 $3,507.1369999999993 $2,372.65 $3,568 $3,907.7179999999998 $4,753.75 $3,349.7169999999996 $4,628.3992399999997 $4,615.5601800000004 $5,413.4338400000006 $2,594.4490000000001 $2,338.504799999999 $2,541.3044999999997 $3,620.4684099999999 $10,095.9545 $1,755.2459999999999 $2,577.2649900000001 $2,611.58916 $2,815.2192999999997 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $3,850 $4,489 $3,597 $4,523.6000000000004 $3,310 $4,000 $4,108 $3,849 $2,846 $18,007.110260000001 $11,094.272390000002 #REF! $16,575 $16,460 $16,459.599999999999 $15,267 YoY Change 0.8 0.42 0.38 0.37 0.41180410089983743 0.29719709641255587 0.18113952439761527 0.13877125216934005 -0.22547218167982541 -0.49484684471601459 -0.4494049690843811 -0.33120667638934342 -0.32346097379443584 0.1023136634757349 2.7656921868276729E-2 -0.22241572603584747 1.08 0.70021708555471407 0.50636250917812808 0.63965911998400982 5.7103727438351903E-2 2.4439121463739388E-2 -8.566344687341132E-2 -2.0017331022530227E-2 -0.24462163242482127 1.6776817488561191E-2 -0.11005199306759095 -0.16616117850953205 -0.14018126888217519 -1 -1 -1 0.23311033760186262 -0.38389490430098572 #REF! 0.7 -0.01 -0.01 -7.2456195776325005E-2 Total U.S. Treatment Sessions Revenues $5,748.7510000000002 $7,386.4830000000002 $7,227.3850000000002 $8,023.9769999999999 $7,239.5487700000012 $8,920 $9,218 $9,909 $8,777.6730000000007 $10,847.351000000001 $10,251.888499999999 $11,243.30969 $8,193.4259999999995 $6,546.6486100000002 $9,083.3856099999994 $11,028.800499999999 $28,386.595999999998 $9,628.61 $10,801 $10,258.61579 $11,244.748890000001 $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $12,988 $11,660 $13,326 $12,858 $9,612 $41,120.22219 $34,852.260719999998 $41,932.974679999999 $45,077 $50,896 $50,896 $50,832 YoY Change 0.25932550740152105 0.20761125423290072 0.27542672764769005 0.23492377906865891 0.21246133963125424 0.21607073991031389 0.11215974180950306 0.13465634170955698 -6.6560579324383751E-2 -0.39647489880248188 -0.11397928196351337 -1.9078829625300497E-2 0.17516286837764827 0.64985180104236573 0.12938239445721389 1.9580405865533779E-2 -1.6607896674597833E-2 4.5693639477826231E-2 0.1564476273265325 0.10716567544444278 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 0.14993646928599191 -1.7157752744486277E-2 7.0378640620732957E-2 3.2787675304021047E-2 -0.25993224514936863 -1 -1 -1 0.16530796582310758 -0.15243014595199111 0.20316369193051309 7.0000000000000007E-2 0.13 0.13 -1.2574662055957475E-3 Total Clinic Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $0 $0 $0 $0 $0 $0 $0 $4,445 $18,659 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $0 $0 $4,445 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 na n/a n/a n/a -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0 0 na Total U.S. Other Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $471 $486 $554 $469 $495 $470 $488 $490 $366 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $1,980 $1,980 $1,943 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.15959298532413202 6.7833062625201279E-2 0.24213998926647551 4.9217002237136542E-2 8.7607748970112365E-2 5.3801073926432297E-2 9.1722595078299829E-2 9.6196868008948444E-2 -0.26060606060606062 -1 -1 -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0.13 0.13 -1.8686868686868641E-2 Total U.S. Revenues $7,346.9226500000004 $10,177.2872 $10,421.701070000001 $11,884.24583 $9,972.814600000012 $12,897.737710000001 $13,518.360389999998 $15,089 $12,545.759 $15,890 $15,293.75468 $17,030 $11,177.5 $9,267.1140899999991 $12,028.93211 $15,046.68909999998 $39,829.898270000005 $11,801.763999999999 $13,809.378989999999 $13,280 $14,556.26310000001 $13,516.902740000001 $16,131.57429 $16,243.556370000002 $17,512.8 $14,964 $17,289 $17,211 $19,871.599999999999 $16,793 $16,130 $17,922 $21,642 $31,483 $0 $0 $0 $60,760.108459999996 $47,519.165110000002 $53,447.169300000001 $63,406 $69,336 $69,335.600000000006 $72,487 YoY Change 0.35 0.26 0.29713568823366732 0.26966407594077846 0.25808829884949591 0.23199900302515908 0.13133207273519076 0.12863675525217055 -0.10909734516660174 -0.41679584078036502 -0.21347423430751666 -0.11649624721080454 5.5892565569626962E-2 0.49014880532241301 0.10400490073095936 -3.2569477312064055E-2 0.14532901522179253 0.16816073349001481 0.22315936521084345 0.20313055411068426 0.10705834671116365 7.1749085934997181E-2 5.9558609454931632E-2 0.1346900552738568 4.100193187034562E-2 -6.9908563995091377E-3 2.336576675346036E-2 0.2357818281485542 0.87476924909188347 -1 -1 -1 0.18034051052656319 -0.2179216542827086 0.12474975467850768 0.19 0.09 0.09 4.5451398704273061E-2 Total International Revenues $132.1 $83.5 $92.5 $272.23500000000001 $179.732 $354 $219.30699999999999 $545.61800000000005 $182 $682 $706.37199999999996 $325.548 $298.822 $473.91300000000001 $418.98599999999999 $532.87300000000005 $580.33500000000004 $486.28800000000001 $393.93900000000002 $519 $466.178 $663.74939000000006 $197.87039000000001 $253.36739 $686 $576 $321 $673.3 $441.6 $624 $320 $608 $851 $492 $1,895.7699999999998 $1,724.5940000000001 $1,865.4050000000002 $1,800 $2,012 $2,011.9 $2,402 YoY Change 0.36057532172596529 3.25 1.3708864864864863 1.004216944918912 1.2618787973204482E-2 0.92655367231638408 2.2209277405645969 -0.40334079887393748 0.6418791208791208 -0.30511290322580642 -0.40684794980548489 0.63684925110889967 0.62735006124047099 -0.16875249254610025 0.23870487319385369 -0.12516115472166922 0.36493063781133817 -0.49771312309773852 -0.51181620423892094 0.4715409135566242 -0.13220259230671394 0.62227405525404778 1.6574059116289588 -0.35626822157434401 2.1535794718957191 0.26298810592791755 -0.11370262390670549 0.24052478134110777 -0.21153846153846156 -1 -1 -1 0.45904444083572726 -9.0293653766015725E-2 8.1648782264115649E-2 -0.03 0.12 0.12 0.19389631691435949 Total Revenues $7,479.226500000008 $10,260.52872 $10,514.201070000001 $12,156.48083 $10,151.813460000001 $13,252.403710000001 $13,737 $15,634.618 $12,728.371999999999 $16,571.754240000002 $16,000.126679999999 $17,355.547999999999 $11,476 $9,741 $12,447.918110000001 $15,578.941909999998 $40,410.233270000004 $12,288.52 $14,203.31799 $13,799 $15,022.204310000001 $14,180.652129999999 $16,329.445 $16,497.5124 $18,198.8 $15,540 $17,610 $17,884.3 $20,313.199999999997 $17,417 $16,450 $18,530 $22,493 $31,975 $0 $0 $0 $62,655.878459999993 $49,243.860019999993 $55,312 $65,206 $71,348 $71,347.5 $74,890 YoY Change 0.35 0.29159072321177626 0.30651867018175616 0.28611382016221221 0.2538027860886245 0.25047158256243618 0.16474679187595531 0.11007176510484618 -9.8392158871535185E-2 -0.41219258631728306 -0.22201127785070751 -0.10236531223329859 7.0760892296967581E-2 0.45809649830612864 0.10853878359905123 -3.5736547656207041E-2 0.15401954109569194 0.14969227693817189 0.19555854772084924 0.21146002440436762 9.5859334079863689E-2 7.8419995290715638E-2 8.4060406585904301E-2 0.11618348462535977 6.6600855081112798E-2 -2.8799735892303113E-3 1.8199002132008646E-2 0.23596061278765634 0.83585003157834303 -1 -1 -1 0.18720207332511252 -0.21405842148653842 0.12322632664327049 0.18 0.09 0.09 4.9651354287115979E-2 2018 2019 2020 2020 2020 2020 2021 2020 2020 2020 2022 2020 2020 2020 2023 2020 2020 2020 2024 2025 2019 2020 2021 2022 2023 2023 2024 U.S. Operating and Financial Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY Active Installed Base Active Installed Base - Beginning of Period 647 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! 647 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 907 #REF! #REF! 752 752 752 752 Active Installed Base - End of Period 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! 752 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1085 #REF! 752 907 907 907 907 Total NeuroStar Systems 14 25 30 40 24 43 47 61 43 61 68 78 #REF! #REF! #REF! #REF! 109 23 36 40 48 46 59 50 58 49 54 43 58 40 50 48 47 31 250 #REF! 147 213 204 204 185 YoY Change 0.71428571428571419 0.72 0.56666666666666665 0.52499999999999991 0.79166666666666674 0.41860465116279078 0.44680851063829796 0.27868852459016402 #REF! #REF! #REF! #REF! -0.39473684210526316 2.857142857142847E-2 2.564102564102555E-2 -0.11111111111111116 1 0.63888888888888884 0.25 0.20833333333333326 6.5217391304347894E-2 -8.4745762711864403E-2 -0.14000000000000001 0 -0.32203389830508478 0 -0.17241379310344829 -0.18965517241379315 -0.22499999999999998 -1 -1 -1 #REF! #REF! #REF! 0.44897959183673503 -0.04 -0.04 -9.3137254901960786E-2 Active Sites Active Sites - Beginning of Period 0 615 637 679 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 916 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1081 1001 1044 1081 #REF! #REF! 916 959 959 959 959 Active Sites - End of Period 615 637 679 707 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 #REF! #REF! 0 1101 1101 1101 1101 NeuroStar System Average Selling Price ($) (4) $75,077.285714285739 $77,094.799999999988 $74,773 $74,757.174999999988 $79,527.83333333343 $75,993.23255813954 $72,930.276595744683 $71,110.655737704918 $68,344.72093023255 $66,132.229508196717 $62,706.355588235296 $63,573.930512820516 #REF! #REF! #REF! #REF! $75,338.798165137618 $69,101.260869565216 $67,801.336111111115 $56,914.728999999999 $52,358.735416666663 $75,760 $72,410.547796610161 $72,755.848399999988 $0 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $64,782.75104000001 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 YoY Change 5.926955905121245E-2 -1.4291194012904018E-2 -2.4644235275504744E-2 -4.8778184332073482E-2 -0.14061074459666201 -0.12975919795193602 -0.14018760773637229 -0.10598587717548236 #REF! #REF! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 Sequential Change 6.3805358259369171E-2 -4.4438446996812098E-2 -4.0302997944419161E-2 -2.4950143383193124E-2 -3.8896207309276565E-2 -3.237252843997096E-2 -5.1803393677160137E-2 1.3835518209385222E-2 #REF! #REF! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0 Average Revenue Per Active Site ($) (1) $8,885.2411128284384 $11,008.171385991058 $10,474.471014492754 $11,067.55448275862 $9,627.595345744696 $11,421.254801536492 $11,296.568627450981 $11,548.951048951049 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $43,874.182380216385 $10,511.582969432315 $12,001.111111111111 $11,162.802818280739 $12,182.826533044421 $9,873.5130761209602 $11,280 $11,364 $11,516.928769657725 $9,666.6666666666661 $11,391.304347826088 $11,916.58394160586 $13,237.544483985765 $11,299.808595789107 $10,000 $11,390 $11,027.444253859348 $8,362.6239777275096 $0 $11,390 $0 YoY Change 8.3488834160617253E-2 3.7525162087421959E-2 7.8485835878561394E-2 4.3496200261978757E-2 NA #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.11614813917964395 0.62052110235716817 9.2514634028795673E-2 .4% -6.0701598909209231E-2 -6.0087028978798251E-2 1.8023894625261105E-2 -5.4658724851784579E-2 -2.0949626324448856E-2 9.8674067221709016E-3 4.8579584139438969E-2 0.14939883268716048 1.756081186977676E-3 -0.12002815909890885 -1.1021060579286424E-2 -4.2501306171829678E-2 -0.13490096782129202 -1 -4.4147013782542266E-2 -1 Use Total Systems Recognized from the Q or K #DIV/0! (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) Three Months EndedMarch 31, 2024 2025 Revenues $17,417 $31,975 YOY Growth 0.83585003157834303 Gross Profit 13088 15738 Gross Margin 0.75144973301946372 0.49219702892885064 Operating Expenses: Sales and Marketing 11641 11999 % of Revenues 0.66836998334960096 0.37526192337763881 General and Administrative 5957 13137 % of Revenues 0.34202216225526783 0.41085222830336199 Research and Development 2349 1616 % of Revenues 0.1348682321869438 5.0539483971853011E-2 Total Operating Expenses 19947 26752 Loss from Operations $-6,859 $,-11,014 ($ in thousands) % of Revenues -0.39381064477234884 -0.34445660672400313 As of March 31, 2025 Cash and Cash Equivalents $20,224 enter Other Assets $,121,764 calculates Total Assets $,141,988 enter Long-term debt, net $55,341 enter Convertible Preferred Stock Warrant Liability $0 11703 Convertible Preferred Stock $0 0.7530888030888031 Accumulated Deficit $-,432,464 enter Total Stockholders’ Equity $35,452 enter 2017 2018 2019 2020 2021 2022 2022 2022 2022 UNIT SALES / ACTIVE SITES 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) 20 29 32 42 30 47 48 65 43 61 68 78 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 46 59 50 58 0 49 54 43 58 0 31 0 0 0 0 250 YoY D 0.5 0.6206896551724137 0.5 0.54761904761904767 0.43333333333333335 0.2978723404255319 0.41666666666666674 0.19999999999999996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -1 -0.16949152542372881 8.0000000000000071E-2 -0.25862068965517238 #DIV/0! -1 -0.42592592592592593 -1 -1 #DIV/0! -1 #DIV/0! Beginning Active Installed Base 0 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Ending Active Installed Base 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.16393442622950816 0.18260869565217397 0.18344827586206902 0.2061170212765957 0.19206145966709354 0.19607843137254899 0.2027972027972027 0.25137816979051819 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Net Active Installed Base Change 24 19 35 27 29 35 42 49 24 45 56 53 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.20833333333333326 0.84210526315789469 0.19999999999999996 0.81481481481481488 -0.17241379310344829 0.28571428571428581 0.33333333333333326 8.163265306122458E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Active Sites (End of Period) 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 YoY D 0.1983739837398375 0.22135007849293564 0.22680412371134029 0.23055162659123063 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -100.0% -100.0% -100.0% -100.0% #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Inactive Systems (Calculation) (2) -4 10 -3 15 -1 -12 -6 -16 -19 -16 -12 -25 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Inactive System Churn % (Calculation) (3) -0.1% -1.5% -0.7% -1.9% -2.0948180815876516E-2 -1.7185821697099892E-2 -1.2295081967213115E-2 -2.4224806201550399E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! (1) = Includes all active systems placed during the period. (2) = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units (3) = Calculation: Inactive Systems / Ending of Prior Period Installed Base 2017 2018 2019 2020 2021 2022 2022 2022 2022 NeuroStar REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total U.S. NeuroStar Revenue ($000) $1,321.41 $2,509.8959999999997 $2,828.9520000000002 $3,459.297 $2,373 $3,568.15 $3,908 $4,754 $3,350 $4,628 $4,616 $5,413 #REF! #REF! #REF! #REF! #REF! #REF! $2,612 $2,815 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $0 $3,850 $4,489 $3,597 $4,523.6000000000004 $0 $2,846 $0 $0 $0 $0 $18,007.110260000001 YoY D 0.79580902218085225 0.42163260947864001 0.38143029644900284 0.37426766189777871 0.41171512852928771 0.29703067415887774 0.18116683725690885 0.13862010938157332 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.08 #REF! 0.50612557427258809 0.63978685612788633 1.08 -0.12138769934609128 0.14107778342653798 -0.22075389948006929 1.08 -1 -0.36600579193584315 -1 1.08 #DIV/0! -1 #DIV/0! U.S. NeuroStar Capital Revenue ($000) (1) $1,083.820000000001 $1,974.9379999999999 $2,219.7345 $2,942.4469999999997 $1,908.6499999999999 $3,267.65 $3,427.6 $4,337.7 $2,938.5729999999999 $4,034.599999999995 $4,264 $4,958.8 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $16,195.687760000001 YoY D 0.76223960882001518 0.65455826967732667 0.54414863579405548 0.47418118321247604 0.53960809996594405 0.23454470338010469 0.24401913875598091 0.14318648131498279 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! U.S. NeuroStar Operating Lease Revenue ($000) (2) $229.8 $293.95800000000003 $289 $234 $258 $181 $269 $231 $182 $187 $184 $176.7 #REF! #REF! #REF! #REF! #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $730.13850000000002 YoY D 0.13 -0.38426577946509366 -6.9204152249134898E-2 -0.02 -0.29457364341085268 3.3149171270718147E-2 -0.31 -0.23506493506493509 #REF! #REF! #REF! #REF! -0.3 #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! U.S. NeuroStar Other ($000) (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $119.5 $210.995 $185 $228.95 $407.25 $167.084 $278 #REF! #REF! #REF! #REF! #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $1,081.2840000000001 YoY D NM -0.50414937759336098 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.39 -0.20811393634920261 0.50270270270270268 #REF! #REF! #REF! #REF! #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 (1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases (2) = Revenue derived from Operating Lease revenue amortization during the period (3) = Revenue derived from Treatment Coils in U.S. 2017 2018 2019 2020 2021 2022 2023 2024 2025 Treatment Session REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Update/Unhide Total U.S. Treatment Session Revenues ($000) $5,749.6779800000004 $7,388.1369999999997 $7,228.5863399999998 $8,025.3639999999996 $7,239.5479999999998 $8,919.991 $9,218 $9,909 $8,777.6730000000007 $10,847.352000000001 $10,251.888000000001 $11,243 #REF! #REF! #REF! #REF! #REF! $10,801 #REF! #REF! $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $9,612 $0 $0 $0 $0 $41,120.22219 $0 $34,852.260719999998 YoY D 0.26 0.20733968522781865 0.27521476073287099 0.2347103508326851 0.21246146858892301 0.21607207899649228 0.11215968756780215 0.13462508830356246 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 4.5693639477826231E-2 #REF! #REF! 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 -9.6871182937141809E-2 -1 -1 -1 -1 #DIV/0! #DIV/0! #DIV/0! Active Sites(End of Period) 0 671 690 725 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 Average Revenue per Active Site ($000) (1) $8.8866738485316894 $11.010636363636364 $10.476212086956522 $11.069467586206896 $0 $14.504065040650406 $14.470957613814758 $14.593519882179676 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $10.511582969432315 $12.001111111111111 $11.16280281828074 $12.182826533044421 $9.8735130761209611 $11.28 $11.364000000000001 $11.516928769657724 $9.6666666666666661 $11.391304347826088 $11.916058394160585 $13.237544483985765 $8.3626239777275089 $0 $11.39 $0 $0 $0 $0 $0 YoY D 8.3314035681520959E-2 3.7291842237985096E-2 7.8306599149118972E-2 4.3315855890089239E-2 NM #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -6.0701598909209099E-2 -6.0087028978798328E-2 1.8023894625261182E-2 -5.4658724851784697E-2 -2.0949626324448987E-2 9.8674067221709624E-3 4.8579584139438914E-2 0.14939883268716059 -0.13490096782129213 -1 -4.414701378254212E-2 -1 -1 #DIV/0! -1 #DIV/0! (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) Q1 2023 15.5 Q2 2023 17.600000000000001 Q3 2023 17.899999999999999 Q4 2023 20.3 Q1 2024 17.399999999999999 Q2 2024 16.5 Q3 2024 18.5 Q4 2024 22.5 Q1 2025 32 Q2 2025 37 Neuronetics, Inc. Supplemental Financial and Operating Information For the period ended March 31, 2025 2017 2018 2019 2020 2017 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2023 2024 Revenue ($ thousands) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY NeuroStar Capital (1) $1,051.820000000003 $1,927.3699999999997 $2,243.19 $2,990.2869999999994 $1,908.65 $3,267.7 $3,427.723 $4,337.75 $2,938.8229999999999 $4,034.659999999998 $4,264.321800000002 $4,958.7665800000004 $2,410.320000000002 $2,223.8835899999999 $2,438.3874999999998 $3,445.80141 $8,211.9290000000001 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $16,195.687760000001 $10,518.104500000001 #REF! $12,941.823 $12,941.823 $12,941.823 $12,941.823 YoY Change 0.76 0.65 0.54 0.47 0.53973908259764736 0.2345276494170212 0.24398388667929116 0.14316559967725206 -0.17993291872290362 -0.44872404417776013 -0.4281498363363665 -0.30510917293469386 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.25142244334511443 -0.35056141759057968 #REF! 0.56999999999999995 0.56999999999999995 0.56999999999999995 0.56999999999999995 Sales $1,876 $3,277 $3,538 $4,385 $2,451 $3,754 $2,969 $4,070.4648999999999 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $13,244.464899999999 $13,244.464899999999 $13,244.464899999999 $13,076 $13,076 $13,076 $13,076 YoY 1.3318827646177938 0.9477318833436239 0.32356153513523145 0.3612288385696758 0.306503198294243 0.1455599633811413 -0.16082532504239688 -7.1729783352337484E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.2883519424900403E-2 1.2883519424900403E-2 1.2883519424900403E-2 0.59231771244003695 0.59231771244003695 0.59231771244003695 0.59231771244003695 Sales-Type-Leases $0 $0 $0 $0 $450 $350 $1,283 $996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $3,079 $3,079 $3,079 $0 $0 $0 $0 YoY nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm Other NeuroStar $32.35 $-9.65 $-,110.6 $-42.3 $37.573 $-69.5 $12.5 $-,107.69926 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $-,127.12626 $-,127.12626 $-,127.12626 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 YoY -0.41530508964719492 -1.2028674739320553 3.7153119737375082 -0.11580267558528445 0.16145285935084996 6.2020725388601035 -1.1130198915009042 1.5460817966903075 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -2.3607834101382341E-2 -2.3607834101382341E-2 -2.3607834101382341E-2 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 NeuroStar Operating Lease (2) $215 $293.95800000000003 $289 $234 $258 $181.13883999999999 $269 $231 $181.94399999999999 $187.08323999999999 $184.44399999999999 $176.66726 $155.417 $114.16689 $87.917000000000002 $79.167000000000002 $1,031.9580000000001 #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $730.13850000000002 $436.66789000000006 $279 $939 $939 $939 $939 YoY Change 0.13 -0.38379346709393869 -6.9204152249134898E-2 -0.02 -0.29479069767441868 3.2816816095322165E-2 -0.3143345724907064 -0.23520666666666667 -0.14579760805522568 -0.38975351292825589 -0.52334041768775341 -0.5518864106456397 #REF! #REF! -0.65876906627842169 7.3679689769727164E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.22350933218443014 -0.40193827609419308 -0.36107049226816301 -0.1 -0.1 -0.1 -0.1 Other (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $120 $210.995 $185 $228.95 $407.25 $167.084 $278 $29 $0 $15 $95.5 $852.0675 #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $1,081.2840000000001 $139.5 #REF! $722 $722 $722 $722 YoY Change NM -0.50207468879668049 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.3937499999999998 -0.20811393634920261 0.50270270270270268 -0.87333478925529595 -1 -0.91022479710804149 -0.65647482014388492 #REF! 1 19.333333333333332 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 0.49867150846506236 -0.87098671579344555 #REF! -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 Total U.S. NeuroStar Advanced Therapy System Revenues $1,274.820000000003 $2,462.3279999999995 $2,852.4075000000003 $3,507.1369999999993 $2,372.65 $3,568 $3,907.7179999999998 $4,753.75 $3,349.7169999999996 $4,628.3992399999997 $4,615.5601800000004 $5,413.4338400000006 $2,594.4490000000001 $2,338.504799999999 $2,541.3044999999997 $3,620.4684099999999 $10,095.9545 $1,755.2459999999999 $2,577.2649900000001 $2,611.58916 $2,815.2192999999997 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $3,850 $4,489 $3,597 $4,523.6000000000004 $3,310 $4,000 $4,108 $3,849 $2,846 $18,007.110260000001 $11,094.272390000002 #REF! $16,575 $16,460 $16,459.599999999999 $15,267 YoY Change 0.8 0.42 0.38 0.37 0.41180410089983743 0.29719709641255587 0.18113952439761527 0.13877125216934005 -0.22547218167982541 -0.49484684471601459 -0.4494049690843811 -0.33120667638934342 -0.32346097379443584 0.1023136634757349 2.7656921868276729E-2 -0.22241572603584747 1.08 0.70021708555471407 0.50636250917812808 0.63965911998400982 5.7103727438351903E-2 2.4439121463739388E-2 -8.566344687341132E-2 -2.0017331022530227E-2 -0.24462163242482127 1.6776817488561191E-2 -0.11005199306759095 -0.16616117850953205 -0.14018126888217519 -1 -1 -1 0.23311033760186262 -0.38389490430098572 #REF! 0.7 -0.01 -0.01 -7.2456195776325005E-2 Total U.S. Treatment Sessions Revenues $5,748.7510000000002 $7,386.4830000000002 $7,227.3850000000002 $8,023.9769999999999 $7,239.5487700000012 $8,920 $9,218 $9,909 $8,777.6730000000007 $10,847.351000000001 $10,251.888499999999 $11,243.30969 $8,193.4259999999995 $6,546.6486100000002 $9,083.3856099999994 $11,028.800499999999 $28,386.595999999998 $9,628.61 $10,801 $10,258.61579 $11,244.748890000001 $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $12,988 $11,660 $13,326 $12,858 $9,612 $41,120.22219 $34,852.260719999998 $41,932.974679999999 $45,077 $50,896 $50,896 $50,832 YoY Change 0.25932550740152105 0.20761125423290072 0.27542672764769005 0.23492377906865891 0.21246133963125424 0.21607073991031389 0.11215974180950306 0.13465634170955698 -6.6560579324383751E-2 -0.39647489880248188 -0.11397928196351337 -1.9078829625300497E-2 0.17516286837764827 0.64985180104236573 0.12938239445721389 1.9580405865533779E-2 -1.6607896674597833E-2 4.5693639477826231E-2 0.1564476273265325 0.10716567544444278 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 0.14993646928599191 -1.7157752744486277E-2 7.0378640620732957E-2 3.2787675304021047E-2 -0.25993224514936863 -1 -1 -1 0.16530796582310758 -0.15243014595199111 0.20316369193051309 7.0000000000000007E-2 0.13 0.13 -1.2574662055957475E-3 Total Clinic Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $0 $0 $0 $0 $0 $0 $0 $4,445 $18,659 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $0 $0 $4,445 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 na n/a n/a n/a -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0 0 na Total U.S. Other Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $471 $486 $554 $469 $495 $470 $488 $490 $366 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $1,980 $1,980 $1,943 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.15959298532413202 6.7833062625201279E-2 0.24213998926647551 4.9217002237136542E-2 8.7607748970112365E-2 5.3801073926432297E-2 9.1722595078299829E-2 9.6196868008948444E-2 -0.26060606060606062 -1 -1 -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0.13 0.13 -1.8686868686868641E-2 Total U.S. Revenues $7,346.9226500000004 $10,177.2872 $10,421.701070000001 $11,884.24583 $9,972.814600000012 $12,897.737710000001 $13,518.360389999998 $15,089 $12,545.759 $15,890 $15,293.75468 $17,030 $11,177.5 $9,267.1140899999991 $12,028.93211 $15,046.68909999998 $39,829.898270000005 $11,801.763999999999 $13,809.378989999999 $13,280 $14,556.26310000001 $13,516.902740000001 $16,131.57429 $16,243.556370000002 $17,512.8 $14,964 $17,289 $17,211 $19,871.599999999999 $16,793 $16,130 $17,922 $21,642 $31,483 $0 $0 $0 $60,760.108459999996 $47,519.165110000002 $53,447.169300000001 $63,406 $69,336 $69,335.600000000006 $72,487 YoY Change 0.35 0.26 0.29713568823366732 0.26966407594077846 0.25808829884949591 0.23199900302515908 0.13133207273519076 0.12863675525217055 -0.10909734516660174 -0.41679584078036502 -0.21347423430751666 -0.11649624721080454 5.5892565569626962E-2 0.49014880532241301 0.10400490073095936 -3.2569477312064055E-2 0.14532901522179253 0.16816073349001481 0.22315936521084345 0.20313055411068426 0.10705834671116365 7.1749085934997181E-2 5.9558609454931632E-2 0.1346900552738568 4.100193187034562E-2 -6.9908563995091377E-3 2.336576675346036E-2 0.2357818281485542 0.87476924909188347 -1 -1 -1 0.18034051052656319 -0.2179216542827086 0.12474975467850768 0.19 0.09 0.09 4.5451398704273061E-2 Total International Revenues $132.1 $83.5 $92.5 $272.23500000000001 $179.732 $354 $219.30699999999999 $545.61800000000005 $182 $682 $706.37199999999996 $325.548 $298.822 $473.91300000000001 $418.98599999999999 $532.87300000000005 $580.33500000000004 $486.28800000000001 $393.93900000000002 $519 $466.178 $663.74939000000006 $197.87039000000001 $253.36739 $686 $576 $321 $673.3 $441.6 $624 $320 $608 $851 $492 $1,895.7699999999998 $1,724.5940000000001 $1,865.4050000000002 $1,800 $2,012 $2,011.9 $2,402 YoY Change 0.36057532172596529 3.25 1.3708864864864863 1.004216944918912 1.2618787973204482E-2 0.92655367231638408 2.2209277405645969 -0.40334079887393748 0.6418791208791208 -0.30511290322580642 -0.40684794980548489 0.63684925110889967 0.62735006124047099 -0.16875249254610025 0.23870487319385369 -0.12516115472166922 0.36493063781133817 -0.49771312309773852 -0.51181620423892094 0.4715409135566242 -0.13220259230671394 0.62227405525404778 1.6574059116289588 -0.35626822157434401 2.1535794718957191 0.26298810592791755 -0.11370262390670549 0.24052478134110777 -0.21153846153846156 -1 -1 -1 0.45904444083572726 -9.0293653766015725E-2 8.1648782264115649E-2 -0.03 0.12 0.12 0.19389631691435949 Total Revenues $7,479.226500000008 $10,260.52872 $10,514.201070000001 $12,156.48083 $10,151.813460000001 $13,252.403710000001 $13,737 $15,634.618 $12,728.371999999999 $16,571.754240000002 $16,000.126679999999 $17,355.547999999999 $11,476 $9,741 $12,447.918110000001 $15,578.941909999998 $40,410.233270000004 $12,288.52 $14,203.31799 $13,799 $15,022.204310000001 $14,180.652129999999 $16,329.445 $16,497.5124 $18,198.8 $15,540 $17,610 $17,884.3 $20,313.199999999997 $17,417 $16,450 $18,530 $22,493 $31,975 $0 $0 $0 $62,655.878459999993 $49,243.860019999993 $55,312 $65,206 $71,348 $71,347.5 $74,890 YoY Change 0.35 0.29159072321177626 0.30651867018175616 0.28611382016221221 0.2538027860886245 0.25047158256243618 0.16474679187595531 0.11007176510484618 -9.8392158871535185E-2 -0.41219258631728306 -0.22201127785070751 -0.10236531223329859 7.0760892296967581E-2 0.45809649830612864 0.10853878359905123 -3.5736547656207041E-2 0.15401954109569194 0.14969227693817189 0.19555854772084924 0.21146002440436762 9.5859334079863689E-2 7.8419995290715638E-2 8.4060406585904301E-2 0.11618348462535977 6.6600855081112798E-2 -2.8799735892303113E-3 1.8199002132008646E-2 0.23596061278765634 0.83585003157834303 -1 -1 -1 0.18720207332511252 -0.21405842148653842 0.12322632664327049 0.18 0.09 0.09 4.9651354287115979E-2 2018 2019 2020 2020 2020 2020 2021 2020 2020 2020 2022 2020 2020 2020 2023 2020 2020 2020 2024 2025 2019 2020 2021 2022 2023 2023 2024 U.S. Operating and Financial Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY Active Installed Base Active Installed Base - Beginning of Period 647 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! 647 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 907 #REF! #REF! 752 752 752 752 Active Installed Base - End of Period 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! 752 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1085 #REF! 752 907 907 907 907 Total NeuroStar Systems 14 25 30 40 24 43 47 61 43 61 68 78 #REF! #REF! #REF! #REF! 109 23 36 40 48 46 59 50 58 49 54 43 58 40 50 48 47 31 250 #REF! 147 213 204 204 185 YoY Change 0.71428571428571419 0.72 0.56666666666666665 0.52499999999999991 0.79166666666666674 0.41860465116279078 0.44680851063829796 0.27868852459016402 #REF! #REF! #REF! #REF! -0.39473684210526316 2.857142857142847E-2 2.564102564102555E-2 -0.11111111111111116 1 0.63888888888888884 0.25 0.20833333333333326 6.5217391304347894E-2 -8.4745762711864403E-2 -0.14000000000000001 0 -0.32203389830508478 0 -0.17241379310344829 -0.18965517241379315 -0.22499999999999998 -1 -1 -1 #REF! #REF! #REF! 0.44897959183673503 -0.04 -0.04 -9.3137254901960786E-2 Active Sites Active Sites - Beginning of Period 0 615 637 679 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 916 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1081 1001 1044 1081 #REF! #REF! 916 959 959 959 959 Active Sites - End of Period 615 637 679 707 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 #REF! #REF! 0 1101 1101 1101 1101 NeuroStar System Average Selling Price ($) (4) $75,077.285714285739 $77,094.799999999988 $74,773 $74,757.174999999988 $79,527.83333333343 $75,993.23255813954 $72,930.276595744683 $71,110.655737704918 $68,344.72093023255 $66,132.229508196717 $62,706.355588235296 $63,573.930512820516 #REF! #REF! #REF! #REF! $75,338.798165137618 $69,101.260869565216 $67,801.336111111115 $56,914.728999999999 $52,358.735416666663 $75,760 $72,410.547796610161 $72,755.848399999988 $0 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $64,782.75104000001 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 YoY Change 5.926955905121245E-2 -1.4291194012904018E-2 -2.4644235275504744E-2 -4.8778184332073482E-2 -0.14061074459666201 -0.12975919795193602 -0.14018760773637229 -0.10598587717548236 #REF! #REF! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 Sequential Change 6.3805358259369171E-2 -4.4438446996812098E-2 -4.0302997944419161E-2 -2.4950143383193124E-2 -3.8896207309276565E-2 -3.237252843997096E-2 -5.1803393677160137E-2 1.3835518209385222E-2 #REF! #REF! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0 Average Revenue Per Active Site ($) (1) $8,885.2411128284384 $11,008.171385991058 $10,474.471014492754 $11,067.55448275862 $9,627.595345744696 $11,421.254801536492 $11,296.568627450981 $11,548.951048951049 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $43,874.182380216385 $10,511.582969432315 $12,001.111111111111 $11,162.802818280739 $12,182.826533044421 $9,873.5130761209602 $11,280 $11,364 $11,516.928769657725 $9,666.6666666666661 $11,391.304347826088 $11,916.58394160586 $13,237.544483985765 $11,299.808595789107 $10,000 $11,390 $11,027.444253859348 $8,362.6239777275096 $0 $11,390 $0 YoY Change 8.3488834160617253E-2 3.7525162087421959E-2 7.8485835878561394E-2 4.3496200261978757E-2 NA #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.11614813917964395 0.62052110235716817 9.2514634028795673E-2 .4% -6.0701598909209231E-2 -6.0087028978798251E-2 1.8023894625261105E-2 -5.4658724851784579E-2 -2.0949626324448856E-2 9.8674067221709016E-3 4.8579584139438969E-2 0.14939883268716048 1.756081186977676E-3 -0.12002815909890885 -1.1021060579286424E-2 -4.2501306171829678E-2 -0.13490096782129202 -1 -4.4147013782542266E-2 -1 Use Total Systems Recognized from the Q or K #DIV/0! (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) Three Months EndedMarch 31, 2024 2025 Revenues $17,417 $31,975 YOY Growth 0.83585003157834303 Gross Profit 13088 15738 Gross Margin 0.75144973301946372 0.49219702892885064 Operating Expenses: Sales and Marketing 11641 11999 % of Revenues 0.66836998334960096 0.37526192337763881 General and Administrative 5957 13137 % of Revenues 0.34202216225526783 0.41085222830336199 Research and Development 2349 1616 % of Revenues 0.1348682321869438 5.0539483971853011E-2 Total Operating Expenses 19947 26752 Loss from Operations $-6,859 $,-11,014 ($ in thousands) % of Revenues -0.39381064477234884 -0.34445660672400313 As of March 31, 2025 Cash and Cash Equivalents $20,224 enter Other Assets $,121,764 calculates Total Assets $,141,988 enter Long-term debt, net $55,341 enter Convertible Preferred Stock Warrant Liability $0 11703 Convertible Preferred Stock $0 0.7530888030888031 Accumulated Deficit $-,432,464 enter Total Stockholders’ Equity $35,452 enter 2017 2018 2019 2020 2021 2022 2022 2022 2022 UNIT SALES / ACTIVE SITES 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) 20 29 32 42 30 47 48 65 43 61 68 78 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 46 59 50 58 0 49 54 43 58 0 31 0 0 0 0 250 YoY D 0.5 0.6206896551724137 0.5 0.54761904761904767 0.43333333333333335 0.2978723404255319 0.41666666666666674 0.19999999999999996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -1 -0.16949152542372881 8.0000000000000071E-2 -0.25862068965517238 #DIV/0! -1 -0.42592592592592593 -1 -1 #DIV/0! -1 #DIV/0! Beginning Active Installed Base 0 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Ending Active Installed Base 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.16393442622950816 0.18260869565217397 0.18344827586206902 0.2061170212765957 0.19206145966709354 0.19607843137254899 0.2027972027972027 0.25137816979051819 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Net Active Installed Base Change 24 19 35 27 29 35 42 49 24 45 56 53 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.20833333333333326 0.84210526315789469 0.19999999999999996 0.81481481481481488 -0.17241379310344829 0.28571428571428581 0.33333333333333326 8.163265306122458E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Active Sites (End of Period) 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 YoY D 0.1983739837398375 0.22135007849293564 0.22680412371134029 0.23055162659123063 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -100.0% -100.0% -100.0% -100.0% #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Inactive Systems (Calculation) (2) -4 10 -3 15 -1 -12 -6 -16 -19 -16 -12 -25 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Inactive System Churn % (Calculation) (3) -0.1% -1.5% -0.7% -1.9% -2.0948180815876516E-2 -1.7185821697099892E-2 -1.2295081967213115E-2 -2.4224806201550399E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! (1) = Includes all active systems placed during the period. (2) = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units (3) = Calculation: Inactive Systems / Ending of Prior Period Installed Base 2017 2018 2019 2020 2021 2022 2022 2022 2022 NeuroStar REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total U.S. NeuroStar Revenue ($000) $1,321.41 $2,509.8959999999997 $2,828.9520000000002 $3,459.297 $2,373 $3,568.15 $3,908 $4,754 $3,350 $4,628 $4,616 $5,413 #REF! #REF! #REF! #REF! #REF! #REF! $2,612 $2,815 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $0 $3,850 $4,489 $3,597 $4,523.6000000000004 $0 $2,846 $0 $0 $0 $0 $18,007.110260000001 YoY D 0.79580902218085225 0.42163260947864001 0.38143029644900284 0.37426766189777871 0.41171512852928771 0.29703067415887774 0.18116683725690885 0.13862010938157332 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.08 #REF! 0.50612557427258809 0.63978685612788633 1.08 -0.12138769934609128 0.14107778342653798 -0.22075389948006929 1.08 -1 -0.36600579193584315 -1 1.08 #DIV/0! -1 #DIV/0! U.S. NeuroStar Capital Revenue ($000) (1) $1,083.820000000001 $1,974.9379999999999 $2,219.7345 $2,942.4469999999997 $1,908.6499999999999 $3,267.65 $3,427.6 $4,337.7 $2,938.5729999999999 $4,034.599999999995 $4,264 $4,958.8 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $16,195.687760000001 YoY D 0.76223960882001518 0.65455826967732667 0.54414863579405548 0.47418118321247604 0.53960809996594405 0.23454470338010469 0.24401913875598091 0.14318648131498279 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! U.S. NeuroStar Operating Lease Revenue ($000) (2) $229.8 $293.95800000000003 $289 $234 $258 $181 $269 $231 $182 $187 $184 $176.7 #REF! #REF! #REF! #REF! #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $730.13850000000002 YoY D 0.13 -0.38426577946509366 -6.9204152249134898E-2 -0.02 -0.29457364341085268 3.3149171270718147E-2 -0.31 -0.23506493506493509 #REF! #REF! #REF! #REF! -0.3 #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! U.S. NeuroStar Other ($000) (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $119.5 $210.995 $185 $228.95 $407.25 $167.084 $278 #REF! #REF! #REF! #REF! #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $1,081.2840000000001 YoY D NM -0.50414937759336098 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.39 -0.20811393634920261 0.50270270270270268 #REF! #REF! #REF! #REF! #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 (1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases (2) = Revenue derived from Operating Lease revenue amortization during the period (3) = Revenue derived from Treatment Coils in U.S. 2017 2018 2019 2020 2021 2022 2023 2024 2025 Treatment Session REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Update/Unhide Total U.S. Treatment Session Revenues ($000) $5,749.6779800000004 $7,388.1369999999997 $7,228.5863399999998 $8,025.3639999999996 $7,239.5479999999998 $8,919.991 $9,218 $9,909 $8,777.6730000000007 $10,847.352000000001 $10,251.888000000001 $11,243 #REF! #REF! #REF! #REF! #REF! $10,801 #REF! #REF! $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $9,612 $0 $0 $0 $0 $41,120.22219 $0 $34,852.260719999998 YoY D 0.26 0.20733968522781865 0.27521476073287099 0.2347103508326851 0.21246146858892301 0.21607207899649228 0.11215968756780215 0.13462508830356246 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 4.5693639477826231E-2 #REF! #REF! 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 -9.6871182937141809E-2 -1 -1 -1 -1 #DIV/0! #DIV/0! #DIV/0! Active Sites(End of Period) 0 671 690 725 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 Average Revenue per Active Site ($000) (1) $8.8866738485316894 $11.010636363636364 $10.476212086956522 $11.069467586206896 $0 $14.504065040650406 $14.470957613814758 $14.593519882179676 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $10.511582969432315 $12.001111111111111 $11.16280281828074 $12.182826533044421 $9.8735130761209611 $11.28 $11.364000000000001 $11.516928769657724 $9.6666666666666661 $11.391304347826088 $11.916058394160585 $13.237544483985765 $8.3626239777275089 $0 $11.39 $0 $0 $0 $0 $0 YoY D 8.3314035681520959E-2 3.7291842237985096E-2 7.8306599149118972E-2 4.3315855890089239E-2 NM #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -6.0701598909209099E-2 -6.0087028978798328E-2 1.8023894625261182E-2 -5.4658724851784697E-2 -2.0949626324448987E-2 9.8674067221709624E-3 4.8579584139438914E-2 0.14939883268716059 -0.13490096782129213 -1 -4.414701378254212E-2 -1 -1 #DIV/0! -1 #DIV/0! (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) Q1 2023 15.5 Q2 2023 17.600000000000001 Q3 2023 17.899999999999999 Q4 2023 20.3 Q1 2024 17.399999999999999 Q2 2024 16.5 Q3 2024 18.5 Q4 2024 22.5 Q1 2025 32 Q2 2025 37
Financial Position ($ in thousands) ($ in thousands) Neuronetics, Inc. Supplemental Financial and Operating Information For the period ended March 31, 2025 2017 2018 2019 2020 2017 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2023 2024 Revenue ($ thousands) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY NeuroStar Capital (1) $1,051.820000000003 $1,927.3699999999997 $2,243.19 $2,990.2869999999994 $1,908.65 $3,267.7 $3,427.723 $4,337.75 $2,938.8229999999999 $4,034.659999999998 $4,264.321800000002 $4,958.7665800000004 $2,410.320000000002 $2,223.8835899999999 $2,438.3874999999998 $3,445.80141 $8,211.9290000000001 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $16,195.687760000001 $10,518.104500000001 #REF! $12,941.823 $12,941.823 $12,941.823 $12,941.823 YoY Change 0.76 0.65 0.54 0.47 0.53973908259764736 0.2345276494170212 0.24398388667929116 0.14316559967725206 -0.17993291872290362 -0.44872404417776013 -0.4281498363363665 -0.30510917293469386 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.25142244334511443 -0.35056141759057968 #REF! 0.56999999999999995 0.56999999999999995 0.56999999999999995 0.56999999999999995 Sales $1,876 $3,277 $3,538 $4,385 $2,451 $3,754 $2,969 $4,070.4648999999999 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $13,244.464899999999 $13,244.464899999999 $13,244.464899999999 $13,076 $13,076 $13,076 $13,076 YoY 1.3318827646177938 0.9477318833436239 0.32356153513523145 0.3612288385696758 0.306503198294243 0.1455599633811413 -0.16082532504239688 -7.1729783352337484E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.2883519424900403E-2 1.2883519424900403E-2 1.2883519424900403E-2 0.59231771244003695 0.59231771244003695 0.59231771244003695 0.59231771244003695 Sales-Type-Leases $0 $0 $0 $0 $450 $350 $1,283 $996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $3,079 $3,079 $3,079 $0 $0 $0 $0 YoY nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm Other NeuroStar $32.35 $-9.65 $-,110.6 $-42.3 $37.573 $-69.5 $12.5 $-,107.69926 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $-,127.12626 $-,127.12626 $-,127.12626 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 YoY -0.41530508964719492 -1.2028674739320553 3.7153119737375082 -0.11580267558528445 0.16145285935084996 6.2020725388601035 -1.1130198915009042 1.5460817966903075 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -2.3607834101382341E-2 -2.3607834101382341E-2 -2.3607834101382341E-2 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 NeuroStar Operating Lease (2) $215 $293.95800000000003 $289 $234 $258 $181.13883999999999 $269 $231 $181.94399999999999 $187.08323999999999 $184.44399999999999 $176.66726 $155.417 $114.16689 $87.917000000000002 $79.167000000000002 $1,031.9580000000001 #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $730.13850000000002 $436.66789000000006 $279 $939 $939 $939 $939 YoY Change 0.13 -0.38379346709393869 -6.9204152249134898E-2 -0.02 -0.29479069767441868 3.2816816095322165E-2 -0.3143345724907064 -0.23520666666666667 -0.14579760805522568 -0.38975351292825589 -0.52334041768775341 -0.5518864106456397 #REF! #REF! -0.65876906627842169 7.3679689769727164E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.22350933218443014 -0.40193827609419308 -0.36107049226816301 -0.1 -0.1 -0.1 -0.1 Other (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $120 $210.995 $185 $228.95 $407.25 $167.084 $278 $29 $0 $15 $95.5 $852.0675 #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $1,081.2840000000001 $139.5 #REF! $722 $722 $722 $722 YoY Change NM -0.50207468879668049 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.3937499999999998 -0.20811393634920261 0.50270270270270268 -0.87333478925529595 -1 -0.91022479710804149 -0.65647482014388492 #REF! 1 19.333333333333332 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 0.49867150846506236 -0.87098671579344555 #REF! -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 Total U.S. NeuroStar Advanced Therapy System Revenues $1,274.820000000003 $2,462.3279999999995 $2,852.4075000000003 $3,507.1369999999993 $2,372.65 $3,568 $3,907.7179999999998 $4,753.75 $3,349.7169999999996 $4,628.3992399999997 $4,615.5601800000004 $5,413.4338400000006 $2,594.4490000000001 $2,338.504799999999 $2,541.3044999999997 $3,620.4684099999999 $10,095.9545 $1,755.2459999999999 $2,577.2649900000001 $2,611.58916 $2,815.2192999999997 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $3,850 $4,489 $3,597 $4,523.6000000000004 $3,310 $4,000 $4,108 $3,849 $2,846 $18,007.110260000001 $11,094.272390000002 #REF! $16,575 $16,460 $16,459.599999999999 $15,267 YoY Change 0.8 0.42 0.38 0.37 0.41180410089983743 0.29719709641255587 0.18113952439761527 0.13877125216934005 -0.22547218167982541 -0.49484684471601459 -0.4494049690843811 -0.33120667638934342 -0.32346097379443584 0.1023136634757349 2.7656921868276729E-2 -0.22241572603584747 1.08 0.70021708555471407 0.50636250917812808 0.63965911998400982 5.7103727438351903E-2 2.4439121463739388E-2 -8.566344687341132E-2 -2.0017331022530227E-2 -0.24462163242482127 1.6776817488561191E-2 -0.11005199306759095 -0.16616117850953205 -0.14018126888217519 -1 -1 -1 0.23311033760186262 -0.38389490430098572 #REF! 0.7 -0.01 -0.01 -7.2456195776325005E-2 Total U.S. Treatment Sessions Revenues $5,748.7510000000002 $7,386.4830000000002 $7,227.3850000000002 $8,023.9769999999999 $7,239.5487700000012 $8,920 $9,218 $9,909 $8,777.6730000000007 $10,847.351000000001 $10,251.888499999999 $11,243.30969 $8,193.4259999999995 $6,546.6486100000002 $9,083.3856099999994 $11,028.800499999999 $28,386.595999999998 $9,628.61 $10,801 $10,258.61579 $11,244.748890000001 $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $12,988 $11,660 $13,326 $12,858 $9,612 $41,120.22219 $34,852.260719999998 $41,932.974679999999 $45,077 $50,896 $50,896 $50,832 YoY Change 0.25932550740152105 0.20761125423290072 0.27542672764769005 0.23492377906865891 0.21246133963125424 0.21607073991031389 0.11215974180950306 0.13465634170955698 -6.6560579324383751E-2 -0.39647489880248188 -0.11397928196351337 -1.9078829625300497E-2 0.17516286837764827 0.64985180104236573 0.12938239445721389 1.9580405865533779E-2 -1.6607896674597833E-2 4.5693639477826231E-2 0.1564476273265325 0.10716567544444278 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 0.14993646928599191 -1.7157752744486277E-2 7.0378640620732957E-2 3.2787675304021047E-2 -0.25993224514936863 -1 -1 -1 0.16530796582310758 -0.15243014595199111 0.20316369193051309 7.0000000000000007E-2 0.13 0.13 -1.2574662055957475E-3 Total Clinic Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $0 $0 $0 $0 $0 $0 $0 $4,445 $18,659 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $0 $0 $4,445 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 na n/a n/a n/a -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0 0 na Total U.S. Other Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $471 $486 $554 $469 $495 $470 $488 $490 $366 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $1,980 $1,980 $1,943 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.15959298532413202 6.7833062625201279E-2 0.24213998926647551 4.9217002237136542E-2 8.7607748970112365E-2 5.3801073926432297E-2 9.1722595078299829E-2 9.6196868008948444E-2 -0.26060606060606062 -1 -1 -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0.13 0.13 -1.8686868686868641E-2 Total U.S. Revenues $7,346.9226500000004 $10,177.2872 $10,421.701070000001 $11,884.24583 $9,972.814600000012 $12,897.737710000001 $13,518.360389999998 $15,089 $12,545.759 $15,890 $15,293.75468 $17,030 $11,177.5 $9,267.1140899999991 $12,028.93211 $15,046.68909999998 $39,829.898270000005 $11,801.763999999999 $13,809.378989999999 $13,280 $14,556.26310000001 $13,516.902740000001 $16,131.57429 $16,243.556370000002 $17,512.8 $14,964 $17,289 $17,211 $19,871.599999999999 $16,793 $16,130 $17,922 $21,642 $31,483 $0 $0 $0 $60,760.108459999996 $47,519.165110000002 $53,447.169300000001 $63,406 $69,336 $69,335.600000000006 $72,487 YoY Change 0.35 0.26 0.29713568823366732 0.26966407594077846 0.25808829884949591 0.23199900302515908 0.13133207273519076 0.12863675525217055 -0.10909734516660174 -0.41679584078036502 -0.21347423430751666 -0.11649624721080454 5.5892565569626962E-2 0.49014880532241301 0.10400490073095936 -3.2569477312064055E-2 0.14532901522179253 0.16816073349001481 0.22315936521084345 0.20313055411068426 0.10705834671116365 7.1749085934997181E-2 5.9558609454931632E-2 0.1346900552738568 4.100193187034562E-2 -6.9908563995091377E-3 2.336576675346036E-2 0.2357818281485542 0.87476924909188347 -1 -1 -1 0.18034051052656319 -0.2179216542827086 0.12474975467850768 0.19 0.09 0.09 4.5451398704273061E-2 Total International Revenues $132.1 $83.5 $92.5 $272.23500000000001 $179.732 $354 $219.30699999999999 $545.61800000000005 $182 $682 $706.37199999999996 $325.548 $298.822 $473.91300000000001 $418.98599999999999 $532.87300000000005 $580.33500000000004 $486.28800000000001 $393.93900000000002 $519 $466.178 $663.74939000000006 $197.87039000000001 $253.36739 $686 $576 $321 $673.3 $441.6 $624 $320 $608 $851 $492 $1,895.7699999999998 $1,724.5940000000001 $1,865.4050000000002 $1,800 $2,012 $2,011.9 $2,402 YoY Change 0.36057532172596529 3.25 1.3708864864864863 1.004216944918912 1.2618787973204482E-2 0.92655367231638408 2.2209277405645969 -0.40334079887393748 0.6418791208791208 -0.30511290322580642 -0.40684794980548489 0.63684925110889967 0.62735006124047099 -0.16875249254610025 0.23870487319385369 -0.12516115472166922 0.36493063781133817 -0.49771312309773852 -0.51181620423892094 0.4715409135566242 -0.13220259230671394 0.62227405525404778 1.6574059116289588 -0.35626822157434401 2.1535794718957191 0.26298810592791755 -0.11370262390670549 0.24052478134110777 -0.21153846153846156 -1 -1 -1 0.45904444083572726 -9.0293653766015725E-2 8.1648782264115649E-2 -0.03 0.12 0.12 0.19389631691435949 Total Revenues $7,479.226500000008 $10,260.52872 $10,514.201070000001 $12,156.48083 $10,151.813460000001 $13,252.403710000001 $13,737 $15,634.618 $12,728.371999999999 $16,571.754240000002 $16,000.126679999999 $17,355.547999999999 $11,476 $9,741 $12,447.918110000001 $15,578.941909999998 $40,410.233270000004 $12,288.52 $14,203.31799 $13,799 $15,022.204310000001 $14,180.652129999999 $16,329.445 $16,497.5124 $18,198.8 $15,540 $17,610 $17,884.3 $20,313.199999999997 $17,417 $16,450 $18,530 $22,493 $31,975 $0 $0 $0 $62,655.878459999993 $49,243.860019999993 $55,312 $65,206 $71,348 $71,347.5 $74,890 YoY Change 0.35 0.29159072321177626 0.30651867018175616 0.28611382016221221 0.2538027860886245 0.25047158256243618 0.16474679187595531 0.11007176510484618 -9.8392158871535185E-2 -0.41219258631728306 -0.22201127785070751 -0.10236531223329859 7.0760892296967581E-2 0.45809649830612864 0.10853878359905123 -3.5736547656207041E-2 0.15401954109569194 0.14969227693817189 0.19555854772084924 0.21146002440436762 9.5859334079863689E-2 7.8419995290715638E-2 8.4060406585904301E-2 0.11618348462535977 6.6600855081112798E-2 -2.8799735892303113E-3 1.8199002132008646E-2 0.23596061278765634 0.83585003157834303 -1 -1 -1 0.18720207332511252 -0.21405842148653842 0.12322632664327049 0.18 0.09 0.09 4.9651354287115979E-2 2018 2019 2020 2020 2020 2020 2021 2020 2020 2020 2022 2020 2020 2020 2023 2020 2020 2020 2024 2025 2019 2020 2021 2022 2023 2023 2024 U.S. Operating and Financial Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY Active Installed Base Active Installed Base - Beginning of Period 647 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! 647 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 907 #REF! #REF! 752 752 752 752 Active Installed Base - End of Period 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! 752 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1085 #REF! 752 907 907 907 907 Total NeuroStar Systems 14 25 30 40 24 43 47 61 43 61 68 78 #REF! #REF! #REF! #REF! 109 23 36 40 48 46 59 50 58 49 54 43 58 40 50 48 47 31 250 #REF! 147 213 204 204 185 YoY Change 0.71428571428571419 0.72 0.56666666666666665 0.52499999999999991 0.79166666666666674 0.41860465116279078 0.44680851063829796 0.27868852459016402 #REF! #REF! #REF! #REF! -0.39473684210526316 2.857142857142847E-2 2.564102564102555E-2 -0.11111111111111116 1 0.63888888888888884 0.25 0.20833333333333326 6.5217391304347894E-2 -8.4745762711864403E-2 -0.14000000000000001 0 -0.32203389830508478 0 -0.17241379310344829 -0.18965517241379315 -0.22499999999999998 -1 -1 -1 #REF! #REF! #REF! 0.44897959183673503 -0.04 -0.04 -9.3137254901960786E-2 Active Sites Active Sites - Beginning of Period 0 615 637 679 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 916 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1081 1001 1044 1081 #REF! #REF! 916 959 959 959 959 Active Sites - End of Period 615 637 679 707 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 #REF! #REF! 0 1101 1101 1101 1101 NeuroStar System Average Selling Price ($) (4) $75,077.285714285739 $77,094.799999999988 $74,773 $74,757.174999999988 $79,527.83333333343 $75,993.23255813954 $72,930.276595744683 $71,110.655737704918 $68,344.72093023255 $66,132.229508196717 $62,706.355588235296 $63,573.930512820516 #REF! #REF! #REF! #REF! $75,338.798165137618 $69,101.260869565216 $67,801.336111111115 $56,914.728999999999 $52,358.735416666663 $75,760 $72,410.547796610161 $72,755.848399999988 $0 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $64,782.75104000001 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 YoY Change 5.926955905121245E-2 -1.4291194012904018E-2 -2.4644235275504744E-2 -4.8778184332073482E-2 -0.14061074459666201 -0.12975919795193602 -0.14018760773637229 -0.10598587717548236 #REF! #REF! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 Sequential Change 6.3805358259369171E-2 -4.4438446996812098E-2 -4.0302997944419161E-2 -2.4950143383193124E-2 -3.8896207309276565E-2 -3.237252843997096E-2 -5.1803393677160137E-2 1.3835518209385222E-2 #REF! #REF! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0 Average Revenue Per Active Site ($) (1) $8,885.2411128284384 $11,008.171385991058 $10,474.471014492754 $11,067.55448275862 $9,627.595345744696 $11,421.254801536492 $11,296.568627450981 $11,548.951048951049 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $43,874.182380216385 $10,511.582969432315 $12,001.111111111111 $11,162.802818280739 $12,182.826533044421 $9,873.5130761209602 $11,280 $11,364 $11,516.928769657725 $9,666.6666666666661 $11,391.304347826088 $11,916.58394160586 $13,237.544483985765 $11,299.808595789107 $10,000 $11,390 $11,027.444253859348 $8,362.6239777275096 $0 $11,390 $0 YoY Change 8.3488834160617253E-2 3.7525162087421959E-2 7.8485835878561394E-2 4.3496200261978757E-2 NA #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.11614813917964395 0.62052110235716817 9.2514634028795673E-2 .4% -6.0701598909209231E-2 -6.0087028978798251E-2 1.8023894625261105E-2 -5.4658724851784579E-2 -2.0949626324448856E-2 9.8674067221709016E-3 4.8579584139438969E-2 0.14939883268716048 1.756081186977676E-3 -0.12002815909890885 -1.1021060579286424E-2 -4.2501306171829678E-2 -0.13490096782129202 -1 -4.4147013782542266E-2 -1 Use Total Systems Recognized from the Q or K #DIV/0! (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) Three Months EndedMarch 31, 2024 2025 Revenues $17,417 $31,975 YOY Growth 0.83585003157834303 Gross Profit 13088 15738 Gross Margin 0.75144973301946372 0.49219702892885064 Operating Expenses: Sales and Marketing 11641 11999 % of Revenues 0.66836998334960096 0.37526192337763881 General and Administrative 5957 13137 % of Revenues 0.34202216225526783 0.41085222830336199 Research and Development 2349 1616 % of Revenues 0.1348682321869438 5.0539483971853011E-2 Total Operating Expenses 19947 26752 Loss from Operations $-6,859 $,-11,014 ($ in thousands) % of Revenues -0.39381064477234884 -0.34445660672400313 As of March 31, 2025 Cash and Cash Equivalents $20,224 enter Other Assets $,121,764 calculates Total Assets $,141,988 enter Long-term debt, net $55,341 enter Convertible Preferred Stock Warrant Liability $0 11703 Convertible Preferred Stock $0 0.7530888030888031 Accumulated Deficit $-,432,464 enter Total Stockholders’ Equity $35,452 enter 2017 2018 2019 2020 2021 2022 2022 2022 2022 UNIT SALES / ACTIVE SITES 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) 20 29 32 42 30 47 48 65 43 61 68 78 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 46 59 50 58 0 49 54 43 58 0 31 0 0 0 0 250 YoY D 0.5 0.6206896551724137 0.5 0.54761904761904767 0.43333333333333335 0.2978723404255319 0.41666666666666674 0.19999999999999996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -1 -0.16949152542372881 8.0000000000000071E-2 -0.25862068965517238 #DIV/0! -1 -0.42592592592592593 -1 -1 #DIV/0! -1 #DIV/0! Beginning Active Installed Base 0 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Ending Active Installed Base 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.16393442622950816 0.18260869565217397 0.18344827586206902 0.2061170212765957 0.19206145966709354 0.19607843137254899 0.2027972027972027 0.25137816979051819 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Net Active Installed Base Change 24 19 35 27 29 35 42 49 24 45 56 53 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.20833333333333326 0.84210526315789469 0.19999999999999996 0.81481481481481488 -0.17241379310344829 0.28571428571428581 0.33333333333333326 8.163265306122458E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Active Sites (End of Period) 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 YoY D 0.1983739837398375 0.22135007849293564 0.22680412371134029 0.23055162659123063 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -100.0% -100.0% -100.0% -100.0% #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Inactive Systems (Calculation) (2) -4 10 -3 15 -1 -12 -6 -16 -19 -16 -12 -25 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Inactive System Churn % (Calculation) (3) -0.1% -1.5% -0.7% -1.9% -2.0948180815876516E-2 -1.7185821697099892E-2 -1.2295081967213115E-2 -2.4224806201550399E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! (1) = Includes all active systems placed during the period. (2) = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units (3) = Calculation: Inactive Systems / Ending of Prior Period Installed Base 2017 2018 2019 2020 2021 2022 2022 2022 2022 NeuroStar REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total U.S. NeuroStar Revenue ($000) $1,321.41 $2,509.8959999999997 $2,828.9520000000002 $3,459.297 $2,373 $3,568.15 $3,908 $4,754 $3,350 $4,628 $4,616 $5,413 #REF! #REF! #REF! #REF! #REF! #REF! $2,612 $2,815 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $0 $3,850 $4,489 $3,597 $4,523.6000000000004 $0 $2,846 $0 $0 $0 $0 $18,007.110260000001 YoY D 0.79580902218085225 0.42163260947864001 0.38143029644900284 0.37426766189777871 0.41171512852928771 0.29703067415887774 0.18116683725690885 0.13862010938157332 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.08 #REF! 0.50612557427258809 0.63978685612788633 1.08 -0.12138769934609128 0.14107778342653798 -0.22075389948006929 1.08 -1 -0.36600579193584315 -1 1.08 #DIV/0! -1 #DIV/0! U.S. NeuroStar Capital Revenue ($000) (1) $1,083.820000000001 $1,974.9379999999999 $2,219.7345 $2,942.4469999999997 $1,908.6499999999999 $3,267.65 $3,427.6 $4,337.7 $2,938.5729999999999 $4,034.599999999995 $4,264 $4,958.8 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $16,195.687760000001 YoY D 0.76223960882001518 0.65455826967732667 0.54414863579405548 0.47418118321247604 0.53960809996594405 0.23454470338010469 0.24401913875598091 0.14318648131498279 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! U.S. NeuroStar Operating Lease Revenue ($000) (2) $229.8 $293.95800000000003 $289 $234 $258 $181 $269 $231 $182 $187 $184 $176.7 #REF! #REF! #REF! #REF! #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $730.13850000000002 YoY D 0.13 -0.38426577946509366 -6.9204152249134898E-2 -0.02 -0.29457364341085268 3.3149171270718147E-2 -0.31 -0.23506493506493509 #REF! #REF! #REF! #REF! -0.3 #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! U.S. NeuroStar Other ($000) (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $119.5 $210.995 $185 $228.95 $407.25 $167.084 $278 #REF! #REF! #REF! #REF! #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $1,081.2840000000001 YoY D NM -0.50414937759336098 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.39 -0.20811393634920261 0.50270270270270268 #REF! #REF! #REF! #REF! #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 (1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases (2) = Revenue derived from Operating Lease revenue amortization during the period (3) = Revenue derived from Treatment Coils in U.S. 2017 2018 2019 2020 2021 2022 2023 2024 2025 Treatment Session REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Update/Unhide Total U.S. Treatment Session Revenues ($000) $5,749.6779800000004 $7,388.1369999999997 $7,228.5863399999998 $8,025.3639999999996 $7,239.5479999999998 $8,919.991 $9,218 $9,909 $8,777.6730000000007 $10,847.352000000001 $10,251.888000000001 $11,243 #REF! #REF! #REF! #REF! #REF! $10,801 #REF! #REF! $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $9,612 $0 $0 $0 $0 $41,120.22219 $0 $34,852.260719999998 YoY D 0.26 0.20733968522781865 0.27521476073287099 0.2347103508326851 0.21246146858892301 0.21607207899649228 0.11215968756780215 0.13462508830356246 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 4.5693639477826231E-2 #REF! #REF! 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 -9.6871182937141809E-2 -1 -1 -1 -1 #DIV/0! #DIV/0! #DIV/0! Active Sites(End of Period) 0 671 690 725 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 Average Revenue per Active Site ($000) (1) $8.8866738485316894 $11.010636363636364 $10.476212086956522 $11.069467586206896 $0 $14.504065040650406 $14.470957613814758 $14.593519882179676 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $10.511582969432315 $12.001111111111111 $11.16280281828074 $12.182826533044421 $9.8735130761209611 $11.28 $11.364000000000001 $11.516928769657724 $9.6666666666666661 $11.391304347826088 $11.916058394160585 $13.237544483985765 $8.3626239777275089 $0 $11.39 $0 $0 $0 $0 $0 YoY D 8.3314035681520959E-2 3.7291842237985096E-2 7.8306599149118972E-2 4.3315855890089239E-2 NM #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -6.0701598909209099E-2 -6.0087028978798328E-2 1.8023894625261182E-2 -5.4658724851784697E-2 -2.0949626324448987E-2 9.8674067221709624E-3 4.8579584139438914E-2 0.14939883268716059 -0.13490096782129213 -1 -4.414701378254212E-2 -1 -1 #DIV/0! -1 #DIV/0! (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) Q1 2023 15.5 Q2 2023 17.600000000000001 Q3 2023 17.899999999999999 Q4 2023 20.3 Q1 2024 17.399999999999999 Q2 2024 16.5 Q3 2024 18.5 Q4 2024 22.5 Q1 2025 32 Q2 2025 37 Neuronetics, Inc. Supplemental Financial and Operating Information For the period ended March 31, 2025 2017 2018 2019 2020 2017 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2023 2024 Revenue ($ thousands) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY NeuroStar Capital (1) $1,051.820000000003 $1,927.3699999999997 $2,243.19 $2,990.2869999999994 $1,908.65 $3,267.7 $3,427.723 $4,337.75 $2,938.8229999999999 $4,034.659999999998 $4,264.321800000002 $4,958.7665800000004 $2,410.320000000002 $2,223.8835899999999 $2,438.3874999999998 $3,445.80141 $8,211.9290000000001 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $16,195.687760000001 $10,518.104500000001 #REF! $12,941.823 $12,941.823 $12,941.823 $12,941.823 YoY Change 0.76 0.65 0.54 0.47 0.53973908259764736 0.2345276494170212 0.24398388667929116 0.14316559967725206 -0.17993291872290362 -0.44872404417776013 -0.4281498363363665 -0.30510917293469386 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.25142244334511443 -0.35056141759057968 #REF! 0.56999999999999995 0.56999999999999995 0.56999999999999995 0.56999999999999995 Sales $1,876 $3,277 $3,538 $4,385 $2,451 $3,754 $2,969 $4,070.4648999999999 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $13,244.464899999999 $13,244.464899999999 $13,244.464899999999 $13,076 $13,076 $13,076 $13,076 YoY 1.3318827646177938 0.9477318833436239 0.32356153513523145 0.3612288385696758 0.306503198294243 0.1455599633811413 -0.16082532504239688 -7.1729783352337484E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.2883519424900403E-2 1.2883519424900403E-2 1.2883519424900403E-2 0.59231771244003695 0.59231771244003695 0.59231771244003695 0.59231771244003695 Sales-Type-Leases $0 $0 $0 $0 $450 $350 $1,283 $996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $3,079 $3,079 $3,079 $0 $0 $0 $0 YoY nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm Other NeuroStar $32.35 $-9.65 $-,110.6 $-42.3 $37.573 $-69.5 $12.5 $-,107.69926 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $-,127.12626 $-,127.12626 $-,127.12626 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 YoY -0.41530508964719492 -1.2028674739320553 3.7153119737375082 -0.11580267558528445 0.16145285935084996 6.2020725388601035 -1.1130198915009042 1.5460817966903075 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -2.3607834101382341E-2 -2.3607834101382341E-2 -2.3607834101382341E-2 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 NeuroStar Operating Lease (2) $215 $293.95800000000003 $289 $234 $258 $181.13883999999999 $269 $231 $181.94399999999999 $187.08323999999999 $184.44399999999999 $176.66726 $155.417 $114.16689 $87.917000000000002 $79.167000000000002 $1,031.9580000000001 #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $730.13850000000002 $436.66789000000006 $279 $939 $939 $939 $939 YoY Change 0.13 -0.38379346709393869 -6.9204152249134898E-2 -0.02 -0.29479069767441868 3.2816816095322165E-2 -0.3143345724907064 -0.23520666666666667 -0.14579760805522568 -0.38975351292825589 -0.52334041768775341 -0.5518864106456397 #REF! #REF! -0.65876906627842169 7.3679689769727164E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.22350933218443014 -0.40193827609419308 -0.36107049226816301 -0.1 -0.1 -0.1 -0.1 Other (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $120 $210.995 $185 $228.95 $407.25 $167.084 $278 $29 $0 $15 $95.5 $852.0675 #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $1,081.2840000000001 $139.5 #REF! $722 $722 $722 $722 YoY Change NM -0.50207468879668049 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.3937499999999998 -0.20811393634920261 0.50270270270270268 -0.87333478925529595 -1 -0.91022479710804149 -0.65647482014388492 #REF! 1 19.333333333333332 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 0.49867150846506236 -0.87098671579344555 #REF! -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 Total U.S. NeuroStar Advanced Therapy System Revenues $1,274.820000000003 $2,462.3279999999995 $2,852.4075000000003 $3,507.1369999999993 $2,372.65 $3,568 $3,907.7179999999998 $4,753.75 $3,349.7169999999996 $4,628.3992399999997 $4,615.5601800000004 $5,413.4338400000006 $2,594.4490000000001 $2,338.504799999999 $2,541.3044999999997 $3,620.4684099999999 $10,095.9545 $1,755.2459999999999 $2,577.2649900000001 $2,611.58916 $2,815.2192999999997 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $3,850 $4,489 $3,597 $4,523.6000000000004 $3,310 $4,000 $4,108 $3,849 $2,846 $18,007.110260000001 $11,094.272390000002 #REF! $16,575 $16,460 $16,459.599999999999 $15,267 YoY Change 0.8 0.42 0.38 0.37 0.41180410089983743 0.29719709641255587 0.18113952439761527 0.13877125216934005 -0.22547218167982541 -0.49484684471601459 -0.4494049690843811 -0.33120667638934342 -0.32346097379443584 0.1023136634757349 2.7656921868276729E-2 -0.22241572603584747 1.08 0.70021708555471407 0.50636250917812808 0.63965911998400982 5.7103727438351903E-2 2.4439121463739388E-2 -8.566344687341132E-2 -2.0017331022530227E-2 -0.24462163242482127 1.6776817488561191E-2 -0.11005199306759095 -0.16616117850953205 -0.14018126888217519 -1 -1 -1 0.23311033760186262 -0.38389490430098572 #REF! 0.7 -0.01 -0.01 -7.2456195776325005E-2 Total U.S. Treatment Sessions Revenues $5,748.7510000000002 $7,386.4830000000002 $7,227.3850000000002 $8,023.9769999999999 $7,239.5487700000012 $8,920 $9,218 $9,909 $8,777.6730000000007 $10,847.351000000001 $10,251.888499999999 $11,243.30969 $8,193.4259999999995 $6,546.6486100000002 $9,083.3856099999994 $11,028.800499999999 $28,386.595999999998 $9,628.61 $10,801 $10,258.61579 $11,244.748890000001 $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $12,988 $11,660 $13,326 $12,858 $9,612 $41,120.22219 $34,852.260719999998 $41,932.974679999999 $45,077 $50,896 $50,896 $50,832 YoY Change 0.25932550740152105 0.20761125423290072 0.27542672764769005 0.23492377906865891 0.21246133963125424 0.21607073991031389 0.11215974180950306 0.13465634170955698 -6.6560579324383751E-2 -0.39647489880248188 -0.11397928196351337 -1.9078829625300497E-2 0.17516286837764827 0.64985180104236573 0.12938239445721389 1.9580405865533779E-2 -1.6607896674597833E-2 4.5693639477826231E-2 0.1564476273265325 0.10716567544444278 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 0.14993646928599191 -1.7157752744486277E-2 7.0378640620732957E-2 3.2787675304021047E-2 -0.25993224514936863 -1 -1 -1 0.16530796582310758 -0.15243014595199111 0.20316369193051309 7.0000000000000007E-2 0.13 0.13 -1.2574662055957475E-3 Total Clinic Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $0 $0 $0 $0 $0 $0 $0 $4,445 $18,659 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $0 $0 $4,445 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 na n/a n/a n/a -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0 0 na Total U.S. Other Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $471 $486 $554 $469 $495 $470 $488 $490 $366 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $1,980 $1,980 $1,943 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.15959298532413202 6.7833062625201279E-2 0.24213998926647551 4.9217002237136542E-2 8.7607748970112365E-2 5.3801073926432297E-2 9.1722595078299829E-2 9.6196868008948444E-2 -0.26060606060606062 -1 -1 -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0.13 0.13 -1.8686868686868641E-2 Total U.S. Revenues $7,346.9226500000004 $10,177.2872 $10,421.701070000001 $11,884.24583 $9,972.814600000012 $12,897.737710000001 $13,518.360389999998 $15,089 $12,545.759 $15,890 $15,293.75468 $17,030 $11,177.5 $9,267.1140899999991 $12,028.93211 $15,046.68909999998 $39,829.898270000005 $11,801.763999999999 $13,809.378989999999 $13,280 $14,556.26310000001 $13,516.902740000001 $16,131.57429 $16,243.556370000002 $17,512.8 $14,964 $17,289 $17,211 $19,871.599999999999 $16,793 $16,130 $17,922 $21,642 $31,483 $0 $0 $0 $60,760.108459999996 $47,519.165110000002 $53,447.169300000001 $63,406 $69,336 $69,335.600000000006 $72,487 YoY Change 0.35 0.26 0.29713568823366732 0.26966407594077846 0.25808829884949591 0.23199900302515908 0.13133207273519076 0.12863675525217055 -0.10909734516660174 -0.41679584078036502 -0.21347423430751666 -0.11649624721080454 5.5892565569626962E-2 0.49014880532241301 0.10400490073095936 -3.2569477312064055E-2 0.14532901522179253 0.16816073349001481 0.22315936521084345 0.20313055411068426 0.10705834671116365 7.1749085934997181E-2 5.9558609454931632E-2 0.1346900552738568 4.100193187034562E-2 -6.9908563995091377E-3 2.336576675346036E-2 0.2357818281485542 0.87476924909188347 -1 -1 -1 0.18034051052656319 -0.2179216542827086 0.12474975467850768 0.19 0.09 0.09 4.5451398704273061E-2 Total International Revenues $132.1 $83.5 $92.5 $272.23500000000001 $179.732 $354 $219.30699999999999 $545.61800000000005 $182 $682 $706.37199999999996 $325.548 $298.822 $473.91300000000001 $418.98599999999999 $532.87300000000005 $580.33500000000004 $486.28800000000001 $393.93900000000002 $519 $466.178 $663.74939000000006 $197.87039000000001 $253.36739 $686 $576 $321 $673.3 $441.6 $624 $320 $608 $851 $492 $1,895.7699999999998 $1,724.5940000000001 $1,865.4050000000002 $1,800 $2,012 $2,011.9 $2,402 YoY Change 0.36057532172596529 3.25 1.3708864864864863 1.004216944918912 1.2618787973204482E-2 0.92655367231638408 2.2209277405645969 -0.40334079887393748 0.6418791208791208 -0.30511290322580642 -0.40684794980548489 0.63684925110889967 0.62735006124047099 -0.16875249254610025 0.23870487319385369 -0.12516115472166922 0.36493063781133817 -0.49771312309773852 -0.51181620423892094 0.4715409135566242 -0.13220259230671394 0.62227405525404778 1.6574059116289588 -0.35626822157434401 2.1535794718957191 0.26298810592791755 -0.11370262390670549 0.24052478134110777 -0.21153846153846156 -1 -1 -1 0.45904444083572726 -9.0293653766015725E-2 8.1648782264115649E-2 -0.03 0.12 0.12 0.19389631691435949 Total Revenues $7,479.226500000008 $10,260.52872 $10,514.201070000001 $12,156.48083 $10,151.813460000001 $13,252.403710000001 $13,737 $15,634.618 $12,728.371999999999 $16,571.754240000002 $16,000.126679999999 $17,355.547999999999 $11,476 $9,741 $12,447.918110000001 $15,578.941909999998 $40,410.233270000004 $12,288.52 $14,203.31799 $13,799 $15,022.204310000001 $14,180.652129999999 $16,329.445 $16,497.5124 $18,198.8 $15,540 $17,610 $17,884.3 $20,313.199999999997 $17,417 $16,450 $18,530 $22,493 $31,975 $0 $0 $0 $62,655.878459999993 $49,243.860019999993 $55,312 $65,206 $71,348 $71,347.5 $74,890 YoY Change 0.35 0.29159072321177626 0.30651867018175616 0.28611382016221221 0.2538027860886245 0.25047158256243618 0.16474679187595531 0.11007176510484618 -9.8392158871535185E-2 -0.41219258631728306 -0.22201127785070751 -0.10236531223329859 7.0760892296967581E-2 0.45809649830612864 0.10853878359905123 -3.5736547656207041E-2 0.15401954109569194 0.14969227693817189 0.19555854772084924 0.21146002440436762 9.5859334079863689E-2 7.8419995290715638E-2 8.4060406585904301E-2 0.11618348462535977 6.6600855081112798E-2 -2.8799735892303113E-3 1.8199002132008646E-2 0.23596061278765634 0.83585003157834303 -1 -1 -1 0.18720207332511252 -0.21405842148653842 0.12322632664327049 0.18 0.09 0.09 4.9651354287115979E-2 2018 2019 2020 2020 2020 2020 2021 2020 2020 2020 2022 2020 2020 2020 2023 2020 2020 2020 2024 2025 2019 2020 2021 2022 2023 2023 2024 U.S. Operating and Financial Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY Active Installed Base Active Installed Base - Beginning of Period 647 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! 647 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 907 #REF! #REF! 752 752 752 752 Active Installed Base - End of Period 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! 752 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1085 #REF! 752 907 907 907 907 Total NeuroStar Systems 14 25 30 40 24 43 47 61 43 61 68 78 #REF! #REF! #REF! #REF! 109 23 36 40 48 46 59 50 58 49 54 43 58 40 50 48 47 31 250 #REF! 147 213 204 204 185 YoY Change 0.71428571428571419 0.72 0.56666666666666665 0.52499999999999991 0.79166666666666674 0.41860465116279078 0.44680851063829796 0.27868852459016402 #REF! #REF! #REF! #REF! -0.39473684210526316 2.857142857142847E-2 2.564102564102555E-2 -0.11111111111111116 1 0.63888888888888884 0.25 0.20833333333333326 6.5217391304347894E-2 -8.4745762711864403E-2 -0.14000000000000001 0 -0.32203389830508478 0 -0.17241379310344829 -0.18965517241379315 -0.22499999999999998 -1 -1 -1 #REF! #REF! #REF! 0.44897959183673503 -0.04 -0.04 -9.3137254901960786E-2 Active Sites Active Sites - Beginning of Period 0 615 637 679 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 916 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1081 1001 1044 1081 #REF! #REF! 916 959 959 959 959 Active Sites - End of Period 615 637 679 707 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 #REF! #REF! 0 1101 1101 1101 1101 NeuroStar System Average Selling Price ($) (4) $75,077.285714285739 $77,094.799999999988 $74,773 $74,757.174999999988 $79,527.83333333343 $75,993.23255813954 $72,930.276595744683 $71,110.655737704918 $68,344.72093023255 $66,132.229508196717 $62,706.355588235296 $63,573.930512820516 #REF! #REF! #REF! #REF! $75,338.798165137618 $69,101.260869565216 $67,801.336111111115 $56,914.728999999999 $52,358.735416666663 $75,760 $72,410.547796610161 $72,755.848399999988 $0 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $64,782.75104000001 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 YoY Change 5.926955905121245E-2 -1.4291194012904018E-2 -2.4644235275504744E-2 -4.8778184332073482E-2 -0.14061074459666201 -0.12975919795193602 -0.14018760773637229 -0.10598587717548236 #REF! #REF! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 Sequential Change 6.3805358259369171E-2 -4.4438446996812098E-2 -4.0302997944419161E-2 -2.4950143383193124E-2 -3.8896207309276565E-2 -3.237252843997096E-2 -5.1803393677160137E-2 1.3835518209385222E-2 #REF! #REF! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0 Average Revenue Per Active Site ($) (1) $8,885.2411128284384 $11,008.171385991058 $10,474.471014492754 $11,067.55448275862 $9,627.595345744696 $11,421.254801536492 $11,296.568627450981 $11,548.951048951049 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $43,874.182380216385 $10,511.582969432315 $12,001.111111111111 $11,162.802818280739 $12,182.826533044421 $9,873.5130761209602 $11,280 $11,364 $11,516.928769657725 $9,666.6666666666661 $11,391.304347826088 $11,916.58394160586 $13,237.544483985765 $11,299.808595789107 $10,000 $11,390 $11,027.444253859348 $8,362.6239777275096 $0 $11,390 $0 YoY Change 8.3488834160617253E-2 3.7525162087421959E-2 7.8485835878561394E-2 4.3496200261978757E-2 NA #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.11614813917964395 0.62052110235716817 9.2514634028795673E-2 .4% -6.0701598909209231E-2 -6.0087028978798251E-2 1.8023894625261105E-2 -5.4658724851784579E-2 -2.0949626324448856E-2 9.8674067221709016E-3 4.8579584139438969E-2 0.14939883268716048 1.756081186977676E-3 -0.12002815909890885 -1.1021060579286424E-2 -4.2501306171829678E-2 -0.13490096782129202 -1 -4.4147013782542266E-2 -1 Use Total Systems Recognized from the Q or K #DIV/0! (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) Three Months EndedMarch 31, 2024 2025 Revenues $17,417 $31,975 YOY Growth 0.83585003157834303 Gross Profit 13088 15738 Gross Margin 0.75144973301946372 0.49219702892885064 Operating Expenses: Sales and Marketing 11641 11999 % of Revenues 0.66836998334960096 0.37526192337763881 General and Administrative 5957 13137 % of Revenues 0.34202216225526783 0.41085222830336199 Research and Development 2349 1616 % of Revenues 0.1348682321869438 5.0539483971853011E-2 Total Operating Expenses 19947 26752 Loss from Operations $-6,859 $,-11,014 ($ in thousands) % of Revenues -0.39381064477234884 -0.34445660672400313 As of March 31, 2025 Cash and Cash Equivalents $20,224 enter Other Assets $,121,764 calculates Total Assets $,141,988 enter Long-term debt, net $55,341 enter Convertible Preferred Stock Warrant Liability $0 11703 Convertible Preferred Stock $0 0.7530888030888031 Accumulated Deficit $-,432,464 enter Total Stockholders’ Equity $35,452 enter 2017 2018 2019 2020 2021 2022 2022 2022 2022 UNIT SALES / ACTIVE SITES 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) 20 29 32 42 30 47 48 65 43 61 68 78 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 46 59 50 58 0 49 54 43 58 0 31 0 0 0 0 250 YoY D 0.5 0.6206896551724137 0.5 0.54761904761904767 0.43333333333333335 0.2978723404255319 0.41666666666666674 0.19999999999999996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -1 -0.16949152542372881 8.0000000000000071E-2 -0.25862068965517238 #DIV/0! -1 -0.42592592592592593 -1 -1 #DIV/0! -1 #DIV/0! Beginning Active Installed Base 0 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Ending Active Installed Base 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.16393442622950816 0.18260869565217397 0.18344827586206902 0.2061170212765957 0.19206145966709354 0.19607843137254899 0.2027972027972027 0.25137816979051819 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Net Active Installed Base Change 24 19 35 27 29 35 42 49 24 45 56 53 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.20833333333333326 0.84210526315789469 0.19999999999999996 0.81481481481481488 -0.17241379310344829 0.28571428571428581 0.33333333333333326 8.163265306122458E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Active Sites (End of Period) 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 YoY D 0.1983739837398375 0.22135007849293564 0.22680412371134029 0.23055162659123063 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -100.0% -100.0% -100.0% -100.0% #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Inactive Systems (Calculation) (2) -4 10 -3 15 -1 -12 -6 -16 -19 -16 -12 -25 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Inactive System Churn % (Calculation) (3) -0.1% -1.5% -0.7% -1.9% -2.0948180815876516E-2 -1.7185821697099892E-2 -1.2295081967213115E-2 -2.4224806201550399E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! (1) = Includes all active systems placed during the period. (2) = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units (3) = Calculation: Inactive Systems / Ending of Prior Period Installed Base 2017 2018 2019 2020 2021 2022 2022 2022 2022 NeuroStar REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total U.S. NeuroStar Revenue ($000) $1,321.41 $2,509.8959999999997 $2,828.9520000000002 $3,459.297 $2,373 $3,568.15 $3,908 $4,754 $3,350 $4,628 $4,616 $5,413 #REF! #REF! #REF! #REF! #REF! #REF! $2,612 $2,815 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $0 $3,850 $4,489 $3,597 $4,523.6000000000004 $0 $2,846 $0 $0 $0 $0 $18,007.110260000001 YoY D 0.79580902218085225 0.42163260947864001 0.38143029644900284 0.37426766189777871 0.41171512852928771 0.29703067415887774 0.18116683725690885 0.13862010938157332 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.08 #REF! 0.50612557427258809 0.63978685612788633 1.08 -0.12138769934609128 0.14107778342653798 -0.22075389948006929 1.08 -1 -0.36600579193584315 -1 1.08 #DIV/0! -1 #DIV/0! U.S. NeuroStar Capital Revenue ($000) (1) $1,083.820000000001 $1,974.9379999999999 $2,219.7345 $2,942.4469999999997 $1,908.6499999999999 $3,267.65 $3,427.6 $4,337.7 $2,938.5729999999999 $4,034.599999999995 $4,264 $4,958.8 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $16,195.687760000001 YoY D 0.76223960882001518 0.65455826967732667 0.54414863579405548 0.47418118321247604 0.53960809996594405 0.23454470338010469 0.24401913875598091 0.14318648131498279 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! U.S. NeuroStar Operating Lease Revenue ($000) (2) $229.8 $293.95800000000003 $289 $234 $258 $181 $269 $231 $182 $187 $184 $176.7 #REF! #REF! #REF! #REF! #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $730.13850000000002 YoY D 0.13 -0.38426577946509366 -6.9204152249134898E-2 -0.02 -0.29457364341085268 3.3149171270718147E-2 -0.31 -0.23506493506493509 #REF! #REF! #REF! #REF! -0.3 #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! U.S. NeuroStar Other ($000) (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $119.5 $210.995 $185 $228.95 $407.25 $167.084 $278 #REF! #REF! #REF! #REF! #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $1,081.2840000000001 YoY D NM -0.50414937759336098 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.39 -0.20811393634920261 0.50270270270270268 #REF! #REF! #REF! #REF! #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 (1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases (2) = Revenue derived from Operating Lease revenue amortization during the period (3) = Revenue derived from Treatment Coils in U.S. 2017 2018 2019 2020 2021 2022 2023 2024 2025 Treatment Session REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Update/Unhide Total U.S. Treatment Session Revenues ($000) $5,749.6779800000004 $7,388.1369999999997 $7,228.5863399999998 $8,025.3639999999996 $7,239.5479999999998 $8,919.991 $9,218 $9,909 $8,777.6730000000007 $10,847.352000000001 $10,251.888000000001 $11,243 #REF! #REF! #REF! #REF! #REF! $10,801 #REF! #REF! $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $9,612 $0 $0 $0 $0 $41,120.22219 $0 $34,852.260719999998 YoY D 0.26 0.20733968522781865 0.27521476073287099 0.2347103508326851 0.21246146858892301 0.21607207899649228 0.11215968756780215 0.13462508830356246 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 4.5693639477826231E-2 #REF! #REF! 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 -9.6871182937141809E-2 -1 -1 -1 -1 #DIV/0! #DIV/0! #DIV/0! Active Sites(End of Period) 0 671 690 725 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 Average Revenue per Active Site ($000) (1) $8.8866738485316894 $11.010636363636364 $10.476212086956522 $11.069467586206896 $0 $14.504065040650406 $14.470957613814758 $14.593519882179676 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $10.511582969432315 $12.001111111111111 $11.16280281828074 $12.182826533044421 $9.8735130761209611 $11.28 $11.364000000000001 $11.516928769657724 $9.6666666666666661 $11.391304347826088 $11.916058394160585 $13.237544483985765 $8.3626239777275089 $0 $11.39 $0 $0 $0 $0 $0 YoY D 8.3314035681520959E-2 3.7291842237985096E-2 7.8306599149118972E-2 4.3315855890089239E-2 NM #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -6.0701598909209099E-2 -6.0087028978798328E-2 1.8023894625261182E-2 -5.4658724851784697E-2 -2.0949626324448987E-2 9.8674067221709624E-3 4.8579584139438914E-2 0.14939883268716059 -0.13490096782129213 -1 -4.414701378254212E-2 -1 -1 #DIV/0! -1 #DIV/0! (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) Q1 2023 15.5 Q2 2023 17.600000000000001 Q3 2023 17.899999999999999 Q4 2023 20.3 Q1 2024 17.399999999999999 Q2 2024 16.5 Q3 2024 18.5 Q4 2024 22.5 Q1 2025 32 Q2 2025 37
Worldwide Quarterly Revenue1 Q1 2025 Revenue of $32.0M, a 7% increase from Q1 2024 ($ in millions) Guidance ($ in millions) (1) 2024 revenue is based on Adjusted Pro forma revenue, pro forma revenue adjusted for Greenbrook store closures, per slide 24
Results of Operations1 ($ in thousands) ($ in thousands) 1 2024 is Adjusted Pro forma financials, financials adjusted for Greenbrook store closures
Annual Revenue1 Annual Revenue by Geography ($ in millions) ($ in millions) Guidance (1) 2024 is Adjusted Pro forma revenue, pro forma revenue adjusted for Greenbrook store closures, per slide 24
Supplemental Information Neuronetics, Inc.
Local Consumables New MTs (New Patient Starts) & Utilization
Supplemental Financial and Operating Information1 ($ in thousands) (1) Actual results as reported and filed with the SEC for Neuronetics Neuronetics, Inc. Supplemental Financial and Operating Information For the period ended March 31, 2025 2017 2018 2019 2020 2017 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2023 2024 Revenue ($ thousands) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY NeuroStar Capital (1) $1,051.820000000003 $1,927.3699999999997 $2,243.19 $2,990.2869999999994 $1,908.65 $3,267.7 $3,427.723 $4,337.75 $2,938.8229999999999 $4,034.659999999998 $4,264.321800000002 $4,958.7665800000004 $2,410.320000000002 $2,223.8835899999999 $2,438.3874999999998 $3,445.80141 $8,211.9290000000001 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $16,195.687760000001 $10,518.104500000001 #REF! $12,941.823 $12,941.823 $12,941.823 $12,941.823 YoY Change 0.76 0.65 0.54 0.47 0.53973908259764736 0.2345276494170212 0.24398388667929116 0.14316559967725206 -0.17993291872290362 -0.44872404417776013 -0.4281498363363665 -0.30510917293469386 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.25142244334511443 -0.35056141759057968 #REF! 0.56999999999999995 0.56999999999999995 0.56999999999999995 0.56999999999999995 Sales $1,876 $3,277 $3,538 $4,385 $2,451 $3,754 $2,969 $4,070.4648999999999 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $13,244.464899999999 $13,244.464899999999 $13,244.464899999999 $13,076 $13,076 $13,076 $13,076 YoY 1.3318827646177938 0.9477318833436239 0.32356153513523145 0.3612288385696758 0.306503198294243 0.1455599633811413 -0.16082532504239688 -7.1729783352337484E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.2883519424900403E-2 1.2883519424900403E-2 1.2883519424900403E-2 0.59231771244003695 0.59231771244003695 0.59231771244003695 0.59231771244003695 Sales-Type-Leases $0 $0 $0 $0 $450 $350 $1,283 $996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $3,079 $3,079 $3,079 $0 $0 $0 $0 YoY nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm Other NeuroStar $32.35 $-9.65 $-,110.6 $-42.3 $37.573 $-69.5 $12.5 $-,107.69926 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $-,127.12626 $-,127.12626 $-,127.12626 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 YoY -0.41530508964719492 -1.2028674739320553 3.7153119737375082 -0.11580267558528445 0.16145285935084996 6.2020725388601035 -1.1130198915009042 1.5460817966903075 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -2.3607834101382341E-2 -2.3607834101382341E-2 -2.3607834101382341E-2 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 NeuroStar Operating Lease (2) $215 $293.95800000000003 $289 $234 $258 $181.13883999999999 $269 $231 $181.94399999999999 $187.08323999999999 $184.44399999999999 $176.66726 $155.417 $114.16689 $87.917000000000002 $79.167000000000002 $1,031.9580000000001 #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $730.13850000000002 $436.66789000000006 $279 $939 $939 $939 $939 YoY Change 0.13 -0.38379346709393869 -6.9204152249134898E-2 -0.02 -0.29479069767441868 3.2816816095322165E-2 -0.3143345724907064 -0.23520666666666667 -0.14579760805522568 -0.38975351292825589 -0.52334041768775341 -0.5518864106456397 #REF! #REF! -0.65876906627842169 7.3679689769727164E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.22350933218443014 -0.40193827609419308 -0.36107049226816301 -0.1 -0.1 -0.1 -0.1 Other (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $120 $210.995 $185 $228.95 $407.25 $167.084 $278 $29 $0 $15 $95.5 $852.0675 #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $1,081.2840000000001 $139.5 #REF! $722 $722 $722 $722 YoY Change NM -0.50207468879668049 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.3937499999999998 -0.20811393634920261 0.50270270270270268 -0.87333478925529595 -1 -0.91022479710804149 -0.65647482014388492 #REF! 1 19.333333333333332 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 0.49867150846506236 -0.87098671579344555 #REF! -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 Total U.S. NeuroStar Advanced Therapy System Revenues $1,274.820000000003 $2,462.3279999999995 $2,852.4075000000003 $3,507.1369999999993 $2,372.65 $3,568 $3,907.7179999999998 $4,753.75 $3,349.7169999999996 $4,628.3992399999997 $4,615.5601800000004 $5,413.4338400000006 $2,594.4490000000001 $2,338.504799999999 $2,541.3044999999997 $3,620.4684099999999 $10,095.9545 $1,755.2459999999999 $2,577.2649900000001 $2,611.58916 $2,815.2192999999997 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $3,850 $4,489 $3,597 $4,523.6000000000004 $3,310 $4,000 $4,108 $3,849 $2,846 $18,007.110260000001 $11,094.272390000002 #REF! $16,575 $16,460 $16,459.599999999999 $15,267 YoY Change 0.8 0.42 0.38 0.37 0.41180410089983743 0.29719709641255587 0.18113952439761527 0.13877125216934005 -0.22547218167982541 -0.49484684471601459 -0.4494049690843811 -0.33120667638934342 -0.32346097379443584 0.1023136634757349 2.7656921868276729E-2 -0.22241572603584747 1.08 0.70021708555471407 0.50636250917812808 0.63965911998400982 5.7103727438351903E-2 2.4439121463739388E-2 -8.566344687341132E-2 -2.0017331022530227E-2 -0.14025974025974031 -0.10893294720427715 0.14206283013622456 -0.14912901229109565 -0.14018126888217519 -1 -1 -1 0.23311033760186262 -0.38389490430098572 #REF! 0.7 -0.01 -0.01 -7.2456195776325005E-2 Total U.S. Treatment Sessions Revenues $5,748.7510000000002 $7,386.4830000000002 $7,227.3850000000002 $8,023.9769999999999 $7,239.5487700000012 $8,920 $9,218 $9,909 $8,777.6730000000007 $10,847.351000000001 $10,251.888499999999 $11,243.30969 $8,193.4259999999995 $6,546.6486100000002 $9,083.3856099999994 $11,028.800499999999 $28,386.595999999998 $9,628.61 $10,801 $10,258.61579 $11,244.748890000001 $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,878 $12,988 $11,660 $13,326 $12,858 $9,612 $41,120.22219 $34,852.260719999998 $41,932.974679999999 $45,077 $50,896 $50,895 $50,832 YoY Change 0.25932550740152105 0.20761125423290072 0.27542672764769005 0.23492377906865891 0.21246133963125424 0.21607073991031389 0.11215974180950306 0.13465634170955698 -6.6560579324383751E-2 -0.39647489880248188 -0.11397928196351337 -1.9078829625300497E-2 0.17516286837764827 0.64985180104236573 0.12938239445721389 1.9580405865533779E-2 -1.6607896674597833E-2 4.5693639477826231E-2 0.1564476273265325 0.10716567544444278 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19503927773940144 0.22033261298506068 -5.3110280980997238E-2 2.0367534456355196E-2 -0.13577093695389164 -0.25993224514936863 -1 -1 -1 0.16530796582310758 -0.15243014595199111 0.20316369193051309 7.0000000000000007E-2 0.13 0.13 -1.2378426171529844E-3 Total U.S. Clinic Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $0 $0 $0 $0 $0 $0 $0 $4,445 $18,659 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $0 $0 $4,445 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 na na n/a n/a -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0 na na Total U.S. Other Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $471 $486 $554 $470 $495 $470 $488 $490 $366 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $1,980 $1,981 $1,943 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.15959298532413202 6.7833062625201279E-2 0.24213998926647551 5.1454138702460961E-2 5.0955414012738842E-2 -3.2921810699588439E-2 -0.11913357400722024 4.2553191489361764E-2 -0.26060606060606062 -1 -1 -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0.13 0.13 -1.9182231196365418E-2 Total U.S. Revenues $7,346.9226500000004 $10,177.2872 $10,421.701070000001 $11,884.24583 $9,972.814600000012 $12,897.737710000001 $13,518.360389999998 $15,089 $12,545.759 $15,890 $15,293.75468 $17,030 $11,177.5 $9,267.1140899999991 $12,028.93211 $15,046.68909999998 $39,829.898270000005 $11,801.763999999999 $13,809.378989999999 $13,280 $14,556.26310000001 $13,516.902740000001 $16,131.57429 $16,243.556370000002 $17,512.8 $14,964 $17,289 $17,211 $19,871.599999999999 $16,793 $16,130 $17,922 $21,642 $31,483 $0 $0 $0 $60,760.108459999996 $47,519.165110000002 $53,447.169300000001 $63,406 $69,336 $69,335.600000000006 $72,487 YoY Change 0.35 0.26 0.29713568823366732 0.26966407594077846 0.25808829884949591 0.23199900302515908 0.13133207273519076 0.12863675525217055 -0.10909734516660174 -0.41679584078036502 -0.21347423430751666 -0.11649624721080454 5.5892565569626962E-2 0.49014880532241301 0.10400490073095936 -3.2569477312064055E-2 0.14532901522179253 0.16816073349001481 0.22315936521084345 0.20313055411068426 0.10705834671116365 7.1749085934997181E-2 5.9558609454931632E-2 0.1346900552738568 0.12222667735899484 -6.7036844236219584E-2 4.1310789611295196E-2 8.9091970450291047E-2 0.87476924909188347 -1 -1 -1 0.18034051052656319 -0.2179216542827086 0.12474975467850768 0.19 0.09 0.09 4.5451398704273061E-2 Total International Revenues $132.1 $83.5 $92.5 $272.23500000000001 $179.732 $354 $219.30699999999999 $545.61800000000005 $182 $682 $706.37199999999996 $325.548 $298.822 $473.91300000000001 $418.98599999999999 $532.87300000000005 $580.33500000000004 $486.28800000000001 $393.93900000000002 $519 $466.178 $663.74939000000006 $197.87039000000001 $253.36739 $686 $576 $321 $673.3 $442 $624 $320 $608 $851 $492 $1,895.7699999999998 $1,724.5940000000001 $1,865.4050000000002 $1,800 $2,012 $2,012.3 $2,402 YoY Change 0.36057532172596529 3.25 1.3708864864864863 1.004216944918912 1.2618787973204482E-2 0.92655367231638408 2.2209277405645969 -0.40334079887393748 0.6418791208791208 -0.30511290322580642 -0.40684794980548489 0.63684925110889967 0.62735006124047099 -0.16875249254610025 0.23870487319385369 -0.12516115472166922 0.36493063781133817 -0.49771312309773852 -0.51181620423892094 0.4715409135566242 -0.13220259230671394 0.62227405525404778 1.6574059116289588 -0.35568513119533529 8.3333333333333259E-2 -3.1152647975077885E-3 -9.6984999257388904E-2 0.92533936651583715 -0.21153846153846156 -1 -1 -1 0.45904444083572726 -9.0293653766015725E-2 8.1648782264115649E-2 -0.03 0.12 0.12 0.1936589971674203 Total Revenues $7,479.226500000008 $10,260.52872 $10,514.201070000001 $12,156.48083 $10,151.813460000001 $13,252.403710000001 $13,737 $15,634.618 $12,728.371999999999 $16,571.754240000002 $16,000.126679999999 $17,355.547999999999 $11,476 $9,741 $12,447.918110000001 $15,578.941909999998 $40,410.233270000004 $12,288.52 $14,203.31799 $13,799 $15,022.204310000001 $14,180.652129999999 $16,329.445 $16,497.5124 $18,198.8 $15,540 $17,610 $17,884.3 $20,313.599999999999 $17,417 $16,450 $18,530 $22,493 $31,975 $0 $0 $0 $62,655.878459999993 $49,243.860019999993 $55,312 $65,206 $71,348 $71,347.899999999994 $74,890 YoY Change 0.35 0.29159072321177626 0.30651867018175616 0.28611382016221221 0.2538027860886245 0.25047158256243618 0.16474679187595531 0.11007176510484618 -9.8392158871535185E-2 -0.41219258631728306 -0.22201127785070751 -0.10236531223329859 7.0760892296967581E-2 0.45809649830612864 0.10853878359905123 -3.5736547656207041E-2 0.15401954109569194 0.14969227693817189 0.19555854772084924 0.21146002440436762 9.5859334079863689E-2 7.8419995290715638E-2 8.4060406585904301E-2 0.11620546409653376 0.12078507078507084 -6.5871663827370863E-2 3.6104292591826459E-2 0.10728772841839951 0.83585003157834303 -1 -1 -1 0.18720207332511252 -0.21405842148653842 0.12322632664327049 0.18 0.09 0.09 4.9645469593358804E-2 2018 2019 2020 2020 2020 2020 2021 2020 2020 2020 2022 2020 2020 2020 2023 2020 2020 2020 2024 2025 2019 2020 2021 2022 2023 2023 2024 U.S. Operating and Financial Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY Active Installed Base Active Installed Base - Beginning of Period 647 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! 647 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 907 #REF! #REF! 752 752 752 752 Active Installed Base - End of Period 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! 752 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1085 #REF! 752 907 907 907 907 Total NeuroStar Systems 14 25 30 40 24 43 47 61 43 61 68 78 #REF! #REF! #REF! #REF! 109 23 36 40 48 46 59 50 58 49 54 43 58 40 50 48 47 31 250 #REF! 147 213 204 204 185 YoY Change 0.71428571428571419 0.72 0.56666666666666665 0.52499999999999991 0.79166666666666674 0.41860465116279078 0.44680851063829796 0.27868852459016402 #REF! #REF! #REF! #REF! -0.39473684210526316 2.857142857142847E-2 2.564102564102555E-2 -0.11111111111111116 1 0.63888888888888884 0.25 0.20833333333333326 6.5217391304347894E-2 -8.4745762711864403E-2 -0.14000000000000001 0 -0.18367346938775508 -7.407407407407407E-2 0.11627906976744184 -0.18965517241379315 -0.22499999999999998 -1 -1 -1 #REF! #REF! #REF! 0.44897959183673503 -0.04 -0.04 -9.3137254901960786E-2 Active Sites Active Sites - Beginning of Period 0 615 637 679 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 916 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1081 1001 1044 1081 #REF! #REF! 916 959 959 959 959 Active Sites - End of Period 615 637 679 707 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 #REF! #REF! 0 1101 1101 1101 1101 NeuroStar System Average Selling Price ($) (4) $75,077.285714285739 $77,094.799999999988 $74,773 $74,757.174999999988 $79,527.83333333343 $75,993.23255813954 $72,930.276595744683 $71,110.655737704918 $68,344.72093023255 $66,132.229508196717 $62,706.355588235296 $63,573.930512820516 #REF! #REF! #REF! #REF! $75,338.798165137618 $69,101.260869565216 $67,801.336111111115 $56,914.728999999999 $52,358.735416666663 $75,760 $72,410.547796610161 $72,755.848399999988 $0 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $64,782.75104000001 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 YoY Change 5.926955905121245E-2 -1.4291194012904018E-2 -2.4644235275504744E-2 -4.8778184332073482E-2 -0.14061074459666201 -0.12975919795193602 -0.14018760773637229 -0.10598587717548236 #REF! #REF! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 Sequential Change 6.3805358259369171E-2 -4.4438446996812098E-2 -4.0302997944419161E-2 -2.4950143383193124E-2 -3.8896207309276565E-2 -3.237252843997096E-2 -5.1803393677160137E-2 1.3835518209385222E-2 #REF! #REF! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0 Average Revenue Per Active Site ($) (1) $8,885.2411128284384 $11,008.171385991058 $10,474.471014492754 $11,067.55448275862 $9,627.595345744696 $11,421.254801536492 $11,296.568627450981 $11,548.951048951049 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $43,874.182380216385 $10,511.582969432315 $12,001.111111111111 $11,162.802818280739 $12,182.826533044421 $9,873.5130761209602 $11,280 $11,364 $11,516.928769657725 $9,666.6666666666661 $11,391.304347826088 $11,916.58394160586 $13,236.654804270464 $11,299.808595789107 $10,000 $11,390 $11,027.444253859348 $8,362.6239777275096 $0 $11,390 $0 YoY Change 8.3488834160617253E-2 3.7525162087421959E-2 7.8485835878561394E-2 4.3496200261978757E-2 NA #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.11614813917964395 0.62052110235716817 9.2514634028795673E-2 .4% -6.0701598909209231E-2 -6.0087028978798251E-2 1.8023894625261105E-2 -5.4658724851784579E-2 -2.0949626324448856E-2 9.8674067221709016E-3 4.8579584139438969E-2 0.14932158295043862 1.756081186977676E-3 -0.12002815909890885 -1.1021060579286424E-2 -4.2501306171829678E-2 -0.13490096782129202 -1 -4.4147013782542266E-2 -1 Use Total Systems Recognized from the Q or K #DIV/0! (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) Three Months EndedMarch 31, 2024 2025 Revenues $17,417 $31,975 YOY Growth 0.83585003157834303 Gross Profit 13088 15738 Gross Margin 0.75144973301946372 0.49219702892885064 Operating Expenses: Sales and Marketing 11641 11999 % of Revenues 0.66836998334960096 0.37526192337763881 General and Administrative 5957 13137 % of Revenues 0.34202216225526783 0.41085222830336199 Research and Development 2349 1616 % of Revenues 0.1348682321869438 5.0539483971853011E-2 Total Operating Expenses 19947 26752 Loss from Operations $-6,859 $,-11,014 ($ in thousands) % of Revenues -0.39381064477234884 -0.34445660672400313 As of March 31, 2025 Cash and Cash Equivalents $20,224 enter Other Assets $,121,764 calculates Total Assets $,141,988 enter Long-term debt, net $55,341 enter Convertible Preferred Stock Warrant Liability $0 11703 Convertible Preferred Stock $0 0.7530888030888031 Accumulated Deficit $-,432,464 enter Total Stockholders’ Equity $35,452 enter 2017 2018 2019 2020 2021 2022 2022 2022 2022 UNIT SALES / ACTIVE SITES 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) 20 29 32 42 30 47 48 65 43 61 68 78 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 46 59 50 58 0 49 54 43 58 0 31 0 0 0 0 250 YoY D 0.5 0.6206896551724137 0.5 0.54761904761904767 0.43333333333333335 0.2978723404255319 0.41666666666666674 0.19999999999999996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -1 -0.16949152542372881 8.0000000000000071E-2 -0.25862068965517238 #DIV/0! -1 -0.42592592592592593 -1 -1 #DIV/0! -1 #DIV/0! Beginning Active Installed Base 0 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Ending Active Installed Base 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.16393442622950816 0.18260869565217397 0.18344827586206902 0.2061170212765957 0.19206145966709354 0.19607843137254899 0.2027972027972027 0.25137816979051819 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Net Active Installed Base Change 24 19 35 27 29 35 42 49 24 45 56 53 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.20833333333333326 0.84210526315789469 0.19999999999999996 0.81481481481481488 -0.17241379310344829 0.28571428571428581 0.33333333333333326 8.163265306122458E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Active Sites (End of Period) 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 YoY D 0.1983739837398375 0.22135007849293564 0.22680412371134029 0.23055162659123063 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -100.0% -100.0% -100.0% -100.0% #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Inactive Systems (Calculation) (2) -4 10 -3 15 -1 -12 -6 -16 -19 -16 -12 -25 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Inactive System Churn % (Calculation) (3) -0.1% -1.5% -0.7% -1.9% -2.0948180815876516E-2 -1.7185821697099892E-2 -1.2295081967213115E-2 -2.4224806201550399E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! (1) = Includes all active systems placed during the period. (2) = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units (3) = Calculation: Inactive Systems / Ending of Prior Period Installed Base 2017 2018 2019 2020 2021 2022 2022 2022 2022 NeuroStar REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total U.S. NeuroStar Revenue ($000) $1,321.41 $2,509.8959999999997 $2,828.9520000000002 $3,459.297 $2,373 $3,568.15 $3,908 $4,754 $3,350 $4,628 $4,616 $5,413 #REF! #REF! #REF! #REF! #REF! #REF! $2,612 $2,815 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $0 $3,850 $4,489 $3,597 $4,523.6000000000004 $0 $2,846 $0 $0 $0 $0 $18,007.110260000001 YoY D 0.79580902218085225 0.42163260947864001 0.38143029644900284 0.37426766189777871 0.41171512852928771 0.29703067415887774 0.18116683725690885 0.13862010938157332 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.08 #REF! 0.50612557427258809 0.63978685612788633 1.08 -0.12138769934609128 0.14107778342653798 -0.22075389948006929 1.08 -1 -0.36600579193584315 -1 1.08 #DIV/0! -1 #DIV/0! U.S. NeuroStar Capital Revenue ($000) (1) $1,083.820000000001 $1,974.9379999999999 $2,219.7345 $2,942.4469999999997 $1,908.6499999999999 $3,267.65 $3,427.6 $4,337.7 $2,938.5729999999999 $4,034.599999999995 $4,264 $4,958.8 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $16,195.687760000001 YoY D 0.76223960882001518 0.65455826967732667 0.54414863579405548 0.47418118321247604 0.53960809996594405 0.23454470338010469 0.24401913875598091 0.14318648131498279 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! U.S. NeuroStar Operating Lease Revenue ($000) (2) $229.8 $293.95800000000003 $289 $234 $258 $181 $269 $231 $182 $187 $184 $176.7 #REF! #REF! #REF! #REF! #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $730.13850000000002 YoY D 0.13 -0.38426577946509366 -6.9204152249134898E-2 -0.02 -0.29457364341085268 3.3149171270718147E-2 -0.31 -0.23506493506493509 #REF! #REF! #REF! #REF! -0.3 #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! U.S. NeuroStar Other ($000) (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $119.5 $210.995 $185 $228.95 $407.25 $167.084 $278 #REF! #REF! #REF! #REF! #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $1,081.2840000000001 YoY D NM -0.50414937759336098 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.39 -0.20811393634920261 0.50270270270270268 #REF! #REF! #REF! #REF! #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 (1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases (2) = Revenue derived from Operating Lease revenue amortization during the period (3) = Revenue derived from Treatment Coils in U.S. 2017 2018 2019 2020 2021 2022 2023 2024 2025 Treatment Session REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Update/Unhide Total U.S. Treatment Session Revenues ($000) $5,749.6779800000004 $7,388.1369999999997 $7,228.5863399999998 $8,025.3639999999996 $7,239.5479999999998 $8,919.991 $9,218 $9,909 $8,777.6730000000007 $10,847.352000000001 $10,251.888000000001 $11,243 #REF! #REF! #REF! #REF! #REF! $10,801 #REF! #REF! $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,878 $9,612 $0 $0 $0 $0 $41,120.22219 $0 $34,852.260719999998 YoY D 0.26 0.20733968522781865 0.27521476073287099 0.2347103508326851 0.21246146858892301 0.21607207899649228 0.11215968756780215 0.13462508830356246 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 4.5693639477826231E-2 #REF! #REF! 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19503927773940144 -9.6871182937141809E-2 -1 -1 -1 -1 #DIV/0! #DIV/0! #DIV/0! Active Sites(End of Period) 0 671 690 725 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 Average Revenue per Active Site ($000) (1) $8.8866738485316894 $11.010636363636364 $10.476212086956522 $11.069467586206896 $0 $14.504065040650406 $14.470957613814758 $14.593519882179676 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $10.511582969432315 $12.001111111111111 $11.16280281828074 $12.182826533044421 $9.8735130761209611 $11.28 $11.364000000000001 $11.516928769657724 $9.6666666666666661 $11.391304347826088 $11.916058394160585 $13.236654804270463 $8.3626239777275089 $0 $11.39 $0 $0 $0 $0 $0 YoY D 8.3314035681520959E-2 3.7291842237985096E-2 7.8306599149118972E-2 4.3315855890089239E-2 NM #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -6.0701598909209099E-2 -6.0087028978798328E-2 1.8023894625261182E-2 -5.4658724851784697E-2 -2.0949626324448987E-2 9.8674067221709624E-3 4.8579584139438914E-2 0.14932158295043862 -0.13490096782129213 -1 -4.414701378254212E-2 -1 -1 #DIV/0! -1 #DIV/0! (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) Q1 2023 15.5 Q2 2023 17.600000000000001 Q3 2023 17.899999999999999 Q4 2023 20.3 Q1 2024 17.399999999999999 Q2 2024 16.5 Q3 2024 18.5 Q4 2024 22.5 Q1 2025 32 Q2 2025 37 Neuronetics, Inc. Supplemental Financial and Operating Information For the period ended March 31, 2025 2017 2018 2019 2020 2017 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2023 2024 Revenue ($ thousands) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY NeuroStar Capital (1) $1,051.820000000003 $1,927.3699999999997 $2,243.19 $2,990.2869999999994 $1,908.65 $3,267.7 $3,427.723 $4,337.75 $2,938.8229999999999 $4,034.659999999998 $4,264.321800000002 $4,958.7665800000004 $2,410.320000000002 $2,223.8835899999999 $2,438.3874999999998 $3,445.80141 $8,211.9290000000001 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $16,195.687760000001 $10,518.104500000001 #REF! $12,941.823 $12,941.823 $12,941.823 $12,941.823 YoY Change 0.76 0.65 0.54 0.47 0.53973908259764736 0.2345276494170212 0.24398388667929116 0.14316559967725206 -0.17993291872290362 -0.44872404417776013 -0.4281498363363665 -0.30510917293469386 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.25142244334511443 -0.35056141759057968 #REF! 0.56999999999999995 0.56999999999999995 0.56999999999999995 0.56999999999999995 Sales $1,876 $3,277 $3,538 $4,385 $2,451 $3,754 $2,969 $4,070.4648999999999 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $13,244.464899999999 $13,244.464899999999 $13,244.464899999999 $13,076 $13,076 $13,076 $13,076 YoY 1.3318827646177938 0.9477318833436239 0.32356153513523145 0.3612288385696758 0.306503198294243 0.1455599633811413 -0.16082532504239688 -7.1729783352337484E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.2883519424900403E-2 1.2883519424900403E-2 1.2883519424900403E-2 0.59231771244003695 0.59231771244003695 0.59231771244003695 0.59231771244003695 Sales-Type-Leases $0 $0 $0 $0 $450 $350 $1,283 $996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $3,079 $3,079 $3,079 $0 $0 $0 $0 YoY nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm Other NeuroStar $32.35 $-9.65 $-,110.6 $-42.3 $37.573 $-69.5 $12.5 $-,107.69926 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $-,127.12626 $-,127.12626 $-,127.12626 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 YoY -0.41530508964719492 -1.2028674739320553 3.7153119737375082 -0.11580267558528445 0.16145285935084996 6.2020725388601035 -1.1130198915009042 1.5460817966903075 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -2.3607834101382341E-2 -2.3607834101382341E-2 -2.3607834101382341E-2 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 NeuroStar Operating Lease (2) $215 $293.95800000000003 $289 $234 $258 $181.13883999999999 $269 $231 $181.94399999999999 $187.08323999999999 $184.44399999999999 $176.66726 $155.417 $114.16689 $87.917000000000002 $79.167000000000002 $1,031.9580000000001 #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $730.13850000000002 $436.66789000000006 $279 $939 $939 $939 $939 YoY Change 0.13 -0.38379346709393869 -6.9204152249134898E-2 -0.02 -0.29479069767441868 3.2816816095322165E-2 -0.3143345724907064 -0.23520666666666667 -0.14579760805522568 -0.38975351292825589 -0.52334041768775341 -0.5518864106456397 #REF! #REF! -0.65876906627842169 7.3679689769727164E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.22350933218443014 -0.40193827609419308 -0.36107049226816301 -0.1 -0.1 -0.1 -0.1 Other (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $120 $210.995 $185 $228.95 $407.25 $167.084 $278 $29 $0 $15 $95.5 $852.0675 #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $1,081.2840000000001 $139.5 #REF! $722 $722 $722 $722 YoY Change NM -0.50207468879668049 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.3937499999999998 -0.20811393634920261 0.50270270270270268 -0.87333478925529595 -1 -0.91022479710804149 -0.65647482014388492 #REF! 1 19.333333333333332 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 0.49867150846506236 -0.87098671579344555 #REF! -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 Total U.S. NeuroStar Advanced Therapy System Revenues $1,274.820000000003 $2,462.3279999999995 $2,852.4075000000003 $3,507.1369999999993 $2,372.65 $3,568 $3,907.7179999999998 $4,753.75 $3,349.7169999999996 $4,628.3992399999997 $4,615.5601800000004 $5,413.4338400000006 $2,594.4490000000001 $2,338.504799999999 $2,541.3044999999997 $3,620.4684099999999 $10,095.9545 $1,755.2459999999999 $2,577.2649900000001 $2,611.58916 $2,815.2192999999997 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $3,850 $4,489 $3,597 $4,523.6000000000004 $3,310 $4,000 $4,108 $3,849 $2,846 $18,007.110260000001 $11,094.272390000002 #REF! $16,575 $16,460 $16,459.599999999999 $15,267 YoY Change 0.8 0.42 0.38 0.37 0.41180410089983743 0.29719709641255587 0.18113952439761527 0.13877125216934005 -0.22547218167982541 -0.49484684471601459 -0.4494049690843811 -0.33120667638934342 -0.32346097379443584 0.1023136634757349 2.7656921868276729E-2 -0.22241572603584747 1.08 0.70021708555471407 0.50636250917812808 0.63965911998400982 5.7103727438351903E-2 2.4439121463739388E-2 -8.566344687341132E-2 -2.0017331022530227E-2 -0.14025974025974031 -0.10893294720427715 0.14206283013622456 -0.14912901229109565 -0.14018126888217519 -1 -1 -1 0.23311033760186262 -0.38389490430098572 #REF! 0.7 -0.01 -0.01 -7.2456195776325005E-2 Total U.S. Treatment Sessions Revenues $5,748.7510000000002 $7,386.4830000000002 $7,227.3850000000002 $8,023.9769999999999 $7,239.5487700000012 $8,920 $9,218 $9,909 $8,777.6730000000007 $10,847.351000000001 $10,251.888499999999 $11,243.30969 $8,193.4259999999995 $6,546.6486100000002 $9,083.3856099999994 $11,028.800499999999 $28,386.595999999998 $9,628.61 $10,801 $10,258.61579 $11,244.748890000001 $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,878 $12,988 $11,660 $13,326 $12,858 $9,612 $41,120.22219 $34,852.260719999998 $41,932.974679999999 $45,077 $50,896 $50,895 $50,832 YoY Change 0.25932550740152105 0.20761125423290072 0.27542672764769005 0.23492377906865891 0.21246133963125424 0.21607073991031389 0.11215974180950306 0.13465634170955698 -6.6560579324383751E-2 -0.39647489880248188 -0.11397928196351337 -1.9078829625300497E-2 0.17516286837764827 0.64985180104236573 0.12938239445721389 1.9580405865533779E-2 -1.6607896674597833E-2 4.5693639477826231E-2 0.1564476273265325 0.10716567544444278 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19503927773940144 0.22033261298506068 -5.3110280980997238E-2 2.0367534456355196E-2 -0.13577093695389164 -0.25993224514936863 -1 -1 -1 0.16530796582310758 -0.15243014595199111 0.20316369193051309 7.0000000000000007E-2 0.13 0.13 -1.2378426171529844E-3 Total U.S. Clinic Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $0 $0 $0 $0 $0 $0 $0 $4,445 $18,659 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $0 $0 $4,445 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 na na n/a n/a -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0 na na Total U.S. Other Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $471 $486 $554 $470 $495 $470 $488 $490 $366 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $1,980 $1,981 $1,943 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.15959298532413202 6.7833062625201279E-2 0.24213998926647551 5.1454138702460961E-2 5.0955414012738842E-2 -3.2921810699588439E-2 -0.11913357400722024 4.2553191489361764E-2 -0.26060606060606062 -1 -1 -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0.13 0.13 -1.9182231196365418E-2 Total U.S. Revenues $7,346.9226500000004 $10,177.2872 $10,421.701070000001 $11,884.24583 $9,972.814600000012 $12,897.737710000001 $13,518.360389999998 $15,089 $12,545.759 $15,890 $15,293.75468 $17,030 $11,177.5 $9,267.1140899999991 $12,028.93211 $15,046.68909999998 $39,829.898270000005 $11,801.763999999999 $13,809.378989999999 $13,280 $14,556.26310000001 $13,516.902740000001 $16,131.57429 $16,243.556370000002 $17,512.8 $14,964 $17,289 $17,211 $19,871.599999999999 $16,793 $16,130 $17,922 $21,642 $31,483 $0 $0 $0 $60,760.108459999996 $47,519.165110000002 $53,447.169300000001 $63,406 $69,336 $69,335.600000000006 $72,487 YoY Change 0.35 0.26 0.29713568823366732 0.26966407594077846 0.25808829884949591 0.23199900302515908 0.13133207273519076 0.12863675525217055 -0.10909734516660174 -0.41679584078036502 -0.21347423430751666 -0.11649624721080454 5.5892565569626962E-2 0.49014880532241301 0.10400490073095936 -3.2569477312064055E-2 0.14532901522179253 0.16816073349001481 0.22315936521084345 0.20313055411068426 0.10705834671116365 7.1749085934997181E-2 5.9558609454931632E-2 0.1346900552738568 0.12222667735899484 -6.7036844236219584E-2 4.1310789611295196E-2 8.9091970450291047E-2 0.87476924909188347 -1 -1 -1 0.18034051052656319 -0.2179216542827086 0.12474975467850768 0.19 0.09 0.09 4.5451398704273061E-2 Total International Revenues $132.1 $83.5 $92.5 $272.23500000000001 $179.732 $354 $219.30699999999999 $545.61800000000005 $182 $682 $706.37199999999996 $325.548 $298.822 $473.91300000000001 $418.98599999999999 $532.87300000000005 $580.33500000000004 $486.28800000000001 $393.93900000000002 $519 $466.178 $663.74939000000006 $197.87039000000001 $253.36739 $686 $576 $321 $673.3 $442 $624 $320 $608 $851 $492 $1,895.7699999999998 $1,724.5940000000001 $1,865.4050000000002 $1,800 $2,012 $2,012.3 $2,402 YoY Change 0.36057532172596529 3.25 1.3708864864864863 1.004216944918912 1.2618787973204482E-2 0.92655367231638408 2.2209277405645969 -0.40334079887393748 0.6418791208791208 -0.30511290322580642 -0.40684794980548489 0.63684925110889967 0.62735006124047099 -0.16875249254610025 0.23870487319385369 -0.12516115472166922 0.36493063781133817 -0.49771312309773852 -0.51181620423892094 0.4715409135566242 -0.13220259230671394 0.62227405525404778 1.6574059116289588 -0.35568513119533529 8.3333333333333259E-2 -3.1152647975077885E-3 -9.6984999257388904E-2 0.92533936651583715 -0.21153846153846156 -1 -1 -1 0.45904444083572726 -9.0293653766015725E-2 8.1648782264115649E-2 -0.03 0.12 0.12 0.1936589971674203 Total Revenues $7,479.226500000008 $10,260.52872 $10,514.201070000001 $12,156.48083 $10,151.813460000001 $13,252.403710000001 $13,737 $15,634.618 $12,728.371999999999 $16,571.754240000002 $16,000.126679999999 $17,355.547999999999 $11,476 $9,741 $12,447.918110000001 $15,578.941909999998 $40,410.233270000004 $12,288.52 $14,203.31799 $13,799 $15,022.204310000001 $14,180.652129999999 $16,329.445 $16,497.5124 $18,198.8 $15,540 $17,610 $17,884.3 $20,313.599999999999 $17,417 $16,450 $18,530 $22,493 $31,975 $0 $0 $0 $62,655.878459999993 $49,243.860019999993 $55,312 $65,206 $71,348 $71,347.899999999994 $74,890 YoY Change 0.35 0.29159072321177626 0.30651867018175616 0.28611382016221221 0.2538027860886245 0.25047158256243618 0.16474679187595531 0.11007176510484618 -9.8392158871535185E-2 -0.41219258631728306 -0.22201127785070751 -0.10236531223329859 7.0760892296967581E-2 0.45809649830612864 0.10853878359905123 -3.5736547656207041E-2 0.15401954109569194 0.14969227693817189 0.19555854772084924 0.21146002440436762 9.5859334079863689E-2 7.8419995290715638E-2 8.4060406585904301E-2 0.11620546409653376 0.12078507078507084 -6.5871663827370863E-2 3.6104292591826459E-2 0.10728772841839951 0.83585003157834303 -1 -1 -1 0.18720207332511252 -0.21405842148653842 0.12322632664327049 0.18 0.09 0.09 4.9645469593358804E-2 2018 2019 2020 2020 2020 2020 2021 2020 2020 2020 2022 2020 2020 2020 2023 2020 2020 2020 2024 2025 2019 2020 2021 2022 2023 2023 2024 U.S. Operating and Financial Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY Active Installed Base Active Installed Base - Beginning of Period 647 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! 647 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 907 #REF! #REF! 752 752 752 752 Active Installed Base - End of Period 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! 752 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1085 #REF! 752 907 907 907 907 Total NeuroStar Systems 14 25 30 40 24 43 47 61 43 61 68 78 #REF! #REF! #REF! #REF! 109 23 36 40 48 46 59 50 58 49 54 43 58 40 50 48 47 31 250 #REF! 147 213 204 204 185 YoY Change 0.71428571428571419 0.72 0.56666666666666665 0.52499999999999991 0.79166666666666674 0.41860465116279078 0.44680851063829796 0.27868852459016402 #REF! #REF! #REF! #REF! -0.39473684210526316 2.857142857142847E-2 2.564102564102555E-2 -0.11111111111111116 1 0.63888888888888884 0.25 0.20833333333333326 6.5217391304347894E-2 -8.4745762711864403E-2 -0.14000000000000001 0 -0.18367346938775508 -7.407407407407407E-2 0.11627906976744184 -0.18965517241379315 -0.22499999999999998 -1 -1 -1 #REF! #REF! #REF! 0.44897959183673503 -0.04 -0.04 -9.3137254901960786E-2 Active Sites Active Sites - Beginning of Period 0 615 637 679 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 916 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1081 1001 1044 1081 #REF! #REF! 916 959 959 959 959 Active Sites - End of Period 615 637 679 707 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 #REF! #REF! 0 1101 1101 1101 1101 NeuroStar System Average Selling Price ($) (4) $75,077.285714285739 $77,094.799999999988 $74,773 $74,757.174999999988 $79,527.83333333343 $75,993.23255813954 $72,930.276595744683 $71,110.655737704918 $68,344.72093023255 $66,132.229508196717 $62,706.355588235296 $63,573.930512820516 #REF! #REF! #REF! #REF! $75,338.798165137618 $69,101.260869565216 $67,801.336111111115 $56,914.728999999999 $52,358.735416666663 $75,760 $72,410.547796610161 $72,755.848399999988 $0 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $64,782.75104000001 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 YoY Change 5.926955905121245E-2 -1.4291194012904018E-2 -2.4644235275504744E-2 -4.8778184332073482E-2 -0.14061074459666201 -0.12975919795193602 -0.14018760773637229 -0.10598587717548236 #REF! #REF! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 Sequential Change 6.3805358259369171E-2 -4.4438446996812098E-2 -4.0302997944419161E-2 -2.4950143383193124E-2 -3.8896207309276565E-2 -3.237252843997096E-2 -5.1803393677160137E-2 1.3835518209385222E-2 #REF! #REF! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0 Average Revenue Per Active Site ($) (1) $8,885.2411128284384 $11,008.171385991058 $10,474.471014492754 $11,067.55448275862 $9,627.595345744696 $11,421.254801536492 $11,296.568627450981 $11,548.951048951049 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $43,874.182380216385 $10,511.582969432315 $12,001.111111111111 $11,162.802818280739 $12,182.826533044421 $9,873.5130761209602 $11,280 $11,364 $11,516.928769657725 $9,666.6666666666661 $11,391.304347826088 $11,916.58394160586 $13,236.654804270464 $11,299.808595789107 $10,000 $11,390 $11,027.444253859348 $8,362.6239777275096 $0 $11,390 $0 YoY Change 8.3488834160617253E-2 3.7525162087421959E-2 7.8485835878561394E-2 4.3496200261978757E-2 NA #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.11614813917964395 0.62052110235716817 9.2514634028795673E-2 .4% -6.0701598909209231E-2 -6.0087028978798251E-2 1.8023894625261105E-2 -5.4658724851784579E-2 -2.0949626324448856E-2 9.8674067221709016E-3 4.8579584139438969E-2 0.14932158295043862 1.756081186977676E-3 -0.12002815909890885 -1.1021060579286424E-2 -4.2501306171829678E-2 -0.13490096782129202 -1 -4.4147013782542266E-2 -1 Use Total Systems Recognized from the Q or K #DIV/0! (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) Three Months EndedMarch 31, 2024 2025 Revenues $17,417 $31,975 YOY Growth 0.83585003157834303 Gross Profit 13088 15738 Gross Margin 0.75144973301946372 0.49219702892885064 Operating Expenses: Sales and Marketing 11641 11999 % of Revenues 0.66836998334960096 0.37526192337763881 General and Administrative 5957 13137 % of Revenues 0.34202216225526783 0.41085222830336199 Research and Development 2349 1616 % of Revenues 0.1348682321869438 5.0539483971853011E-2 Total Operating Expenses 19947 26752 Loss from Operations $-6,859 $,-11,014 ($ in thousands) % of Revenues -0.39381064477234884 -0.34445660672400313 As of March 31, 2025 Cash and Cash Equivalents $20,224 enter Other Assets $,121,764 calculates Total Assets $,141,988 enter Long-term debt, net $55,341 enter Convertible Preferred Stock Warrant Liability $0 11703 Convertible Preferred Stock $0 0.7530888030888031 Accumulated Deficit $-,432,464 enter Total Stockholders’ Equity $35,452 enter 2017 2018 2019 2020 2021 2022 2022 2022 2022 UNIT SALES / ACTIVE SITES 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) 20 29 32 42 30 47 48 65 43 61 68 78 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 46 59 50 58 0 49 54 43 58 0 31 0 0 0 0 250 YoY D 0.5 0.6206896551724137 0.5 0.54761904761904767 0.43333333333333335 0.2978723404255319 0.41666666666666674 0.19999999999999996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -1 -0.16949152542372881 8.0000000000000071E-2 -0.25862068965517238 #DIV/0! -1 -0.42592592592592593 -1 -1 #DIV/0! -1 #DIV/0! Beginning Active Installed Base 0 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Ending Active Installed Base 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.16393442622950816 0.18260869565217397 0.18344827586206902 0.2061170212765957 0.19206145966709354 0.19607843137254899 0.2027972027972027 0.25137816979051819 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Net Active Installed Base Change 24 19 35 27 29 35 42 49 24 45 56 53 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.20833333333333326 0.84210526315789469 0.19999999999999996 0.81481481481481488 -0.17241379310344829 0.28571428571428581 0.33333333333333326 8.163265306122458E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Active Sites (End of Period) 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 YoY D 0.1983739837398375 0.22135007849293564 0.22680412371134029 0.23055162659123063 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -100.0% -100.0% -100.0% -100.0% #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Inactive Systems (Calculation) (2) -4 10 -3 15 -1 -12 -6 -16 -19 -16 -12 -25 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Inactive System Churn % (Calculation) (3) -0.1% -1.5% -0.7% -1.9% -2.0948180815876516E-2 -1.7185821697099892E-2 -1.2295081967213115E-2 -2.4224806201550399E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! (1) = Includes all active systems placed during the period. (2) = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units (3) = Calculation: Inactive Systems / Ending of Prior Period Installed Base 2017 2018 2019 2020 2021 2022 2022 2022 2022 NeuroStar REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total U.S. NeuroStar Revenue ($000) $1,321.41 $2,509.8959999999997 $2,828.9520000000002 $3,459.297 $2,373 $3,568.15 $3,908 $4,754 $3,350 $4,628 $4,616 $5,413 #REF! #REF! #REF! #REF! #REF! #REF! $2,612 $2,815 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $0 $3,850 $4,489 $3,597 $4,523.6000000000004 $0 $2,846 $0 $0 $0 $0 $18,007.110260000001 YoY D 0.79580902218085225 0.42163260947864001 0.38143029644900284 0.37426766189777871 0.41171512852928771 0.29703067415887774 0.18116683725690885 0.13862010938157332 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.08 #REF! 0.50612557427258809 0.63978685612788633 1.08 -0.12138769934609128 0.14107778342653798 -0.22075389948006929 1.08 -1 -0.36600579193584315 -1 1.08 #DIV/0! -1 #DIV/0! U.S. NeuroStar Capital Revenue ($000) (1) $1,083.820000000001 $1,974.9379999999999 $2,219.7345 $2,942.4469999999997 $1,908.6499999999999 $3,267.65 $3,427.6 $4,337.7 $2,938.5729999999999 $4,034.599999999995 $4,264 $4,958.8 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $16,195.687760000001 YoY D 0.76223960882001518 0.65455826967732667 0.54414863579405548 0.47418118321247604 0.53960809996594405 0.23454470338010469 0.24401913875598091 0.14318648131498279 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! U.S. NeuroStar Operating Lease Revenue ($000) (2) $229.8 $293.95800000000003 $289 $234 $258 $181 $269 $231 $182 $187 $184 $176.7 #REF! #REF! #REF! #REF! #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $730.13850000000002 YoY D 0.13 -0.38426577946509366 -6.9204152249134898E-2 -0.02 -0.29457364341085268 3.3149171270718147E-2 -0.31 -0.23506493506493509 #REF! #REF! #REF! #REF! -0.3 #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! U.S. NeuroStar Other ($000) (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $119.5 $210.995 $185 $228.95 $407.25 $167.084 $278 #REF! #REF! #REF! #REF! #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $1,081.2840000000001 YoY D NM -0.50414937759336098 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.39 -0.20811393634920261 0.50270270270270268 #REF! #REF! #REF! #REF! #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 (1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases (2) = Revenue derived from Operating Lease revenue amortization during the period (3) = Revenue derived from Treatment Coils in U.S. 2017 2018 2019 2020 2021 2022 2023 2024 2025 Treatment Session REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Update/Unhide Total U.S. Treatment Session Revenues ($000) $5,749.6779800000004 $7,388.1369999999997 $7,228.5863399999998 $8,025.3639999999996 $7,239.5479999999998 $8,919.991 $9,218 $9,909 $8,777.6730000000007 $10,847.352000000001 $10,251.888000000001 $11,243 #REF! #REF! #REF! #REF! #REF! $10,801 #REF! #REF! $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,878 $9,612 $0 $0 $0 $0 $41,120.22219 $0 $34,852.260719999998 YoY D 0.26 0.20733968522781865 0.27521476073287099 0.2347103508326851 0.21246146858892301 0.21607207899649228 0.11215968756780215 0.13462508830356246 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 4.5693639477826231E-2 #REF! #REF! 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19503927773940144 -9.6871182937141809E-2 -1 -1 -1 -1 #DIV/0! #DIV/0! #DIV/0! Active Sites(End of Period) 0 671 690 725 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 Average Revenue per Active Site ($000) (1) $8.8866738485316894 $11.010636363636364 $10.476212086956522 $11.069467586206896 $0 $14.504065040650406 $14.470957613814758 $14.593519882179676 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $10.511582969432315 $12.001111111111111 $11.16280281828074 $12.182826533044421 $9.8735130761209611 $11.28 $11.364000000000001 $11.516928769657724 $9.6666666666666661 $11.391304347826088 $11.916058394160585 $13.236654804270463 $8.3626239777275089 $0 $11.39 $0 $0 $0 $0 $0 YoY D 8.3314035681520959E-2 3.7291842237985096E-2 7.8306599149118972E-2 4.3315855890089239E-2 NM #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -6.0701598909209099E-2 -6.0087028978798328E-2 1.8023894625261182E-2 -5.4658724851784697E-2 -2.0949626324448987E-2 9.8674067221709624E-3 4.8579584139438914E-2 0.14932158295043862 -0.13490096782129213 -1 -4.414701378254212E-2 -1 -1 #DIV/0! -1 #DIV/0! (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) Q1 2023 15.5 Q2 2023 17.600000000000001 Q3 2023 17.899999999999999 Q4 2023 20.3 Q1 2024 17.399999999999999 Q2 2024 16.5 Q3 2024 18.5 Q4 2024 22.5 Q1 2025 32 Q2 2025 37
Supplemental Financial and Operating Information1 ($ in thousands) (1) 2024 revenue is Adjusted Pro forma revenue, pro forma revenue adjusted for Greenbrook store closures, per slide 24 $000s NS 3310 4000 4108 3849 Proforma /Adjusted Proforma Revenue Q1-24 Q2-24 Q3-24 Q4-24 Total 12988 11660 13326 12858 TS $10,224.716 $9,504.98308 $11,073.277 $11,579.70931 NNI $14,532.857960000001 $14,167.228060000001 $16,138 $16,770 $61,608.86020000002 Clinic $15,234.380363423368 $18,003.758999999998 $17,419.976180000001 $17,164.668999999998 GB $18,012.190363423368 $20,408.66999999999 $19,072.13018 $18,003.758999999998 $75,496.146543423369 495 470 488 490 Other $374.28399999999999 $341.79200000000003 $348.40600000000001 $490 Total Proforma (filings) $32,545.48323423369 $34,575.295060000004 $35,210.13018 $34,773.758999999998 $,137,104.23256342337 Adjusted For Store Closures $-2,777.81 $-2,404.308 $-1,652.154 $-,839.9 $-7,673.362000000001 $29,143.38036342337 $31,850.534079999998 $32,949.659180000002 $33,083.37831 $,127,026.95193342338 Adjusted Proforma Revenue (internal) $29,767.238323423368 $32,170.987060000003 $33,557.976179999998 $33,934.669000000002 $,129,430.87056342338 INT 624 320 608 851 $29,767.38036342337 $32,170.534079999998 $33,557.659180000002 $33,934.37831 $,129,429.95193342338 $0.14204000000245287 $-0.452980000005482 $-0.3169999999954598 $-0.29069000000163214 $-0.91863000000012107 TS Other Total Q1 $2,763,284 $,120,716 $2,884,000 Q2 $2,155,016.9199999995 $,128,208 $2,283,224.9199999995 Q3 $2,252,723 $,139,594 $2,392,317 Q4 $1,278,290.69 $0 $1,278,290.69 67.8 $8,449,314.6099999994 $,388,518 $8,837,832.6099999994 2017 2018 2019 2020 2021 2022 2022 2022 2022 UNIT SALES / ACTIVE SITES 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) 20 29 32 42 30 47 48 65 43 61 68 78 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 46 59 50 58 0 49 54 43 58 0 31 0 0 0 0 250 YoY D 0.5 0.6206896551724137 0.5 0.54761904761904767 0.43333333333333335 0.2978723404255319 0.41666666666666674 0.19999999999999996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -1 -0.16949152542372881 8.0000000000000071E-2 -0.25862068965517238 #DIV/0! -1 -0.42592592592592593 -1 -1 #DIV/0! -1 #DIV/0! Beginning Active Installed Base 0 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Ending Active Installed Base 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.16393442622950816 0.18260869565217397 0.18344827586206902 0.2061170212765957 0.19206145966709354 0.19607843137254899 0.2027972027972027 0.25137816979051819 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Net Active Installed Base Change 24 19 35 27 29 35 42 49 24 45 56 53 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.20833333333333326 0.84210526315789469 0.19999999999999996 0.81481481481481488 -0.17241379310344829 0.28571428571428581 0.33333333333333326 8.163265306122458E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Active Sites (End of Period) 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 YoY D 0.1983739837398375 0.22135007849293564 0.22680412371134029 0.23055162659123063 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -100.0% -100.0% -100.0% -100.0% #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Inactive Systems (Calculation) (2) -4 10 -3 15 -1 -12 -6 -16 -19 -16 -12 -25 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Inactive System Churn % (Calculation) (3) -0.1% -1.5% -0.7% -1.9% -2.0948180815876516E-2 -1.7185821697099892E-2 -1.2295081967213115E-2 -2.4224806201550399E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! (1) = Includes all active systems placed during the period. (2) = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units (3) = Calculation: Inactive Systems / Ending of Prior Period Installed Base 2017 2018 2019 2020 2021 2022 2022 2022 2022 NeuroStar REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total U.S. NeuroStar Revenue ($000) $1,321.41 $2,509.8959999999997 $2,828.9520000000002 $3,459.297 $2,373 $3,568.15 $3,908 $4,754 $3,350 $4,628 $4,616 $5,413 #REF! #REF! #REF! #REF! #REF! #REF! $2,612 $2,815 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $0 $3,850 $4,489 $3,597 $4,523.6000000000004 $0 $2,846 $0 $0 $0 $0 $18,007.110260000001 YoY D 0.79580902218085225 0.42163260947864001 0.38143029644900284 0.37426766189777871 0.41171512852928771 0.29703067415887774 0.18116683725690885 0.13862010938157332 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.08 #REF! 0.50612557427258809 0.63978685612788633 1.08 -0.12138769934609128 0.14107778342653798 -0.22075389948006929 1.08 -1 -0.36600579193584315 -1 1.08 #DIV/0! -1 #DIV/0! U.S. NeuroStar Capital Revenue ($000) (1) $1,083.820000000001 $1,974.9379999999999 $2,219.7345 $2,942.4469999999997 $1,908.6499999999999 $3,267.65 $3,427.6 $4,337.7 $2,938.5729999999999 $4,034.599999999995 $4,264 $4,958.8 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $16,195.687760000001 YoY D 0.76223960882001518 0.65455826967732667 0.54414863579405548 0.47418118321247604 0.53960809996594405 0.23454470338010469 0.24401913875598091 0.14318648131498279 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! U.S. NeuroStar Operating Lease Revenue ($000) (2) $229.8 $293.95800000000003 $289 $234 $258 $181 $269 $231 $182 $187 $184 $176.7 #REF! #REF! #REF! #REF! #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $730.13850000000002 YoY D 0.13 -0.38426577946509366 -6.9204152249134898E-2 -0.02 -0.29457364341085268 3.3149171270718147E-2 -0.31 -0.23506493506493509 #REF! #REF! #REF! #REF! -0.3 #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! U.S. NeuroStar Other ($000) (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $119.5 $210.995 $185 $228.95 $407.25 $167.084 $278 #REF! #REF! #REF! #REF! #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $1,081.2840000000001 YoY D NM -0.50414937759336098 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.39 -0.20811393634920261 0.50270270270270268 #REF! #REF! #REF! #REF! #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 (1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases (2) = Revenue derived from Operating Lease revenue amortization during the period (3) = Revenue derived from Treatment Coils in U.S. 2017 2018 2019 2020 2021 2022 2023 2024 2025 Treatment Session REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Update/Unhide Total U.S. Treatment Session Revenues ($000) $5,749.6779800000004 $7,388.1369999999997 $7,228.5863399999998 $8,025.3639999999996 $7,239.5479999999998 $8,919.991 $9,218 $9,909 $8,777.6730000000007 $10,847.352000000001 $10,251.888000000001 $11,243 #REF! #REF! #REF! #REF! #REF! $10,801 #REF! #REF! $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $9,612 $0 $0 $0 $0 $41,120.22219 $0 $34,852.260719999998 YoY D 0.26 0.20733968522781865 0.27521476073287099 0.2347103508326851 0.21246146858892301 0.21607207899649228 0.11215968756780215 0.13462508830356246 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 4.5693639477826231E-2 #REF! #REF! 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 -9.6871182937141809E-2 -1 -1 -1 -1 #DIV/0! #DIV/0! #DIV/0! Active Sites(End of Period) 0 671 690 725 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 Average Revenue per Active Site ($000) (1) $8.8866738485316894 $11.010636363636364 $10.476212086956522 $11.069467586206896 $0 $14.504065040650406 $14.470957613814758 $14.593519882179676 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $10.511582969432315 $12.001111111111111 $11.16280281828074 $12.182826533044421 $9.8735130761209611 $11.28 $11.364000000000001 $11.516928769657724 $9.6666666666666661 $11.391304347826088 $11.916058394160585 $13.237544483985765 $8.3626239777275089 $0 $11.39 $0 $0 $0 $0 $0 YoY D 8.3314035681520959E-2 3.7291842237985096E-2 7.8306599149118972E-2 4.3315855890089239E-2 NM #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -6.0701598909209099E-2 -6.0087028978798328E-2 1.8023894625261182E-2 -5.4658724851784697E-2 -2.0949626324448987E-2 9.8674067221709624E-3 4.8579584139438914E-2 0.14939883268716059 -0.13490096782129213 -1 -4.414701378254212E-2 -1 -1 #DIV/0! -1 #DIV/0! (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) Q1 2023 15.5 Q2 2023 17.600000000000001 Q3 2023 17.899999999999999 Q4 2023 20.3 Q1 2024 17.399999999999999 Q2 2024 16.5 Q3 2024 18.5 Q4 2024 22.5 Q1 2025 32 Q2 2025 37 March 31, 2024 https://neuronetics.sharepoint.com/sites/FinanceDepartment/Shared Documents/FPA/FPA Kristen/Investor Deck/2025/Q1 2025/[Revenue for IR Deck Q1 2025 adjusted for Pro forma.xlsx]Supplemental CorpDeck Intercompany revenue/ prepaid Total Consolidated STIM STIM STIM STIM STIM GB Neuronetics Greenbrook Eliminations Adjustments I/S Nine months ended 9.30 STIM Q4.24 Acquiree fees paid by STIM Eliminations STIM Q4.24 after adjustments GB Q4.24 after adjustments Consolidated Q4.24 Revenues $ 17,417 $ 18,012.189999999999 $ -2,883.6198799999997 -2,883.6198799999997 $ 32,545.570120000004 52,397 ,-34,980 $,-34,980 18,012.189999999999 $,-16,967.810000000001 Cost of revenues 4,329 15,606.44360000018 -2,883.6198799999997 -2,883.6198799999997 17,051.42448000002 13,129 -8,800 12,722.424480000018 $12,722.424480000018 2905 Gross profit 13,088 2,406.1456399999806 0 0 15,494.145639999984 39,268 ,-26,180 0 0 $,-34,980 $5,289.7655199999808 $,-29,690.234480000021 12,716.335639999985 2884 Operating expenses: 21 Sales and marketing 11,641 7,085.4390400000266 0 18,726.439040000027 35,820 ,-24,179 $,-24,179 7,085.4390400000266 $,-17,093.560959999973 .7% General and administrative 5,957 5,534.739999999996 0 11,491.74000000001 19,540 ,-13,583 #REF! 0 #REF! 5,534.739999999996 #REF! Research and development 2,349 124.444 0 0 2,473.444 6,999 -4,650 $-4,650 124.444 $-4,525.5559999999996 Total operating expenses 19,947 12,743.957040000027 0 0 32,690.957040000027 62,359 ,-42,412 #REF! 0 #REF! $12,743.957040000027 #REF! Loss from operations -6,859 ,-10,337.811400000046 0 0 ,-17,196.811400000042 ,-23,091 16,232 #REF! 0 #REF! $-7,454.1915200000458 #REF! Other (income) expense: Interest expense 1,826 4,202.402 -4,194 -4,194 1,834.402 5,529 -3,703 $-3,703 8.4020000000000437 $-3,694.598 Loss on extinguishment of debt 0 0 0 0 4,427 -4,427 $-4,427 0 $-4,427 Other income, net -,812 -6.5000000000000002E-2 0 0 -,812.6500000000005 -2,001 1,189 $1,189 -6.5000000000000002E-2 $1,188.9349999999999 Net loss before non- controlling interest -7,873 ,-14,540.148400000046 4,194 4,194 ,-18,219.148400000046 ,-31,046 23,173 #REF! 0 #REF! $-7,462.5285200000462 #REF! Non-controlling interest -,321.84899999999999 0 -,321.84899999999999 Net Loss $ -7,873 $ ,-14,218.299400000045 $ 4,194 4,194 $ ,-17,897.299400000047 ,-31,046 23,173 #REF! 0 #REF! $-7,462.5285200000462 #REF! Net loss per share of common stock outstanding, basic and diluted $ -0.26713490770901194 0 $ -0.60726450190011017 Weighted average common shares outstanding, basic and diluted 29,472 29,472 Q3.24 adjustments per 8KA TS expense per GB Dev. Cost Var Deprec. Expense Elim I/C COGs GB Reclass 60% of R. personnel to Mktg TOTAL $5,515,743.4000000451 0.6 $3,309,446.40000027 COGs to Mkting 0.4 $2,206,297.360000018 NNI IC Revenue 13158183 Neuronetics, Inc. Supplemental Financial and Operating Information For the period ended March 31, 2025 2017 2018 2019 2020 2017 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2023 2024 Revenue ($ thousands) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY NeuroStar Capital (1) $1,051.820000000003 $1,927.3699999999997 $2,243.19 $2,990.2869999999994 $1,908.65 $3,267.7 $3,427.723 $4,337.75 $2,938.8229999999999 $4,034.659999999998 $4,264.321800000002 $4,958.7665800000004 $2,410.320000000002 $2,223.8835899999999 $2,438.3874999999998 $3,445.80141 $8,211.9290000000001 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $16,195.687760000001 $10,518.104500000001 #REF! $12,941.823 $12,941.823 $12,941.823 $12,941.823 YoY Change 0.76 0.65 0.54 0.47 0.53973908259764736 0.2345276494170212 0.24398388667929116 0.14316559967725206 -0.17993291872290362 -0.44872404417776013 -0.4281498363363665 -0.30510917293469386 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.25142244334511443 -0.35056141759057968 #REF! 0.56999999999999995 0.56999999999999995 0.56999999999999995 0.56999999999999995 Sales $1,876 $3,277 $3,538 $4,385 $2,451 $3,754 $2,969 $4,070.4648999999999 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $13,244.464899999999 $13,244.464899999999 $13,244.464899999999 $13,076 $13,076 $13,076 $13,076 YoY 1.3318827646177938 0.9477318833436239 0.32356153513523145 0.3612288385696758 0.306503198294243 0.1455599633811413 -0.16082532504239688 -7.1729783352337484E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.2883519424900403E-2 1.2883519424900403E-2 1.2883519424900403E-2 0.59231771244003695 0.59231771244003695 0.59231771244003695 0.59231771244003695 Sales-Type-Leases $0 $0 $0 $0 $450 $350 $1,283 $996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $3,079 $3,079 $3,079 $0 $0 $0 $0 YoY nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm Other NeuroStar $32.35 $-9.65 $-,110.6 $-42.3 $37.573 $-69.5 $12.5 $-,107.69926 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $-,127.12626 $-,127.12626 $-,127.12626 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 YoY -0.41530508964719492 -1.2028674739320553 3.7153119737375082 -0.11580267558528445 0.16145285935084996 6.2020725388601035 -1.1130198915009042 1.5460817966903075 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -2.3607834101382341E-2 -2.3607834101382341E-2 -2.3607834101382341E-2 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 NeuroStar Operating Lease (2) $215 $293.95800000000003 $289 $234 $258 $181.13883999999999 $269 $231 $181.94399999999999 $187.08323999999999 $184.44399999999999 $176.66726 $155.417 $114.16689 $87.917000000000002 $79.167000000000002 $1,031.9580000000001 #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $730.13850000000002 $436.66789000000006 $279 $939 $939 $939 $939 YoY Change 0.13 -0.38379346709393869 -6.9204152249134898E-2 -0.02 -0.29479069767441868 3.2816816095322165E-2 -0.3143345724907064 -0.23520666666666667 -0.14579760805522568 -0.38975351292825589 -0.52334041768775341 -0.5518864106456397 #REF! #REF! -0.65876906627842169 7.3679689769727164E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.22350933218443014 -0.40193827609419308 -0.36107049226816301 -0.1 -0.1 -0.1 -0.1 Other (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $120 $210.995 $185 $228.95 $407.25 $167.084 $278 $29 $0 $15 $95.5 $852.0675 #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $1,081.2840000000001 $139.5 #REF! $722 $722 $722 $722 YoY Change NM -0.50207468879668049 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.3937499999999998 -0.20811393634920261 0.50270270270270268 -0.87333478925529595 -1 -0.91022479710804149 -0.65647482014388492 #REF! 1 19.333333333333332 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 0.49867150846506236 -0.87098671579344555 #REF! -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 Total U.S. NeuroStar Advanced Therapy System Revenues $1,274.820000000003 $2,462.3279999999995 $2,852.4075000000003 $3,507.1369999999993 $2,372.65 $3,568 $3,907.7179999999998 $4,753.75 $3,349.7169999999996 $4,628.3992399999997 $4,615.5601800000004 $5,413.4338400000006 $2,594.4490000000001 $2,338.504799999999 $2,541.3044999999997 $3,620.4684099999999 $10,095.9545 $1,755.2459999999999 $2,577.2649900000001 $2,611.58916 $2,815.2192999999997 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $3,850 $4,489 $3,597 $4,523.6000000000004 $3,310 $4,000 $4,108 $3,849 $2,846 $18,007.110260000001 $11,094.272390000002 #REF! $16,575 $16,460 $16,459.599999999999 $15,267 YoY Change 0.8 0.42 0.38 0.37 0.41180410089983743 0.29719709641255587 0.18113952439761527 0.13877125216934005 -0.22547218167982541 -0.49484684471601459 -0.4494049690843811 -0.33120667638934342 -0.32346097379443584 0.1023136634757349 2.7656921868276729E-2 -0.22241572603584747 1.08 0.70021708555471407 0.50636250917812808 0.63965911998400982 5.7103727438351903E-2 2.4439121463739388E-2 -8.566344687341132E-2 -2.0017331022530227E-2 -0.14025974025974031 -0.10893294720427715 0.14206283013622456 -0.14912901229109565 -0.14018126888217519 -1 -1 -1 0.23311033760186262 -0.38389490430098572 #REF! 0.7 -0.01 -0.01 -7.2456195776325005E-2 Total U.S. Treatment Sessions Revenues $5,748.7510000000002 $7,386.4830000000002 $7,227.3850000000002 $8,023.9769999999999 $7,239.5487700000012 $8,920 $9,218 $9,909 $8,777.6730000000007 $10,847.351000000001 $10,251.888499999999 $11,243.30969 $8,193.4259999999995 $6,546.6486100000002 $9,083.3856099999994 $11,028.800499999999 $28,386.595999999998 $9,628.61 $10,801 $10,258.61579 $11,244.748890000001 $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $10,224.716 $9,504.98308 $11,073.277 $11,579.70931 $9,612 $41,120.22219 $34,852.260719999998 $41,932.974679999999 $45,077 $50,896 $50,896 $42,382.685389999999 YoY Change 0.25932550740152105 0.20761125423290072 0.27542672764769005 0.23492377906865891 0.21246133963125424 0.21607073991031389 0.11215974180950306 0.13465634170955698 -6.6560579324383751E-2 -0.39647489880248188 -0.11397928196351337 -1.9078829625300497E-2 0.17516286837764827 0.64985180104236573 0.12938239445721389 1.9580405865533779E-2 -1.6607896674597833E-2 4.5693639477826231E-2 0.1564476273265325 0.10716567544444278 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 -3.9301324814431937E-2 -0.22811571544583398 -0.15212274119448699 -0.22174142684320186 -5.9924989603623247E-2 -1 -1 -1 0.16530796582310758 -0.15243014595199111 0.20316369193051309 7.0000000000000007E-2 0.13 0.13 -0.16726883468248976 Total U.S. Clinic Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $0 $0 $0 $0 $15,234.380363423368 $18,003.758999999998 $17,419.976180000001 $17,164.668999999998 $18,659 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $0 $0 $67,822.78454342336 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.22479546623365754 n/a n/a -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0 0 na Total U.S. Other Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $471 $486 $554 $469 $374.28399999999999 $341.79200000000003 $348.40600000000001 $490 $366 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $1,980 $1,980 $1,554.482 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.15959298532413202 6.7833062625201279E-2 0.24213998926647551 4.9217002237136542E-2 -0.20534182590233552 -0.29672427983539085 -0.37110830324909749 4.4776119402984982E-2 -2.2132925799660086E-2 -1 -1 -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0.13 0.13 -0.21490808080808077 Total U.S. Revenues $7,346.9226500000004 $10,177.2872 $10,421.701070000001 $11,884.24583 $9,972.814600000012 $12,897.737710000001 $13,518.360389999998 $15,089 $12,545.759 $15,890 $15,293.75468 $17,030 $11,177.5 $9,267.1140899999991 $12,028.93211 $15,046.68909999998 $39,829.898270000005 $11,801.763999999999 $13,809.378989999999 $13,280 $14,556.26310000001 $13,516.902740000001 $16,131.57429 $16,243.556370000002 $17,512.8 $14,964 $17,289 $17,211 $19,871.599999999999 $29,143.38036342337 $31,850.534079999998 $32,949.659180000002 $33,083.37831 $31,483 $0 $0 $0 $60,760.108459999996 $47,519.165110000002 $53,447.169300000001 $63,406 $69,336 $69,335.600000000006 $,127,026.95193342336 YoY Change 0.35 0.26 0.29713568823366732 0.26966407594077846 0.25808829884949591 0.23199900302515908 0.13133207273519076 0.12863675525217055 -0.10909734516660174 -0.41679584078036502 -0.21347423430751666 -0.11649624721080454 5.5892565569626962E-2 0.49014880532241301 0.10400490073095936 -3.2569477312064055E-2 0.14532901522179253 0.16816073349001481 0.22315936521084345 0.20313055411068426 0.10705834671116365 7.1749085934997181E-2 5.9558609454931632E-2 0.1346900552738568 0.94756618306758678 0.84224270229625753 0.91445349950612997 0.66485729936190352 8.0279624648930126E-2 -1 -1 -1 0.18034051052656319 -0.2179216542827086 0.12474975467850768 0.19 0.09 0.09 0.83205960478344965 Total International Revenues $132.1 $83.5 $92.5 $272.23500000000001 $179.732 $354 $219.30699999999999 $545.61800000000005 $182 $682 $706.37199999999996 $325.548 $298.822 $473.91300000000001 $418.98599999999999 $532.87300000000005 $580.33500000000004 $486.28800000000001 $393.93900000000002 $519 $466.178 $663.74939000000006 $197.87039000000001 $253.36739 $686 $576 $321 $673.3 $441.6 $624 $320 $608 $851 $492 $1,895.7699999999998 $1,724.5940000000001 $1,865.4050000000002 $1,800 $2,012 $2,011.9 $2,402 YoY Change 0.36057532172596529 3.25 1.3708864864864863 1.004216944918912 1.2618787973204482E-2 0.92655367231638408 2.2209277405645969 -0.40334079887393748 0.6418791208791208 -0.30511290322580642 -0.40684794980548489 0.63684925110889967 0.62735006124047099 -0.16875249254610025 0.23870487319385369 -0.12516115472166922 0.36493063781133817 -0.49771312309773852 -0.51181620423892094 0.4715409135566242 -0.13220259230671394 0.62227405525404778 1.6574059116289588 -0.35626822157434401 8.3333333333333259E-2 -3.1152647975077885E-3 -9.6984999257388904E-2 0.92708333333333326 -0.21153846153846156 -1 -1 -1 0.45904444083572726 -9.0293653766015725E-2 8.1648782264115649E-2 -0.03 0.12 0.12 0.19389631691435949 Total Revenues $7,479.226500000008 $10,260.52872 $10,514.201070000001 $12,156.48083 $10,151.813460000001 $13,252.403710000001 $13,737 $15,634.618 $12,728.371999999999 $16,571.754240000002 $16,000.126679999999 $17,355.547999999999 $11,476 $9,741 $12,447.918110000001 $15,578.941909999998 $40,410.233270000004 $12,288.52 $14,203.31799 $13,799 $15,022.204310000001 $14,180.652129999999 $16,329.445 $16,497.5124 $18,198.8 $15,540 $17,610 $17,884.3 $20,313.199999999997 $29,767.38036342337 $32,170.534079999998 $33,557.659180000002 $33,934.37831 $31,975 $0 $0 $0 $62,655.878459999993 $49,243.860019999993 $55,312 $65,206 $71,348 $71,347.5 $,129,429.95193342336 YoY Change 0.35 0.29159072321177626 0.30651867018175616 0.28611382016221221 0.2538027860886245 0.25047158256243618 0.16474679187595531 0.11007176510484618 -9.8392158871535185E-2 -0.41219258631728306 -0.22201127785070751 -0.10236531223329859 7.0760892296967581E-2 0.45809649830612864 0.10853878359905123 -3.5736547656207041E-2 0.15401954109569194 0.14969227693817189 0.19555854772084924 0.21146002440436762 9.5859334079863689E-2 7.8419995290715638E-2 8.4060406585904301E-2 0.11618348462535977 0.91553284191913575 0.82683328109028942 0.87637532248955807 0.6705579775712347 7.416237537950221E-2 -1 -1 -1 0.18720207332511252 -0.21405842148653842 0.12322632664327049 0.18 0.09 0.09 0.81407830594517483 2018 2019 2020 2020 2020 2020 2021 2020 2020 2020 2022 2020 2020 2020 2023 2020 2020 2020 2024 2025 2019 2020 2021 2022 2023 2023 2024 U.S. Operating and Financial Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY Active Installed Base Active Installed Base - Beginning of Period 647 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! 647 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 907 #REF! #REF! 752 752 752 752 Active Installed Base - End of Period 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! 752 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1085 #REF! 752 907 907 907 907 Total NeuroStar Systems 14 25 30 40 24 43 47 61 43 61 68 78 #REF! #REF! #REF! #REF! 109 23 36 40 48 46 59 50 58 49 54 43 58 40 50 48 47 31 250 #REF! 147 213 204 204 185 YoY Change 0.71428571428571419 0.72 0.56666666666666665 0.52499999999999991 0.79166666666666674 0.41860465116279078 0.44680851063829796 0.27868852459016402 #REF! #REF! #REF! #REF! -0.39473684210526316 2.857142857142847E-2 2.564102564102555E-2 -0.11111111111111116 1 0.63888888888888884 0.25 0.20833333333333326 6.5217391304347894E-2 -8.4745762711864403E-2 -0.14000000000000001 0 -0.32203389830508478 0 -0.17241379310344829 -0.18965517241379315 -0.22499999999999998 -1 -1 -1 #REF! #REF! #REF! 0.44897959183673503 -0.04 -0.04 -9.3137254901960786E-2 Active Sites Active Sites - Beginning of Period 0 615 637 679 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 916 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1081 1001 1044 1081 #REF! #REF! 916 959 959 959 959 Active Sites - End of Period 615 637 679 707 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 #REF! #REF! 0 1101 1101 1101 1101 NeuroStar System Average Selling Price ($) (4) $75,077.285714285739 $77,094.799999999988 $74,773 $74,757.174999999988 $79,527.83333333343 $75,993.23255813954 $72,930.276595744683 $71,110.655737704918 $68,344.72093023255 $66,132.229508196717 $62,706.355588235296 $63,573.930512820516 #REF! #REF! #REF! #REF! $75,338.798165137618 $69,101.260869565216 $67,801.336111111115 $56,914.728999999999 $52,358.735416666663 $75,760 $72,410.547796610161 $72,755.848399999988 $0 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $64,782.75104000001 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 YoY Change 5.926955905121245E-2 -1.4291194012904018E-2 -2.4644235275504744E-2 -4.8778184332073482E-2 -0.14061074459666201 -0.12975919795193602 -0.14018760773637229 -0.10598587717548236 #REF! #REF! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 Sequential Change 6.3805358259369171E-2 -4.4438446996812098E-2 -4.0302997944419161E-2 -2.4950143383193124E-2 -3.8896207309276565E-2 -3.237252843997096E-2 -5.1803393677160137E-2 1.3835518209385222E-2 #REF! #REF! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0 Average Revenue Per Active Site ($) (1) $8,885.2411128284384 $11,008.171385991058 $10,474.471014492754 $11,067.55448275862 $9,627.595345744696 $11,421.254801536492 $11,296.568627450981 $11,548.951048951049 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $43,874.182380216385 $10,511.582969432315 $12,001.111111111111 $11,162.802818280739 $12,182.826533044421 $9,873.5130761209602 $11,280 $11,364 $11,516.928769657725 $9,666.6666666666661 $11,391.304347826088 $11,916.58394160586 $13,237.544483985765 $8,895.6986253697578 $8,151.7865180102917 $11,390 $9,931.1400600343059 $8,362.6239777275096 $0 $11,390 $0 YoY Change 8.3488834160617253E-2 3.7525162087421959E-2 7.8485835878561394E-2 4.3496200261978757E-2 NA #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.11614813917964395 0.62052110235716817 9.2514634028795673E-2 .4% -6.0701598909209231E-2 -6.0087028978798251E-2 1.8023894625261105E-2 -5.4658724851784579E-2 -2.0949626324448856E-2 9.8674067221709016E-3 4.8579584139438969E-2 0.14939883268716048 -0.21137423533956046 -0.28266574111137877 -1.1021060579286424E-2 -0.13769197859426785 -0.13490096782129202 -1 -4.4147013782542266E-2 -1 *2024 is Adjusted Pro forma revenue, pro forma revenue adjusted for Greenbrook store closures Use Total Systems Recognized from the Q or K #DIV/0! (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) Three Months EndedMarch 31, 2024 2025 Revenues $29,767.38036342337 $31,975 YOY Growth 7.4162375379502321E-2 Gross Profit 12716.335639999985 15738 Gross Margin 0.42719028294559525 0.49219702892885064 Operating Expenses: Sales and Marketing 18726.439040000027 11999 % of Revenues 0.62909261115264659 0.37526192337763881 General and Administrative 11491.074000000001 13137 % of Revenues 0.38602906469121623 0.41085222830336199 Research and Development 2473.444 1616 % of Revenues 8.3092431037003214E-2 5.0539483971853011E-2 Total Operating Expenses 32690.957040000027 26752 Loss from Operations $,-19,974.62140000004 $,-11,014 ($ in thousands) % of Revenues -0.67102382393527082 -0.34445660672400313 As of March 31, 2025 Cash and Cash Equivalents $20,224 enter Other Assets $,121,764 calculates Total Assets $,141,988 enter Long-term debt, net $55,341 enter Convertible Preferred Stock Warrant Liability $0 11703 Convertible Preferred Stock $0 0.7530888030888031 Accumulated Deficit $-,432,464 enter Total Stockholders’ Equity $35,452 enter $000s NS 3310 4000 4108 3849 Proforma /Adjusted Proforma Revenue Q1-24 Q2-24 Q3-24 Q4-24 Total 12988 11660 13326 12858 TS $10,224.716 $9,504.98308 $11,073.277 $11,579.70931 NNI $14,532.857960000001 $14,167.228060000001 $16,138 $16,770 $61,608.86020000002 Clinic $15,234.380363423368 $18,003.758999999998 $17,419.976180000001 $17,164.668999999998 GB $18,012.190363423368 $20,408.66999999999 $19,072.13018 $18,003.758999999998 $75,496.146543423369 495 470 488 490 Other $374.28399999999999 $341.79200000000003 $348.40600000000001 $490 Total Proforma (filings) $32,545.48323423369 $34,575.295060000004 $35,210.13018 $34,773.758999999998 $,137,104.23256342337 Adjusted For Store Closures $-2,777.81 $-2,404.308 $-1,652.154 $-,839.9 $-7,673.362000000001 $29,143.38036342337 $31,850.534079999998 $32,949.659180000002 $33,083.37831 $,127,026.95193342338 Adjusted Proforma Revenue (internal) $29,767.238323423368 $32,170.987060000003 $33,557.976179999998 $33,934.669000000002 $,129,430.87056342338 INT 624 320 608 851 $29,767.38036342337 $32,170.534079999998 $33,557.659180000002 $33,934.37831 $,129,429.95193342338 $0.14204000000245287 $-0.452980000005482 $-0.3169999999954598 $-0.29069000000163214 $-0.91863000000012107 TS Other Total Q1 $2,763,284 $,120,716 $2,884,000 Q2 $2,155,016.9199999995 $,128,208 $2,283,224.9199999995 Q3 $2,252,723 $,139,594 $2,392,317 Q4 $1,278,290.69 $0 $1,278,290.69 67.8 $8,449,314.6099999994 $,388,518 $8,837,832.6099999994 2017 2018 2019 2020 2021 2022 2022 2022 2022 UNIT SALES / ACTIVE SITES 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) 20 29 32 42 30 47 48 65 43 61 68 78 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 46 59 50 58 0 49 54 43 58 0 31 0 0 0 0 250 YoY D 0.5 0.6206896551724137 0.5 0.54761904761904767 0.43333333333333335 0.2978723404255319 0.41666666666666674 0.19999999999999996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -1 -0.16949152542372881 8.0000000000000071E-2 -0.25862068965517238 #DIV/0! -1 -0.42592592592592593 -1 -1 #DIV/0! -1 #DIV/0! Beginning Active Installed Base 0 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Ending Active Installed Base 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.16393442622950816 0.18260869565217397 0.18344827586206902 0.2061170212765957 0.19206145966709354 0.19607843137254899 0.2027972027972027 0.25137816979051819 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Net Active Installed Base Change 24 19 35 27 29 35 42 49 24 45 56 53 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! YoY D 0.20833333333333326 0.84210526315789469 0.19999999999999996 0.81481481481481488 -0.17241379310344829 0.28571428571428581 0.33333333333333326 8.163265306122458E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Active Sites (End of Period) 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 YoY D 0.1983739837398375 0.22135007849293564 0.22680412371134029 0.23055162659123063 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -100.0% -100.0% -100.0% -100.0% #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Inactive Systems (Calculation) (2) -4 10 -3 15 -1 -12 -6 -16 -19 -16 -12 -25 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! Inactive System Churn % (Calculation) (3) -0.1% -1.5% -0.7% -1.9% -2.0948180815876516E-2 -1.7185821697099892E-2 -1.2295081967213115E-2 -2.4224806201550399E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! (1) = Includes all active systems placed during the period. (2) = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units (3) = Calculation: Inactive Systems / Ending of Prior Period Installed Base 2017 2018 2019 2020 2021 2022 2022 2022 2022 NeuroStar REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-21 Q3-21 Q4-21 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Q1-23 Q2-23 Q3-23 Q4-23 Don’t update Total U.S. NeuroStar Revenue ($000) $1,321.41 $2,509.8959999999997 $2,828.9520000000002 $3,459.297 $2,373 $3,568.15 $3,908 $4,754 $3,350 $4,628 $4,616 $5,413 #REF! #REF! #REF! #REF! #REF! #REF! $2,612 $2,815 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $0 $3,850 $4,489 $3,597 $4,523.6000000000004 $0 $2,846 $0 $0 $0 $0 $18,007.110260000001 YoY D 0.79580902218085225 0.42163260947864001 0.38143029644900284 0.37426766189777871 0.41171512852928771 0.29703067415887774 0.18116683725690885 0.13862010938157332 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.08 #REF! 0.50612557427258809 0.63978685612788633 1.08 -0.12138769934609128 0.14107778342653798 -0.22075389948006929 1.08 -1 -0.36600579193584315 -1 1.08 #DIV/0! -1 #DIV/0! U.S. NeuroStar Capital Revenue ($000) (1) $1,083.820000000001 $1,974.9379999999999 $2,219.7345 $2,942.4469999999997 $1,908.6499999999999 $3,267.65 $3,427.6 $4,337.7 $2,938.5729999999999 $4,034.599999999995 $4,264 $4,958.8 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $16,195.687760000001 YoY D 0.76223960882001518 0.65455826967732667 0.54414863579405548 0.47418118321247604 0.53960809996594405 0.23454470338010469 0.24401913875598091 0.14318648131498279 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! U.S. NeuroStar Operating Lease Revenue ($000) (2) $229.8 $293.95800000000003 $289 $234 $258 $181 $269 $231 $182 $187 $184 $176.7 #REF! #REF! #REF! #REF! #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $730.13850000000002 YoY D 0.13 -0.38426577946509366 -6.9204152249134898E-2 -0.02 -0.29457364341085268 3.3149171270718147E-2 -0.31 -0.23506493506493509 #REF! #REF! #REF! #REF! -0.3 #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! #REF! #REF! -0.3 #REF! U.S. NeuroStar Other ($000) (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $119.5 $210.995 $185 $228.95 $407.25 $167.084 $278 #REF! #REF! #REF! #REF! #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 #REF! #REF! #REF! #REF! $0 $1,081.2840000000001 YoY D NM -0.50414937759336098 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.39 -0.20811393634920261 0.50270270270270268 #REF! #REF! #REF! #REF! #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 (1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases (2) = Revenue derived from Operating Lease revenue amortization during the period (3) = Revenue derived from Treatment Coils in U.S. 2017 2018 2019 2020 2021 2022 2023 2024 2025 Treatment Session REVENUE 1Q-17 2Q-17 3Q-17 4Q-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Update/Unhide Total U.S. Treatment Session Revenues ($000) $5,749.6779800000004 $7,388.1369999999997 $7,228.5863399999998 $8,025.3639999999996 $7,239.5479999999998 $8,919.991 $9,218 $9,909 $8,777.6730000000007 $10,847.352000000001 $10,251.888000000001 $11,243 #REF! #REF! #REF! #REF! #REF! $10,801 #REF! #REF! $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $9,612 $0 $0 $0 $0 $41,120.22219 $0 $34,852.260719999998 YoY D 0.26 0.20733968522781865 0.27521476073287099 0.2347103508326851 0.21246146858892301 0.21607207899649228 0.11215968756780215 0.13462508830356246 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 4.5693639477826231E-2 #REF! #REF! 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 -9.6871182937141809E-2 -1 -1 -1 -1 #DIV/0! #DIV/0! #DIV/0! Active Sites(End of Period) 0 671 690 725 615 637 679 707 737 778 833 870 #REF! #REF! #REF! #REF! 900 919 923 959 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 1001 1044 1081 1101 0 Average Revenue per Active Site ($000) (1) $8.8866738485316894 $11.010636363636364 $10.476212086956522 $11.069467586206896 $0 $14.504065040650406 $14.470957613814758 $14.593519882179676 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $10.511582969432315 $12.001111111111111 $11.16280281828074 $12.182826533044421 $9.8735130761209611 $11.28 $11.364000000000001 $11.516928769657724 $9.6666666666666661 $11.391304347826088 $11.916058394160585 $13.237544483985765 $8.3626239777275089 $0 $11.39 $0 $0 $0 $0 $0 YoY D 8.3314035681520959E-2 3.7291842237985096E-2 7.8306599149118972E-2 4.3315855890089239E-2 NM #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -6.0701598909209099E-2 -6.0087028978798328E-2 1.8023894625261182E-2 -5.4658724851784697E-2 -2.0949626324448987E-2 9.8674067221709624E-3 4.8579584139438914E-2 0.14939883268716059 -0.13490096782129213 -1 -4.414701378254212E-2 -1 -1 #DIV/0! -1 #DIV/0! (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) Q1 2023 15.5 Q2 2023 17.600000000000001 Q3 2023 17.899999999999999 Q4 2023 20.3 Q1 2024 17.399999999999999 Q2 2024 16.5 Q3 2024 18.5 Q4 2024 22.5 Q1 2025 32 Q2 2025 37 March 31, 2024 https://neuronetics.sharepoint.com/sites/FinanceDepartment/Shared Documents/FPA/FPA Kristen/Investor Deck/2025/Q1 2025/[Revenue for IR Deck Q1 2025 adjusted for Pro forma.xlsx]Supplemental CorpDeck Intercompany revenue/ prepaid Total Consolidated STIM STIM STIM STIM STIM GB Neuronetics Greenbrook Eliminations Adjustments I/S Nine months ended 9.30 STIM Q4.24 Acquiree fees paid by STIM Eliminations STIM Q4.24 after adjustments GB Q4.24 after adjustments Consolidated Q4.24 Revenues $ 17,417 $ 18,012.189999999999 $ -2,883.6198799999997 -2,883.6198799999997 $ 32,545.570120000004 52,397 ,-34,980 $,-34,980 18,012.189999999999 $,-16,967.810000000001 Cost of revenues 4,329 15,606.44360000018 -2,883.6198799999997 -2,883.6198799999997 17,051.42448000002 13,129 -8,800 12,722.424480000018 $12,722.424480000018 2905 Gross profit 13,088 2,406.1456399999806 0 0 15,494.145639999984 39,268 ,-26,180 0 0 $,-34,980 $5,289.7655199999808 $,-29,690.234480000021 12,716.335639999985 2884 Operating expenses: 21 Sales and marketing 11,641 7,085.4390400000266 0 18,726.439040000027 35,820 ,-24,179 $,-24,179 7,085.4390400000266 $,-17,093.560959999973 .7% General and administrative 5,957 5,534.739999999996 0 11,491.74000000001 19,540 ,-13,583 #REF! 0 #REF! 5,534.739999999996 #REF! Research and development 2,349 124.444 0 0 2,473.444 6,999 -4,650 $-4,650 124.444 $-4,525.5559999999996 Total operating expenses 19,947 12,743.957040000027 0 0 32,690.957040000027 62,359 ,-42,412 #REF! 0 #REF! $12,743.957040000027 #REF! Loss from operations -6,859 ,-10,337.811400000046 0 0 ,-17,196.811400000042 ,-23,091 16,232 #REF! 0 #REF! $-7,454.1915200000458 #REF! Other (income) expense: Interest expense 1,826 4,202.402 -4,194 -4,194 1,834.402 5,529 -3,703 $-3,703 8.4020000000000437 $-3,694.598 Loss on extinguishment of debt 0 0 0 0 4,427 -4,427 $-4,427 0 $-4,427 Other income, net -,812 -6.5000000000000002E-2 0 0 -,812.6500000000005 -2,001 1,189 $1,189 -6.5000000000000002E-2 $1,188.9349999999999 Net loss before non- controlling interest -7,873 ,-14,540.148400000046 4,194 4,194 ,-18,219.148400000046 ,-31,046 23,173 #REF! 0 #REF! $-7,462.5285200000462 #REF! Non-controlling interest -,321.84899999999999 0 -,321.84899999999999 Net Loss $ -7,873 $ ,-14,218.299400000045 $ 4,194 4,194 $ ,-17,897.299400000047 ,-31,046 23,173 #REF! 0 #REF! $-7,462.5285200000462 #REF! Net loss per share of common stock outstanding, basic and diluted $ -0.26713490770901194 0 $ -0.60726450190011017 Weighted average common shares outstanding, basic and diluted 29,472 29,472 Q3.24 adjustments per 8KA TS expense per GB Dev. Cost Var Deprec. Expense Elim I/C COGs GB Reclass 60% of R. personnel to Mktg TOTAL $5,515,743.4000000451 0.6 $3,309,446.40000027 COGs to Mkting 0.4 $2,206,297.360000018 NNI IC Revenue 13158183 Neuronetics, Inc. Supplemental Financial and Operating Information For the period ended March 31, 2025 2017 2018 2019 2020 2017 2021 2022 2023 2024 2025 2019 2020 2021 2022 2023 2023 2024 Revenue ($ thousands) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY NeuroStar Capital (1) $1,051.820000000003 $1,927.3699999999997 $2,243.19 $2,990.2869999999994 $1,908.65 $3,267.7 $3,427.723 $4,337.75 $2,938.8229999999999 $4,034.659999999998 $4,264.321800000002 $4,958.7665800000004 $2,410.320000000002 $2,223.8835899999999 $2,438.3874999999998 $3,445.80141 $8,211.9290000000001 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $16,195.687760000001 $10,518.104500000001 #REF! $12,941.823 $12,941.823 $12,941.823 $12,941.823 YoY Change 0.76 0.65 0.54 0.47 0.53973908259764736 0.2345276494170212 0.24398388667929116 0.14316559967725206 -0.17993291872290362 -0.44872404417776013 -0.4281498363363665 -0.30510917293469386 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.25142244334511443 -0.35056141759057968 #REF! 0.56999999999999995 0.56999999999999995 0.56999999999999995 0.56999999999999995 Sales $1,876 $3,277 $3,538 $4,385 $2,451 $3,754 $2,969 $4,070.4648999999999 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $13,244.464899999999 $13,244.464899999999 $13,244.464899999999 $13,076 $13,076 $13,076 $13,076 YoY 1.3318827646177938 0.9477318833436239 0.32356153513523145 0.3612288385696758 0.306503198294243 0.1455599633811413 -0.16082532504239688 -7.1729783352337484E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1.2883519424900403E-2 1.2883519424900403E-2 1.2883519424900403E-2 0.59231771244003695 0.59231771244003695 0.59231771244003695 0.59231771244003695 Sales-Type-Leases $0 $0 $0 $0 $450 $350 $1,283 $996 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $3,079 $3,079 $3,079 $0 $0 $0 $0 YoY nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm nm Other NeuroStar $32.35 $-9.65 $-,110.6 $-42.3 $37.573 $-69.5 $12.5 $-,107.69926 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $-,127.12626 $-,127.12626 $-,127.12626 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 $-,130.19999999999999 YoY -0.41530508964719492 -1.2028674739320553 3.7153119737375082 -0.11580267558528445 0.16145285935084996 6.2020725388601035 -1.1130198915009042 1.5460817966903075 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -2.3607834101382341E-2 -2.3607834101382341E-2 -2.3607834101382341E-2 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 -5.1201879717093064 NeuroStar Operating Lease (2) $215 $293.95800000000003 $289 $234 $258 $181.13883999999999 $269 $231 $181.94399999999999 $187.08323999999999 $184.44399999999999 $176.66726 $155.417 $114.16689 $87.917000000000002 $79.167000000000002 $1,031.9580000000001 #REF! #REF! $30 $85 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $730.13850000000002 $436.66789000000006 $279 $939 $939 $939 $939 YoY Change 0.13 -0.38379346709393869 -6.9204152249134898E-2 -0.02 -0.29479069767441868 3.2816816095322165E-2 -0.3143345724907064 -0.23520666666666667 -0.14579760805522568 -0.38975351292825589 -0.52334041768775341 -0.5518864106456397 #REF! #REF! -0.65876906627842169 7.3679689769727164E-2 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.22350933218443014 -0.40193827609419308 -0.36107049226816301 -0.1 -0.1 -0.1 -0.1 Other (3) $8 $241 $320.21749999999997 $282.85000000000002 $206 $120 $210.995 $185 $228.95 $407.25 $167.084 $278 $29 $0 $15 $95.5 $852.0675 #REF! #REF! $305 $217 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $1,081.2840000000001 $139.5 #REF! $722 $722 $722 $722 YoY Change NM -0.50207468879668049 -0.34108847892448091 -0.34594307937069124 0.11140776699029131 2.3937499999999998 -0.20811393634920261 0.50270270270270268 -0.87333478925529595 -1 -0.91022479710804149 -0.65647482014388492 #REF! 1 19.333333333333332 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 #REF! 1 #REF! 1.26 0.49867150846506236 -0.87098671579344555 #REF! -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 -0.15324196733240025 Total U.S. NeuroStar Advanced Therapy System Revenues $1,274.820000000003 $2,462.3279999999995 $2,852.4075000000003 $3,507.1369999999993 $2,372.65 $3,568 $3,907.7179999999998 $4,753.75 $3,349.7169999999996 $4,628.3992399999997 $4,615.5601800000004 $5,413.4338400000006 $2,594.4490000000001 $2,338.504799999999 $2,541.3044999999997 $3,620.4684099999999 $10,095.9545 $1,755.2459999999999 $2,577.2649900000001 $2,611.58916 $2,815.2192999999997 $3,642.266999999999 $4,381.9099699999997 $3,934 $4,616 $3,850 $4,489 $3,597 $4,523.6000000000004 $3,310 $4,000 $4,108 $3,849 $2,846 $18,007.110260000001 $11,094.272390000002 #REF! $16,575 $16,460 $16,459.599999999999 $15,267 YoY Change 0.8 0.42 0.38 0.37 0.41180410089983743 0.29719709641255587 0.18113952439761527 0.13877125216934005 -0.22547218167982541 -0.49484684471601459 -0.4494049690843811 -0.33120667638934342 -0.32346097379443584 0.1023136634757349 2.7656921868276729E-2 -0.22241572603584747 1.08 0.70021708555471407 0.50636250917812808 0.63965911998400982 5.7103727438351903E-2 2.4439121463739388E-2 -8.566344687341132E-2 -2.0017331022530227E-2 -0.14025974025974031 -0.10893294720427715 0.14206283013622456 -0.14912901229109565 -0.14018126888217519 -1 -1 -1 0.23311033760186262 -0.38389490430098572 #REF! 0.7 -0.01 -0.01 -7.2456195776325005E-2 Total U.S. Treatment Sessions Revenues $5,748.7510000000002 $7,386.4830000000002 $7,227.3850000000002 $8,023.9769999999999 $7,239.5487700000012 $8,920 $9,218 $9,909 $8,777.6730000000007 $10,847.351000000001 $10,251.888499999999 $11,243.30969 $8,193.4259999999995 $6,546.6486100000002 $9,083.3856099999994 $11,028.800499999999 $28,386.595999999998 $9,628.61 $10,801 $10,258.61579 $11,244.748890000001 $9,468.6990400000013 $11,294.537 $11,863.551890000002 $12,449.8 $10,643 $12,314 $13,060 $14,879 $10,224.716 $9,504.98308 $11,073.277 $11,579.70931 $9,612 $41,120.22219 $34,852.260719999998 $41,932.974679999999 $45,077 $50,896 $50,896 $42,382.685389999999 YoY Change 0.25932550740152105 0.20761125423290072 0.27542672764769005 0.23492377906865891 0.21246133963125424 0.21607073991031389 0.11215974180950306 0.13465634170955698 -6.6560579324383751E-2 -0.39647489880248188 -0.11397928196351337 -1.9078829625300497E-2 0.17516286837764827 0.64985180104236573 0.12938239445721389 1.9580405865533779E-2 -1.6607896674597833E-2 4.5693639477826231E-2 0.1564476273265325 0.10716567544444278 0.12401925069528863 9.026160169292452E-2 0.1008507503565188 0.19511960031486453 -3.9301324814431937E-2 -0.22811571544583398 -0.15212274119448699 -0.22174142684320186 -5.9924989603623247E-2 -1 -1 -1 0.16530796582310758 -0.15243014595199111 0.20316369193051309 7.0000000000000007E-2 0.13 0.13 -0.16726883468248976 Total U.S. Clinic Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $0 $0 $0 $0 $15,234.380363423368 $18,003.758999999998 $17,419.976180000001 $17,164.668999999998 $18,659 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $0 $0 $67,822.78454342336 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.22479546623365754 n/a n/a -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0 0 na Total U.S. Other Revenues $324.08965000000001 $328.21771999999976 $341.90857000000085 $353.13183000000066 $359.29917999999998 $410 $392 $426 $418.36900000000003 $414.767 $426 $374 $390.17500000000001 $382.41500000000002 $404.24200000000002 $396.8 $1,347.3477700000012 $418.90800000000002 $431.11399999999998 $409.22012999999998 $496.05811999999997 $406.17700000000002 $455.12732 $446.00448 $447 $471 $486 $554 $469 $374.28399999999999 $341.79200000000003 $348.40600000000001 $490 $366 $1,632.77601 $1,573.6320000000001 $1,754 $1,754 $1,980 $1,980 $1,554.482 YoY Change 0.10864132810165317 0.24917082478057639 0.14650533620727613 0.20634834871724594 0.16440288007336967 1.1626829268292616E-2 8.6734693877551061E-2 -0.1220657276995305 -6.739027031161493E-2 -7.8000419512642027E-2 -5.1075117370891987E-2 6.0962566844919852E-2 7.3641314794643531E-2 0.12734594615796957 1.2314727316805163E-2 0.25014647177419347 -3.0390921156912776E-2 5.5700626748377502E-2 8.9888906491476961E-2 -9.8895911632290168E-2 0.15959298532413202 6.7833062625201279E-2 0.24213998926647551 4.9217002237136542E-2 -0.20534182590233552 -0.29672427983539085 -0.37110830324909749 4.4776119402984982E-2 -2.2132925799660086E-2 -1 -1 -1 2.8844366729678717E-2 -3.6222978312867249E-2 0.12 0 0.13 0.13 -0.21490808080808077 Total U.S. Revenues $7,346.9226500000004 $10,177.2872 $10,421.701070000001 $11,884.24583 $9,972.814600000012 $12,897.737710000001 $13,518.360389999998 $15,089 $12,545.759 $15,890 $15,293.75468 $17,030 $11,177.5 $9,267.1140899999991 $12,028.93211 $15,046.68909999998 $39,829.898270000005 $11,801.763999999999 $13,809.378989999999 $13,280 $14,556.26310000001 $13,516.902740000001 $16,131.57429 $16,243.556370000002 $17,512.8 $14,964 $17,289 $17,211 $19,871.599999999999 $29,143.38036342337 $31,850.534079999998 $32,949.659180000002 $33,083.37831 $31,483 $0 $0 $0 $60,760.108459999996 $47,519.165110000002 $53,447.169300000001 $63,406 $69,336 $69,335.600000000006 $,127,026.95193342336 YoY Change 0.35 0.26 0.29713568823366732 0.26966407594077846 0.25808829884949591 0.23199900302515908 0.13133207273519076 0.12863675525217055 -0.10909734516660174 -0.41679584078036502 -0.21347423430751666 -0.11649624721080454 5.5892565569626962E-2 0.49014880532241301 0.10400490073095936 -3.2569477312064055E-2 0.14532901522179253 0.16816073349001481 0.22315936521084345 0.20313055411068426 0.10705834671116365 7.1749085934997181E-2 5.9558609454931632E-2 0.1346900552738568 0.94756618306758678 0.84224270229625753 0.91445349950612997 0.66485729936190352 8.0279624648930126E-2 -1 -1 -1 0.18034051052656319 -0.2179216542827086 0.12474975467850768 0.19 0.09 0.09 0.83205960478344965 Total International Revenues $132.1 $83.5 $92.5 $272.23500000000001 $179.732 $354 $219.30699999999999 $545.61800000000005 $182 $682 $706.37199999999996 $325.548 $298.822 $473.91300000000001 $418.98599999999999 $532.87300000000005 $580.33500000000004 $486.28800000000001 $393.93900000000002 $519 $466.178 $663.74939000000006 $197.87039000000001 $253.36739 $686 $576 $321 $673.3 $441.6 $624 $320 $608 $851 $492 $1,895.7699999999998 $1,724.5940000000001 $1,865.4050000000002 $1,800 $2,012 $2,011.9 $2,402 YoY Change 0.36057532172596529 3.25 1.3708864864864863 1.004216944918912 1.2618787973204482E-2 0.92655367231638408 2.2209277405645969 -0.40334079887393748 0.6418791208791208 -0.30511290322580642 -0.40684794980548489 0.63684925110889967 0.62735006124047099 -0.16875249254610025 0.23870487319385369 -0.12516115472166922 0.36493063781133817 -0.49771312309773852 -0.51181620423892094 0.4715409135566242 -0.13220259230671394 0.62227405525404778 1.6574059116289588 -0.35626822157434401 8.3333333333333259E-2 -3.1152647975077885E-3 -9.6984999257388904E-2 0.92708333333333326 -0.21153846153846156 -1 -1 -1 0.45904444083572726 -9.0293653766015725E-2 8.1648782264115649E-2 -0.03 0.12 0.12 0.19389631691435949 Total Revenues $7,479.226500000008 $10,260.52872 $10,514.201070000001 $12,156.48083 $10,151.813460000001 $13,252.403710000001 $13,737 $15,634.618 $12,728.371999999999 $16,571.754240000002 $16,000.126679999999 $17,355.547999999999 $11,476 $9,741 $12,447.918110000001 $15,578.941909999998 $40,410.233270000004 $12,288.52 $14,203.31799 $13,799 $15,022.204310000001 $14,180.652129999999 $16,329.445 $16,497.5124 $18,198.8 $15,540 $17,610 $17,884.3 $20,313.199999999997 $29,767.38036342337 $32,170.534079999998 $33,557.659180000002 $33,934.37831 $31,975 $0 $0 $0 $62,655.878459999993 $49,243.860019999993 $55,312 $65,206 $71,348 $71,347.5 $,129,429.95193342336 YoY Change 0.35 0.29159072321177626 0.30651867018175616 0.28611382016221221 0.2538027860886245 0.25047158256243618 0.16474679187595531 0.11007176510484618 -9.8392158871535185E-2 -0.41219258631728306 -0.22201127785070751 -0.10236531223329859 7.0760892296967581E-2 0.45809649830612864 0.10853878359905123 -3.5736547656207041E-2 0.15401954109569194 0.14969227693817189 0.19555854772084924 0.21146002440436762 9.5859334079863689E-2 7.8419995290715638E-2 8.4060406585904301E-2 0.11618348462535977 0.91553284191913575 0.82683328109028942 0.87637532248955807 0.6705579775712347 7.416237537950221E-2 -1 -1 -1 0.18720207332511252 -0.21405842148653842 0.12322632664327049 0.18 0.09 0.09 0.81407830594517483 2018 2019 2020 2020 2020 2020 2021 2020 2020 2020 2022 2020 2020 2020 2023 2020 2020 2020 2024 2025 2019 2020 2021 2022 2023 2023 2024 U.S. Operating and Financial Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY FY FY FY FY FY FY Active Installed Base Active Installed Base - Beginning of Period 647 671 690 725 752 781 816 858 907 931 976 1032 #REF! #REF! #REF! #REF! 647 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 907 #REF! #REF! 752 752 752 752 Active Installed Base - End of Period 671 690 725 752 781 816 858 907 931 976 1032 1085 #REF! #REF! #REF! #REF! 752 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 1085 #REF! 752 907 907 907 907 Total NeuroStar Systems 14 25 30 40 24 43 47 61 43 61 68 78 #REF! #REF! #REF! #REF! 109 23 36 40 48 46 59 50 58 49 54 43 58 40 50 48 47 31 250 #REF! 147 213 204 204 185 YoY Change 0.71428571428571419 0.72 0.56666666666666665 0.52499999999999991 0.79166666666666674 0.41860465116279078 0.44680851063829796 0.27868852459016402 #REF! #REF! #REF! #REF! -0.39473684210526316 2.857142857142847E-2 2.564102564102555E-2 -0.11111111111111116 1 0.63888888888888884 0.25 0.20833333333333326 6.5217391304347894E-2 -8.4745762711864403E-2 -0.14000000000000001 0 -0.32203389830508478 0 -0.17241379310344829 -0.18965517241379315 -0.22499999999999998 -1 -1 -1 #REF! #REF! #REF! 0.44897959183673503 -0.04 -0.04 -9.3137254901960786E-2 Active Sites Active Sites - Beginning of Period 0 615 637 679 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 916 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1081 1001 1044 1081 #REF! #REF! 916 959 959 959 959 Active Sites - End of Period 615 637 679 707 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 900 919 923 959 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 1001 1044 1081 1101 #REF! #REF! 0 1101 1101 1101 1101 NeuroStar System Average Selling Price ($) (4) $75,077.285714285739 $77,094.799999999988 $74,773 $74,757.174999999988 $79,527.83333333343 $75,993.23255813954 $72,930.276595744683 $71,110.655737704918 $68,344.72093023255 $66,132.229508196717 $62,706.355588235296 $63,573.930512820516 #REF! #REF! #REF! #REF! $75,338.798165137618 $69,101.260869565216 $67,801.336111111115 $56,914.728999999999 $52,358.735416666663 $75,760 $72,410.547796610161 $72,755.848399999988 $0 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $64,782.75104000001 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 $60,759.732394366198 YoY Change 5.926955905121245E-2 -1.4291194012904018E-2 -2.4644235275504744E-2 -4.8778184332073482E-2 -0.14061074459666201 -0.12975919795193602 -0.14018760773637229 -0.10598587717548236 #REF! #REF! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #DIV/0! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 -0.19351338388508776 Sequential Change 6.3805358259369171E-2 -4.4438446996812098E-2 -4.0302997944419161E-2 -2.4950143383193124E-2 -3.8896207309276565E-2 -3.237252843997096E-2 -5.1803393677160137E-2 1.3835518209385222E-2 #REF! #REF! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #DIV/0! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0 Average Revenue Per Active Site ($) (1) $8,885.2411128284384 $11,008.171385991058 $10,474.471014492754 $11,067.55448275862 $9,627.595345744696 $11,421.254801536492 $11,296.568627450981 $11,548.951048951049 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! $43,874.182380216385 $10,511.582969432315 $12,001.111111111111 $11,162.802818280739 $12,182.826533044421 $9,873.5130761209602 $11,280 $11,364 $11,516.928769657725 $9,666.6666666666661 $11,391.304347826088 $11,916.58394160586 $13,237.544483985765 $8,895.6986253697578 $8,151.7865180102917 $11,390 $9,931.1400600343059 $8,362.6239777275096 $0 $11,390 $0 YoY Change 8.3488834160617253E-2 3.7525162087421959E-2 7.8485835878561394E-2 4.3496200261978757E-2 NA #REF! #REF! #REF! #REF! #REF! #REF! #REF! 0.11614813917964395 0.62052110235716817 9.2514634028795673E-2 .4% -6.0701598909209231E-2 -6.0087028978798251E-2 1.8023894625261105E-2 -5.4658724851784579E-2 -2.0949626324448856E-2 9.8674067221709016E-3 4.8579584139438969E-2 0.14939883268716048 -0.21137423533956046 -0.28266574111137877 -1.1021060579286424E-2 -0.13769197859426785 -0.13490096782129202 -1 -4.4147013782542266E-2 -1 *2024 is Adjusted Pro forma revenue, pro forma revenue adjusted for Greenbrook store closures Use Total Systems Recognized from the Q or K #DIV/0! (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) Three Months EndedMarch 31, 2024 2025 Revenues $29,767.38036342337 $31,975 YOY Growth 7.4162375379502321E-2 Gross Profit 12716.335639999985 15738 Gross Margin 0.42719028294559525 0.49219702892885064 Operating Expenses: Sales and Marketing 18726.439040000027 11999 % of Revenues 0.62909261115264659 0.37526192337763881 General and Administrative 11491.074000000001 13137 % of Revenues 0.38602906469121623 0.41085222830336199 Research and Development 2473.444 1616 % of Revenues 8.3092431037003214E-2 5.0539483971853011E-2 Total Operating Expenses 32690.957040000027 26752 Loss from Operations $,-19,974.62140000004 $,-11,014 ($ in thousands) % of Revenues -0.67102382393527082 -0.34445660672400313 As of March 31, 2025 Cash and Cash Equivalents $20,224 enter Other Assets $,121,764 calculates Total Assets $,141,988 enter Long-term debt, net $55,341 enter Convertible Preferred Stock Warrant Liability $0 11703 Convertible Preferred Stock $0 0.7530888030888031 Accumulated Deficit $-,432,464 enter Total Stockholders’ Equity $35,452 enter